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Summary
The investigations reported in this thesis are observational studies of various aspects 
of the upper airway and breathing pattern in patients attending a Problem Asthma 
Clinic (PAC) based in a large city hospital. We hypothesised that Vocal Cord 
Dysfunction (VCD) would be present in a proportion of patients attending our clinic 
and that the Forced Oscillation Technique (FOT) would play a role in the non- 
invasive identification of this. In addition we explored the relationships between 
structural nasal, laryngeal and vocal pathology and symptoms, along with a detailed 
assessment of vocal morbidity by both patient reported (Voice Symptom Score — 
VoiSS) and Speech and Language Therapy assessment (GRBAS score) methods. We 
hypothesised further that a strategy of performing challenge testing with Histamine 
and Exercise challenge would be helpful in the diagnosis of VCD. Finally we 
proposed that patients felt to have dysfunctional breathing (DB) on the basis of 
Nijmegen scores would have different physiological measurements of breathing 
pattern to those not felt to have DB and that physiotherapist delivered breathing 
control therapy (BCT) would produce an improvement in Nijmegen scores and 
asthma related quality of life.
Firstly, the clinical characteristics of a cohort of 49 new-patient referrals to the PAC, 
along with interrelationships between psychological conelates of asthma (Hospital 
Anxiety and Depression (HAD), Asthma related quality of life (AQLQ), perceived 
control of asthma, hyperventilation (Nijmegen) score) are described. Of this cohort, 
39 (79.6%) had definite evidence of asthma. There were statistically significant
17
correlations between baseline questionnaire scores, with the most convincing 
relationship seen between Nijmegen and HAD (Anxiety) (r = 0.70, p = 0.006). After 1 
year attendance at the clinic, which included regular re-enforcement of self­
management training, there were no differences seen in any questionnaire parameter.
Our first pilot study involved wide ranging assessment of the upper airway in 43 
patients attending the PAC. We found no evidence of VCD, as classically described in 
current literature, but did find evidence of other structural and functional laryngeal 
abnormalities, nasal pathology and vocal morbidity. Laryngitis was the most frequent 
structural abnormality (15 patients). Functional abnormalities iucluded glottic chink 
(5), phonatiug with false cords (5) and reduced cord mobility (2). Individual 
laryngopharyngeal symptoms were poor predictors of laryngeal pathology but 
symptom combinations increased the likelihood of any laryngoscopic abnormality. 
The lack of VCD identification prevented any conclusion being made regarding the 
role of FOT in VCD diagnosis. At nasendoscopy 22 patients had normal examination 
(median NSS 4), 8 had polyps (median NSS 5), 7 had deviated nasal septum (median 
NSS 4), 4 oedematous mucosa (median NSS 7) and 2 had other abnormalities. 
Individual nasal symptoms were poor predictors of individual nasal pathologies, but 
hyposmia was the best individual predictor of any abnormality (Positive Predictive 
Value (PPV) 80%). Combination of symptoms increased the likelihood of any 
nasendoscopic abnormality with obstruction, rhinorrhoea and hyposmia together 
having a PPV of 100%. Only 1 patient had evidence of laryngeal candidiasis, 
emphasising that dysphonia (in 13 patients as defined by SLT assessment) in patients 
with asthma is more complicated than may be initially assumed. VoiSS scores were
18
higher in patients with laryngeal abnormalities (median VoiSS 33 vs 22, 95% Cl for 
difference 0.0, 21.0, p = 0.044) while GRBAS did not differ in this group.
Given the lack of positive identification of VCD in our pilot study, we investigated 
the role of challenge testing in VCD diagnosis by combined histamine challenge and 
progressive exercise testing. We recruited 9 patients we suspected this diagnosis as a 
C O-existing factor with asthma to the study, 7 of whom completed the protocol. We 
found no evidence this diagnostic strategy was of value with no change in laryngeal 
appearance after either challenge in any patient.
We performed a more comprehensive observational survey of nasal symptomatology 
and nasal pathology to help determine the value of routine nasendoscopy in a problem 
asthma clinic by inviting as many patients with asthma as were attending the clinic to 
attend a simple study run in parallel with their attendance at the PAC. A control group 
of patients with COPD or Interstitial Lung Disease was used for comparison. This 
study suffered form poor recruitment rate in both groups (26 with asthma recruited 
versus 7 controls). We found proportionally more patients in the control group had 
any nasendoscopic abnormality (5/6, 83%) compared with the Asthma group (15/21, 
71%), but only one in the control group actually required further ENT review for this 
in comparison with 11 out of 21 patients with asthma requiring further ENT review. 
Individual symptoms seemed to be better individual predictors of a general 
abnormality than in our pilot study and intriguingly the best individual predictor was 
“ loss of smell or taste” (PPV 83.3%).
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The other mam component of this thesis addresses the issue of hyperventilation or 
dysfunctional breathing along with breathing pattern characterisation and 
investigation of the role of breathing control therapy in patients with asthma. 102 
patients attending our clinic completed Nijmegen and Mini-AQLQ questionnaires. 
Patient with a positive Nijmegen score (n = 65, said to have evidence of dysfunctional 
breathing -  “DB”) were referred for breathing control therapy (BCT) and progressive 
exercise testing (PET) to seek confirmation of hypeiwentilation. We aimed to collect 
follow up questionnaire data at six months in both the group who received BCT and 
the group who did not (those with negative Nijmegen scores -  “Non-DB”). We found 
a strong relationship between Nijmegen score and Mini-AQLQ (r = -0.63, p < 0.001) 
and a less strong relationship between level of asthma symptoms and Nijmegen scores 
(r = 0.43, p < 0.001) at baseline. There was poor agreement between Nijmegen 
identified hyperventilation and PET identified hyperventilation. Follow up data 
(available in 29 patients) showed no significant change in either of Nijmegen scores 
or Mini-AQLQ, after a moderate intensity intervention delivered by a specialist 
respiratory physiotherapist in parallel with attendance at the problem asthma clinic, 
although 8 patients had Nijmegen scores that fell to within the normal range and 9 
also had clmically significant improvements in Mini-AQLQ. This data suggests that 
the Nijmegen questionnaire overestimates the prevalence of HVS, by wrongly 
attributing symptoms of poor asthma control to hyperventilation.
A subgroup of the above patients (n = 78; 31 DB, 47 Non-DB) underwent 
physiological assessment of breathing pattern. Data on inspiratory time (T i), 
expiratory time (Te), expiratory / inspiratory time ratio (Tg/Ti), Tidal volume (Vt) for 
each breath was available from each recording. Subsequently, minute ventilation
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(Vmin) and respiratory frequency (R f) could be calculated. Other than a statistically 
significant difference observed was in the measurement of V t (95% Cl 0.01, 0.39, p = 
0.044) there were no differences in between those with positive and those with 
negative Nijmegen Scores. Breath-to-breath variability for Ti, Te, Te/Ti and Vt also did 
not differ between the two groups. Follow up data subsequent to breathing control 
therapy (31 patients - 16 Non-DB, 15 DB) showed there was no significant difference 
at follow up from baseline measurement in any breathing pattern characteristic.
21
CHAPTER 1
REVIEW OF THE LITERATURE
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1.1 Severe Asthma
There are a variety of patients with asthma who require input from secondary care. 
Such patients include those in whom initial diagnosis is not immediately apparent, 
those who have not responded to initial treatment in primary care and those recently 
discharged from hospital requiring fruther monitoring and self management training. 
There is then the group of patients who require long term management in specialist 
clinics with “Severe Asthma”. Wliile there are very good clinical indicators to define 
the severity of an acute exacerbation of asthma ( )^, it has been much harder to reach 
consensus on clear definition of “severe” asthma over the longer term. A multitude of 
labels have been given to this clinical entity for example clironic severe, severe 
persistent, difficult, difficult to control, treatment resistant. “Difficult Asthma” has 
been previously defined as “failure to achieve control when maximally recommended 
doses of inhaled therapy are prescribed” ( )^. It is clear however that a number of 
factors influence either patients’ or doctors perception of severity of disease in 
addition to a particular level of treatment taken such as compliance, level of cun'ent 
symptoms, frequency of exacerbations, degiee of airflow obstruction, bronchial 
hyper-reactivity, exhaled markers of aiiway inflammation and of course any 
aggravating factors. These factors may not necessarily correlate with each other, for 
example the patient who has frequent exacerbations but with minimal symptoms and 
lung function impafrment in between may be on a high level of treatment to minimise 
such exacerbations. One simple, treatment based description of severity is to use the 
current British Thoracic Society (BTS) guidelines step wise approach, with BTS Step 
4 or 5 representing severe asthma. The European Respiratory Society (ERS) Task 
force defines difficult / therapy resistant astlima as “asthma which is poorly controlled
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in terms of chronic symptoms, episodic exacerbations, persistent and variable airways 
obstruction and a continued requirement for short acting beta agonists despite delivery 
of a reasonable dose of inhaled corticosteroids (> 2000 mcg/day beclomethasone, 
1600 mcg/day budesonide or 1000 mcg/day fluticasone) +/- regular courses or a 
regular dose of oral corticosteroid” ( )^. Despite this there remains an argument for 
more specific definition of “asthma phenotypes” which could guide both clinical 
management and clinical research and which ultimately could be linked to genotype 
r t .  An example of an asthma phenotype is that of the “brittle asthmatic”, with two 
sub-types recognised ( )^. Type I brittle asthma is characterised by wide variations in 
peak flow (> 40% diurnal variation for > 50% of the time over a period of at least 150 
days) despite therapy consisting pf at least 1500 mcg/day beclomethasone or 
eauivalent. Type II brittle asthma is characterised by sudden acute attacks without an 
obvious trigger on a background of well controlled asthma and apparent normal 
airway function. More recent work has attemped teasing out of different aspects of the 
severe asthma phenotype by comparing 163 patients with “severe asthma” with 158 
controlled asthma, with principle findings being of female predominance and more 
neutrophilic inflammation the severe group ( )^. The definition of severe asthma (one 
asthma exacerbation in the last year despite treatment with > 1200 mcg/day 
beclomethasone or equivalent) was different in this study to that of the ERS task force 
described above.
Due partly to difficulties in reaching consensus as to diagnostic criteria for severe 
asthma precise figures for its prevalence of are not available, but some hints come 
from survey data. 4.6% of 3373 patients with asthma had treatment consistent with 
severe asthma in an English community survey (^), and in a French survey of 4362
24
patients with asthma, 5.1% were on such treatment, 9% had an FEVl < 60% predicted 
and 16-17% had continuous daily and frequent nocturnal symptoms(^).
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1.2 Vocal Cord Dysfunction
In asthma inflammation and obstruction in the lower airways manifests itself by the 
symptoms of wheeze and breathlessness. Involvement of the upper airway can 
produce symptoms which can be difficult to distinguish from those of asthma. In 
Vocal Cord Dysfunction (VCD) there is abnormal adduction of the vocal cords during 
respiration leading to afrflow obstruction and symptoms which can mimic asthma. 
This condition has also previously been given the name of paroxysmal vocal cord 
motion, paroxysmal vocal cord dysfunction, paradoxical movement of vocal cords, 
episodic paroxysmal laryngospasm and initable larynx syndrome ( )^. This condition 
continues to present both diagnostic and therapeutic dilemmas to respfratory 
physicians.
Epidemiology
Tme population figures for incidence and prevalence of VCD are not known. In a 
group of 1025 patients evaluated for exertional dyspnoea, 29 (2.4%) were found to 
have VCD (^ )^. In a smaller study of 105 army recmits evaluated for dyspnoea 10 
(9.5%) had VCD (“ ).
The incidence in patients with asthma has been explored in more detail but still 
remains unclear. One tertiary refenal centre evaluated patients with refractory asthma 
and found 22 out of 132 (16.7%) to have VCD in addition to asthma (^ )^. In one of 
the largest case series of 95 patients with VCD, 53 also had asthma (^ )^. This case 
series also suggested a high incidence of psychiatric problems in patients with this
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condition. In the 42 patients with pure VCD, 9 had had psychiatric hospitalisations, 
73% had a major psychiatric disorder and 37% had a personality disorder. 38% of 
these patients also had a history of sexual, physical or emotional abuse. Similar 
degrees of psychiatric morbidity were found in those with VCD and asthma. 
Christopher proposed that VCD is a form of conversion disorder, a view 
supported by Seiner’s small series (^ )^. This is not however confirmed by later work 
(i6;i7)^  Newman’s series and a further series of 22 patients suggest that this is 
typically a condition of younger females. Other case reports implicate occupationally 
inhaled irritants(^^), child abuse (^ )^, brain-stem compression (^ )^, cystic fibrosis (^ )^, 
working in health care and gastro-oesophageal reflux (^ )^.
Pathophysiology
There is no clear consensus on how this condition arises. First of all the innervation of 
the larynx must be considered. Sensory information is transmitted via the vagus nerve 
to the medulla. A variety of other factors such as stress, emotion and ambient 
temperature also input to this part of the central nervous system. These may influence 
the motor outflow, also via the vagus. Consequently a base line autonomic balance 
can be said to exist Ayres and Gabbott propose that this can become
“imbalanced” by either laryngeal hyperresponsiveness (initiated by some form of 
inflammatory insult) or perhaps from a central stimulus such as ill-defined 
psychological factors (Figure I -  adapted from Ayres (^ )^). Morrison(^^) proposed a 
similar mechanism whereby the threshold for stimulating glottic spasm is lowered by 
clironic irritation of the larynx by gastro-oesophageal reflux. Such an imbalance may 
favour adduction of the vocal cords.
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There remains the possibility that more than one of these factors may exist in any one 
patient and that depending on the persistence or degree of such factors, a vicious cycle 
encoui aging persistence may be created. The ultimate result is of abnormal adduction 
of the vocal cords with creation of a characteristic posterior glottic “chink” visualised 
at laryngoscopy This occurs during the respiratory cycle leading to upper
airway obstruction and symptoms. This most commonly occurs during inspiration, but 
can also occur during expiration in addition or in isolation Due to the variable
nature of the factors described above, the symptoms are also variable.
Figure 1 -  Vocal Cord Dysfunction - Proposed Pathogenesis
EMOTIONAL
TRIGGERS
INFLAMMATORY
INSULT
SYMPTOMS
LARYNGEAL
HYPER-RESPONSIVENESS
ALTERED AUTONOMIC 
BALANCE 
(t VAGAL TONE)
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If laryngeal hyperresponsiveness is the basis of VCD, what provides the initial insult? 
This may be due to upper airway hyper-responsiveness occurring in association with 
the lower airway hyper-responsiveness of asthma. Bucca demonstrated that 
histamine provocation testing could produce extrathoracic (upper) airway narrowing 
as measured by a 25% decrease in mid-inspiratory flow in 25 of 40 patients with 
episodic breathlessness with wheeze and / or cough. This extrathoracic airway 
hyperresponsiveness (EA-HR) was observed with or without lower airway bronchial 
hyperresponsiveness (BHR) as measured by a 20% fall in FEV, in response to 
histamine. Although laryngoscopy was only performed in 7 of these 25 patients, it is 
interesting that in addition to mucosal oedema and pharyngoconstriction, adduction of 
the vocal cords dui'ing forced inspiration was seen in all 7 of these patients. Five of 
the 15 patients who had no evidence of EA-HR also had laryngoscopy but with 
normal findings. This study did not state how many patients had asthma and so it is 
unclear if EA-HR was a phenomenon distinct from or part of the spectrum of asthma. 
The same group later showed that isolated EA-HR was responsible for asthma-like 
symptoms in 117 of a larger sample of 441 patients, but laryngeal examination was 
not undertaken in this study EA-HR occurred in association with BHR in a 
further subgroup of 179 patients in this study. This raises the possibility that a reflex 
can be triggered by stimulation of pharyngo-laryngeal receptors independent of the 
lower airways, and this is supported by the finding of EA-HR in 72% of patients with 
sinusitis (^ )^.
Other workers have suggested that stimuli such as acid reflux or inhaled irritants 
could initiate or contribute to laryngeal hyperresponsiveness. Perkner described 9 
patients from a cohort of 127 VCD patients with symptoms relating to irritant
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exposure to ammonia and fumes from cleaning fluids. In this same group, 28 had 
symptomatic gastro-oesophageal reflux disease (GORD), hut this was not defined 
objectively. In Powell’s cohort 19 of 22 patients had laryngoscopic changes 
suggestive of reflux disease. The relationship of GORD, and perhaps even more 
importantly laryngopharyngeal reflux disease to VCD has not been prospectively 
evaluated.
Clinical Features
Cliristopher used the term Vocal Cord Dysfunction to describe five patients with 
dramatic episodes of wheezing, previously thought to have asthma. Further 
investigation demonstrated no objective evidence of asthma but each had marked 
flattening of the inspiratoiy limb of a flow-volume loop and characteristic 
laryngoscopic abnormalities. Other case reports and the large series mentioned 
above have described the clinical featui'es of VCD in detail. The patient may complain 
of wheezing, “noisy breathing”, stridor, dyspnoea, cough or tluoat tightness. VCD has 
been shown to account for “choking” dui'ing athletic activities in patients previously 
felt to have exercise-induced asthma(^^). Because of these symptoms, asthma is 
commonly misdiagnosed, as several case reports describe, and the patients may have 
been on long term high dose steroids resulting in a Cushingoid appearance. Other 
clues to the diagnosis are inspiratory stridor heard over the trachea, the absence of 
typical asthma features (in particular BHR) and lack of response to conventional 
asthma therapy. If a patient is ventilated for presumed severe asthma and found to 
have noi*mal inflation pressures, this would also suggest the diagnosis.
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Examination may be unhelpful. Careful listening to patients breathing may reveal 
insphatory stridor rather than expiratory wheeze, but the timing of abnormal vocal 
cord adduction can be inspiratory or expiratory. Similarly, pronounced inspkatory 
noise heard by auscultating over the trachea may help in some cases. As a result of 
profound upper airway obstruction, hypoventilation and therefore hypoxia can rarely 
occur and in some cases lead to intubation and mechanical ventilation (^ )^.
Diagnosis
Perhaps the most significant problem in the diagnosis of VCD lies in the episodic 
nature of symptoms. Visualisation of the cords, with characteristic adduction of the 
anterior two thirds and creation of a posterior glottic chink during inspiration and /or 
expiration must be regarded as the gold standard of diagnosis In between
attacks, the cords may be normal. Other diagnostic tests detailed below can be helpful 
in suggesting VCD as a diagnosis.
Spirometrv
Measurement of Forced Expiratory Volume in one second (FEVi) and Forced Vital 
Capacity (FVC) are likely to be normal unless lower airway obstruction is present. 
FEVl is not a sensitive measure of extrathoracic aiiivay narrowingf^®).
Measurement of flow-volume loops is more helpful if VCD is present. Truncation of 
the inspiratory limb is characteristic (although not specific for VCD) resulting in a 
Mid-expiratory flow / Mid-inspiratory flow (MEFg/MIFg^) ratio exceeding 1.5
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The Flow Volume Loop (FVL) may only be abnormal in about a fifth of 
asymptomatic patients An atypical expiratory limb with abrupt drop and rise has 
been described presumably due to expiratory VCD.
Estimation of mid-mspiratory flow (MIF50) is a more numerical method of measuring 
extrathoracic airflow obstruction and in a small sample of patients, was shown to 
correlate well with mid-inspiratory glottis area measured laryngoscopically (^ )^.
Specific Challenge Testing
Given the episodic nature of symptoms, if a particular precipitant can he identified, it 
would seem logical to attempt provocation testing to aid diagnosis. Seiner 
reported reproduction of symptoms with cooked com in one VCD patient but also 
with placebo during food challenge in another patient initially felt to have symptoms 
related to egg products. In this latter patient methacholine also produced stridor. In 
Perkner’s description of irritant-associated VCD, these were all diagnosed by 
laryngoscopy within 24 hours of exposure, but no formal challenge tests were 
subsequently performed
Bronchial provocation tests
Methacholine and histamine are bronchoconstrictors that act directly on bronchial 
smooth muscle. The ability of histamine challenge to detect extrathoracic airway 
hyperresponsiveness has been discussed. It seems simplistic however to presume that 
upper airway obstruction demonstrated in this way will always be due to VCD. In
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Newman’s cohort Methacholine challenge Testing (MCT) induced VCD in 9 of 
12 subjects with normal laryngoscopy. Morris C^) demonstrated changes in 
inspiratory limbs of flow-volume loops in 4 out of 10 VCD patients with MCT but did 
not correlate these findings with laryngoscopy. There has only been one prospective 
evaluation of MCT in the diagnosis of VCD. In this study 10 known VCD
patients, 12 patients with exercise induced asthma (EIA) and 12 controls underwent
laryngoscopy before and after MCT challenge testing. The findings in the 10 known 
VCD patients were as follows:
• 2 had VCD changes before and after MCT
• 2 had VCD changes induced by MCT
• 6 had no VCD changes, but 3 demonstrated truncation of the 
inspii'atory limb of the FVL suggesting extrathoracic akway 
hyperresponsiveness.
In addition, 7 of the 10 patients had bronchial hyperresponsiveness with MCT. None 
of the control group or EIA patients developed VCD post MCT although I EIA 
patient developed inspiratory FVL flattening with MCT. This study highlights the 
importance of correlating any FVL abnormalities with laryngoscopic appearances.
Exercise Testing
Case reports have described VCD in association with exercise(" '^^ ’'^ )^. McFadden(^^) 
described 7 elite athletes who developed VCD during sporting competitions. Attempts 
were made to recreate symptoms by exercise testing. This was only successful in 3/7 
patients (2 in treadmill and 1 by bicycle ergometry) with 3 further patients being 
examined after their individual sporting activity and the remaining patient positive by
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hyperventilation testing. The diagnosis was made by laryngoscopy in only 3 of these 
patients with FVL used in the others. Interestingly MCT did not provoke symptoms in 
any of these patients. In the same study previously quoted by Morris(^^), 40 patients 
and 12 controls were evaluated for exertional dyspnoea. Progressive cardiopulmonary 
exercise testing with pre and post test laryngoscopy was performed in all patients. 
Two patients had evidence of VCD pre and post-exercise. Exercise provoked VCD in 
a further 8 patients, with the remaining 30 patients and 12 controls having no evidence 
of VCD. It is not clear how many of these patients had asthma although 6 of the VCD 
patients had BHR on MCT.
More recently, the use of continuous transnasal laryngoscopy during exercise has 
been described in the diagnosis of exercise induced laryngeal dysfunction in a group 
of patients predominantly with laryngomalacia, rather than VCD(^^). This technique 
may be help fill to clarify the role of challenge testing in the diagnosis of VCD in 
future studies.
Forced Oscillation Technique
The forced oscillation technique (FOT) uses small oscillating forces in the form of 
sound waves to measure the impedance (the opposition to flow of these forces) of the 
respiratory system. The input is usually applied via a mouthpiece through which the 
subject performs tidal breathing. Impedance and thence resistance are calculated fi-om 
the mouth pressure and flow after the effects of breathing have been removed by 
signal processing. Its merits include the rapid acquisition of data and that it does not 
require maximum effort manoeuvres('^^). It is therefore easier for some patients to
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perform than routine pulmonary function tests which involve forced manoeuvres. This 
may be particularly relevant for patients with suspected upper airway symptoms who 
anecdotally often have difficulty with these.
Although there are no published data on this technique in the clinical setting of VCD, 
Rigau mimicked VCD in a model using variable resistance to simulate normal 
respiratory anatomy and found that the changes in oscillatory resistance were in 
agreement with the degree of area reduction in the model As with changes in the 
inspiratory limb of the FVL, changes in FOT measured resistance will not be specific 
for obstmction at the cords, but rather more of a reflection of upper airways 
obstruction in general.
Other methods of diagnosis
One case reportf^^) demonstrated VCD by means of airway radiographs and 
fluoroscopy in a patient where laryngoscopy was not performed.
Zelcer(^°) has described abnormalities in Multidimensional voice programme analysis 
whereby VCD patients had differences in soft phonation indexes compared with 
normal subjects. One case of VCD has been reported under hypnotic suggestion(^^).
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Treatment
There are no randomised controlled trials of any form of treatment for VCD. Evidence 
is limited to case reports and series describing the course of the condition.
The patients from Chi'istopher’s series were treated by a speech pathologist They 
were taught to focus attention away from the larynx and inspiratory phase of breathing. 
Instead they were taught to concentrate on active expiration using anterior abdominal 
muscles and to relax oropharyngeal muscles. Short-teim psychotherapy was also 
administered to these patients and they all experienced a reduction in frequency and 
severity of attacks. Seiner emphasised the importance of thorough psychological 
assessment, and the prevalence of psychiatric morbidity is discussed above 
This may not he appropriate in all cases and may be counterproductive in patients 
who have been dismissed as “mad” by doctors previously. Together with speech 
therapeutic strategies similar to those used for treatment of other voice disorders 
(such as laryngitis, hoarseness), Newman(^^) emphasises the importance of cessation 
of unnecessary medications, as patients mislabelled as asthma may often have been 
prescribed significant doses of inhaled or oral corticosteroids resulting in side effects. 
Powell also treated his group with speech therapy and psychological counselling as 
well as raising interesting questions about the role of anti-reflux therapy in cases 
where this can be implicated. More recently, Sullivan(^^) reported success of a speech 
therapy programme in 20 adolescent female athletes with VCD.
In the acute setting, a mixture of helium and oxygen (heliox) has been described as 
beneficial. Weir detailed dramatic results in 4 VCD patients(^^). The mechanism of
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action of Heliox is likely to relate to the low density of such a gas mixture allowing 
improving flow of air through the adducted cords (^ )^. Lisboa found varying degrees 
of increased inspimtory resistance in asthmatics compared with normal, which was 
corrected by breathing heliox Such a benefit from heliox has been described in 
other patients with fixed upper airway obstruction (^ )^.
Other therapies for which there is anecdotal evidence of benefit include intralaryngeal 
injection of botulinum toxin and a portable facemask with adjustable resistance to 
inspiration but not expiration
Conclusions -  Vocal Cord Dysfunction
Recognition and description of vocal cord dysfunction have improved over the last 
two decades. Respiratory physicians are more aware of the possibility of VCD 
underlying or mimicking poorly controlled asthma and will consider the diagnosis in 
others with atypical asthma like symptoms. Visualisation of the cords during an attack 
of symptoms is the current gold standard for diagnosis. It may be that VCD represents 
one end of a spectrum of “upper airways dysfunction” in patients who have 
extrathoracic hyperresponsiveness with or without associated asthma. Important 
questions remain regarding epidemiology within the general and asthmatic 
populations as well as the pathological mechanisms underlying VCD. These questions 
are beyond the scope of our proposed investigation.
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1.3 Voice Problems and Asthma
Bearing in mind the above discussion regarding vocal cord dysfunction and the fact 
that inhaled medication for asthma has the potential for direct effects on the larynx, it 
is reasonable to consider the effect asthma or its treatment may have on patients’ 
voice. Up to 50% of patients taking inhaled corticosteroids may suffer from dysphonia 
which is usually reversible(^^). This is usually attributed to fungal infection or steroid- 
induced adductor myasthenia of the larynx(^^), although laryngoscopy or voice 
laboratory assessment may reveal more complicated abnonnalities(^^’^ ®) such as 
apposition abnormalities and cycle to cycle irregularity.
Much of the voice literature is focused on patients attending otolaryngology clinics 
and voice morbidity in patients with asthma has not heen extensively studied. Baker 
found that half of 80 young adults with asthma or allergy had abnormalities in vocal 
quality (assessed by Speech and Language Therapists) Studies assessing
prevalence of voice problems in patients with asthma have concentrated on using 
patient administered questionnaires as the principle outcome measuie. In a sample of 
255 patients attending an asthma clinic, 88 (34%) reported voice “huskiness” and 40 
(16%) reported “reduced power” (^ ®). A more recent study found 169 / 280 (63%) 
patients attending asthma clinics complained of “voice disturbance” in general but this 
was not characterised further (^ )^.
The presence of dysphonia is clearly important to patients, as recent work has 
demonstrated quality of life as measuied by SF-36 questionnafre was significantly
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impaired in dysphonie patients (attending an ENT clinic) without significant stmctural 
laryngeal disease in comparison to noimals (^ )^.
Assessment by Speech and Language Therapists (SLT) can include sophisticated 
perceptual, acoustic, aerodynamic and endoscopic methods to diagnose and plan 
treatment for voice disorders( '^^). There are a number of protocols available for 
perceptual analysis of the voice, with the GRBAS scale the recognised gold standard 
tool for this in the UK(^^). With this method, overall Grade (Overall degree of voice 
deviance, G), Roughness (impression of irregular pulses or of low frequency noise, 
R), Breathiness (audible turbulent air leakage, B), Asthenicity (A), and Strain (S), is 
assessed on a 4-point scale by SLT to deteimine the degree of vocal impairment. 
Several studies have shown that there is reasonable inter-rater reliability in the use of 
this scale (^ '^^ )^. A number of studies have shown that this scale can correlate with 
various objective acoustic measurements of voice(^^’^ )^ but it is unclear how the 
degree of impairment as determined by SLT relates to patients’ perceptions.
A number of instruments are available for the self assessment of voice quality, 
including the Vocal Handicap Index (VHI)(^^) and Voice Related Quality of Life (V- 
RQOL)(^^). The Voice Symptom Scale (VoiSS) is a 30 item questionnaire which has 
been thoroughly evaluated as a tool for the self assessment of voice quality (^ "^ ’^ )^. It 
consists of a total score with three robust subscales assessing voice impairment, 
emotional reaction and laryngopharyngeal symptoms (physical component). It has 
been extensively investigated and refined in over 800 subjects, its subscales have 
shown good internal consistencies and has been subjected to the most rigorous
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psychometric evaluation(^^). There is no data in for any of the above instruments in 
studies of patients with asthma.
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1.4 Nasal Disease and Asthma
An association between asthma and nasal disease has long been recognised. 
Epidemiological data for the prevalence of allergic rhinitis varies between surveys as 
well as geographically, and its coexistence with asthma has been found to be between 
30% and 80%(^^). The impact of allergic rhinitis on asthma has been comprehensively 
documented (^ )^. A postal survey of 4300 patients in Finland found a significantly 
higher incidence of allergic rhinitis in asthmatics than non-asthmatics (73.1 vs. 
39.6%)(^^). The true incidence of nasal polyps is not known. Their prevalence in 
asthma has been found to be between 7 and 15% with higher frequency in 
patients over 50 years. Aspirin-intolerant patients have a higher frequency again 
(36%)( °^).
It has long been debated to whether nasal inflammation and asthma are part of the 
same disease process and whether appropriate treatment of sinusitis can improve 
asthma symptoms or lung frmction. A recent review(^^) of studies examining the 
surgical treatment of sinus disease concluded that in general the influence on asthma 
is positive. However the benefits are largely subjective and there is large variation in 
the severity of asthma and extent of sinus disease in such studies. While treatment of 
allergic rhinitis in patients with co-existing asthma is recommended by current 
guidelines(^), there is no evidence that this will specifically improve asthma 
control(^^"^ )^.
Nasal symptoms are protean and occur commonly in asthmatic patients(^^’^ )^. In a 
general population survey of 8469 subjects(^®), asthma (and also chronic
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bronchitis/emphysema -  CBE) was found to be more common in patients complaining 
of nasal symptoms than in the whole sample. Nasal symptoms were more frequent in 
asthmatics than those with CBE. In the group with self-reported asthma, there was a 
higher incidence of recurrent or permanent nasal symptoms (46%), compared with a 
general population incidence of recurrent nasal symptoms of 26%. It is not clear from 
these studies however how individual nasal symptoms relate to the likelihood of 
finding specific nasal pathology at nasendoscopy and in day to day clinical experience 
it is difficult to know which patients will benefit fr om seeing an ENT surgeon on the 
basis of their symptoms.
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1.5 Hyperventilation and Dysfunctional Breathing Pattern
Hyperventilation is defined as breathing in excess of the body’s metabolic 
requirements and results in a reduction in arterial pC02, respiratory alkalosis and 
wide ranging symptoms(^^). The term “hyperventilation syndrome (HVS)”, coined 
over 60 years ago described patients with hypocapnic symptoms and those of 
anxiety(^^) and is recognised as a complicating factor in those with severe 
asthma(^’^ )^. Despite this, however, there remains no clear consensus on the gold 
standard for diagnosis of HVS. Demonstration of a respiratory alkalosis by 
measurement of arterial blood gases will be of value during the attack, but will not 
always be helpM when assessing a patient in between episodes. The fact that a degree 
of hyperventilation may be or is commonly seen with symptomatic asthma further 
complicates the issue. It is also clear that some patients, who may not necessarily be 
hyperventilating, may have other breathing pattern abnormalities such as frequent 
sighing or irregularity of breathing(^^) which may manifest themselves as intermittent 
breathlessness or sensation of over-breathing which is perhaps best brought under the 
term “dysfunctional breathing”(^ )^.
It can be difficult to tease out the contribution of these different factors when patients 
report poorly controlled astlima and some patients may be mislabelled as having 
asthma because of atypical breathing symptoms. There is a need to identify the best 
way to diagnose and manage such patients.
The Hyperventilation Provocation Test (HVPT), in which patients voluntarily 
hyperventilate and, if HVS is present, should reproduce their symptoms along with
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demonstrating a delay in the recovery of end-tidal C02 concentration, has been 
proposed as the diagnostic test of choice( '^ '^^^). The ability to accurately categorise 
patients by this test has heen challenged recently with isocapnic over breathing 
recreating a similar amount of HVS symptoms(^^’^ )^. Mental-load tests have also been 
reported to reproduce the HVS symptoms(^^’^ ®°). Furthermore, none of these studies 
have attempted to explore the role of this test in an asthmatic population. In clinical 
practice, progressive exercise testing is often employed to detect hyperventilation but 
there is no data on sensitivity or specificity in its detection of HVS in asthmatics.
The Nijmegen score is a 16-item questionnaire designed to identify patients with 
hyperventilation on the basis of frequency of symptoms such as “feeling tense”, “short 
of breath” and “tingling fingers”. This has been found to have a sensitivity of 91% 
and specificity of 95% in the diagnosis of HVS(^°^) (using clinical diagnosis as the 
gold standard), but this has not been extensively validated in asthmatics. Some of the 
questions relate to typical asthma symptoms with the probability that this would tend 
to overestimate hyperventilation in this group.
There has been interest in recent years in using this questionnafre in patients with 
asthma to diagnose HVS. Thomas(^°^) used the Nijmegen questiomiafre to estimate 
the prevalence of dysfunctional breathing in a primary care sample of asthmatics and 
found that 63/219 (29%) scored positively. It is not clear however how many patients 
also had poorly controlled asthma. In a smaller hospital based survey of 76 patients 
42% had evidence of hyperventilation as determined by Nijmegen and/or HVPT (^ ^^ ). 
The relative proportions of patients diagnosed by Nijmegen score and HVPT is not 
described in this abstract.
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Following identification of dysfunctional breathing, patients are usually managed with 
relaxation techniques or breathing control therapy, however there is very little data 
confirming its efficacy in patients with asthma. Following identification of a group of 
patients with possible dysfunctional breathing (positive Nijmegen score) from a 
General Practice asthma cohort as described above, Thomas went on to conduct a 
randomised controlled trial of breathing retraining(^®' )^. Patients with a positive score 
benefited in terms of health related quality of life scores 1 month after breathing 
retiaining exercises compared to a control group with only improvement in activities 
domain significantly gi'eater than controls after 6 months. The Nijmegen score of the 
study patients fell but the difference was only statistically significant at 6 months. 
There was very little change in asthma therapy in either group in this study during 
follow-up. The patients in this study had mild to moderate asthma and whether this 
can be extrapolated to cohorts in secondary care, with more severe disease has not 
been investigated. In another group of non-asthmatics with HVS, a 2-3 month 
programme of breathing control was found to improve Nijmegen scores(^® )^.
There has also been recent interest in the use of breathing training in patients with 
asthma. The Buteyko breathing technique (which addresses asthma symptoms rather 
than hyperventilation) reduced asthma symptoms and bronchodilator use compared 
with placebo in a randomised controlled trial of patients with symptomatic asthma and 
ongoing airflow obstruction (^ *^ )^. A recent review (^ ^^ ) confirmed that while there is 
no evidence that routine measures of lung function are improved, there is a general 
trend of improvement in quality of life measurements with this method.
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There are no comparative data on the most effective form of breathing retraining nor 
which health care professional (physiotherapist, speech and language therapist) should 
administer it.
In addition to the above diagnostic tests for the clinical syndrome of HVS, the 
breathing pattern of the patient can also be assessed. Several methods exist for 
measuring this objectively. Using respiratory inductive plethysmography (RIP), rib 
cage movements can be analysed to calculate respiratory frequency, tidal volume and 
minute ventilation, mean inspiratoiy time and fractional inspiratory time(^^^). Tobin 
recorded breathing pattern by RIP over a fifteen minute period (after ten minutes rest) 
in symptomatic asthmatics and found an increased tidal volume, minute ventilation 
and shortened fractional inspiratoiy time without an increase m respiratory fi'equency 
compared to non-asthmatics(^^^’^ °^). Asymptomatic asthmatics had no difference in 
their breathing pattern compared to normals.
The breathing pattern can be influenced by breathing through a mouth-piece. This has 
heen shown to increase tidal volume(^^^’^ ^^ ) and in one series decrease respiratory 
frequency(^*^) compared to natural breathing monitored with an external device. 
However, although mean values change, the breath to breath variability does not 
change when breathing via a mouthpiece and nose-clip(^^^). Measuring breathing 
pattern with the RIP device is however potentially too time-consuming to be of a 
practical use in an out-patient clinic setting and it is not entirely clear if these long 
sampling periods are important.
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1.6 Psychological correlates of asthma
Although in the past asthma was considered primarily a psychological condition, 
experience with inhaled corticosteroids and other treatments over the past 40 years 
has emphasised the importance of airway inflammation, bronchial hyper-reactivity 
and smooth muscle spasm as key patho-physiological factors. Nevertheless, there is 
evidence of a role of psychological factors contributing to asthma morbidity.
Firstly, studies of fatal or near fatal asthma have found evidence of psychological 
factors present in such patients ^ population study of 95 cases of death due
to asthma in Scotland over 3 years in the mid-1990’s, retrospective questioning of 
patients’ General Practitioner revealed presence of any psychological or social factor 
in 55 / 95 (58%) and specific depression in 10 / 95 (11%)(^ '^ )^. Campbell examined 
characteristics of 154 patients who had suffered a near fatal attack of asthma and 80 
who had died from asthma. 17% and 22% respectively had undergone psychological 
assessment, but the precise frequency of definite or even GP reported psychiatric 
caseness in this study is unclear In a more detailed study of 77 patients with near 
fatal asthma, 33 (43%) scored positively on the General Health Questionnaire 
suggesting a co-existing psychiatric diagnosis(^^^).
Clinic based studies have also examined this issue. Using the General Health 
Questionnafre to detect a psychiatric disorder, ten Brinke found 2 1 / 9 8  (21.4%) of 
patients with severe asthma scored positively (*^ )^. Another study also suggested that 
psychiatric caseness is more prevalent in brittle asthma compared with non-brittle 
asthma (^ ^^ ). In a group of 73 patients with asthma evaluated in a tertiary centre to
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examine the factors predicting therapy resistant asthma (TRA), Heaney found 32 / 65  
patients who attended for psychiatric interview had an ICDIO psychiatric diagnosis 
(^ 19) Nascimento found 45 / 86 (52.3%) of asthma clinic patients had evidence of at 
least one anxiety disorder while another survey found an increased prevalence 
compared to controls of panic disorder and agoraphobia
Population based studies have shown disparate findings. Janson, in a random selection 
of 708 people (from an original random population sample of 3600), found no 
relationship between anxiety or depression and evidence of asthma (either self 
reported or by objective measures) (^ ^^ ). More recently however a large population 
based study found that, of the 7619 out of a possible 10,080 subjects, who participated 
in the study, there was a higher prevalence of psychological distress (17.9% vs. 
12.2%), anxiety / depression (40.5% vs. 31.2%) and specific mental health conditions 
(16.2% vs. 10.8%) in 834 patients who had self reported asthma (^ ^^ ). The Kessler 
Psychological Distress Scale was used in this study, and no objective clarification of 
asthma was sought. Rimmington found that levels of anxiety and depression 
(measured by the HAD score) were related to levels of symptoms but not with 
measures of lung function (^ "^^ ).
It is therefore likely that asthma is associated with psychological morbidity and that 
such factors are more common in severe asthma and contribute to some asthma deaths.
The Hospital Anxiety and Depression scale (HAD) is a simple, self-assessment 
instrument to detect anxiety and depression in the outpatient setting (^ ^^ ). Patients are 
scored on 7 items for both anxiety and depression, each on a scale of 0 to 21. A score
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of > 11 is said to indicate definite anxiety or depression, with score 8 - 1 0  being 
borderline. Several studies have used this tool in the setting of an asthma clinic, which 
are discussed further with reference to our results in Chapter 2.
The Asthma Quality of Life Questionnaire (AQLQ) is a valid instrument with 
excellent measurement properties in terms of evaluation and discrimination of aspects 
of impairment of function, of most concern to patients with asthma Four
domains are assessed: symptoms, emotional function, environmental stimuli, and 
activities limitation. The AQLQ has 32 items and can be self administered. A shorter, 
15 item version of this questionnaire, the “Mini-AQLQ” has been developed and 
validated This also measures impairment in the aforementioned 4 functional 
domains. In the 9 week observational study where the instrument was validated, the 
Mini-AQLQ was administered with the full AQLQ and was found to have good 
reliability and responsiveness The Mini-AQLQ is increasingly being used in 
clinical trials of asthma treatment to measure quality of life outcome The
minimal clinically important change is +/- 0.5 on the 7 point scale
Self management programmes are an integral aspect of asthma management, and 
current guidelines advise this for all patients with asthma ( )^. Different patients may 
have differing perception of their ability to control then condition, and a specific 
questionnaire has been developed to measure an individuaFs level of perceived 
control of day to day asthma and exacerbations C^^). In the validation study of the 
Perceived control of asthma questiomiaire (PCAQ), greater perceived control was 
associated with greater asthma self efficacy (evaluated by a separate self-efficacy 
score) and better asthma-specific quality of life (measured by the Marks Asthma
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Quality of Life Questionnaire). The authors hypothesised that asthma self 
management education might improve perceived control and asthma quality of life. 
This has not been extensively studied, but one recent study found PCAQ scores 
improved along with AQLQ scores following a behaviour modifying education 
programme to enhance self-management skills and promote behaviour change (^ ^^ ).
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Aims of the Thesis
We hypothesise that a significant number of patients attending the PAC have co­
existing upper airway problems contributing to ongoing symptoms. We wish to 
determine the precise nature of these diagnoses and the optimal diagnostic evaluation. 
We propose that breathing control for the treatment of dysfunctional breathing in our 
cohort of patients will improve asthma related quality of life and Nijmegen scores and 
that such therapy will influence physiological measurements of breathing pattern.
This thesis will therefore address the following primary research questions:
1 What are the clinical characteristics of the patients referred to the PAC? 
What proportion have definite asthma, what is their psychological 
profiling and is there any evidence this changes with treatment 
optimisation?
2 What is the spectrum of upper airway problems in a Problem Asthma 
Clinic? More specifically, what is the frequency of Vocal Cord 
Dysfunction and the role of the Forced Oscillation Technique in its 
diagnosis?
3 What is the degree of voice morbidity in the PAC, and how does perceived 
morbidity by the patient relate to assessment by an experienced Speech 
and Language Therapist?
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4 How well do upper airway symptoms predict structural or functional 
abnormalities of the nasal cavity or larynx?
5 Is there a role for routine rhinoscopy in a problem asthma clinic?
6 What is the role of histamine challenge and progressive exercise testing in 
the diagnosis of Vocal Cord Dysfunction?
7 What are the breathing pattern characteristics of patients attending the 
PAC?
8 Do patients with asthma suspected of having dysfunctional breathing / 
Hyperventilation Syndrome (HVS) have a different breathing pattern from 
other patients?
9 Does breathing control training influence breathing pattern, Nijmegen 
scores and asthma related quality of life in patients with moderate to 
severe asthma?
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CHAPTER 2
REFERRALS TO THE PROBLEM ASTHMA CLINIC
CHARACTERISATION OF A NEW PATIENT COHORT
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2.1 Introduction
With the background of recently published studies detailing the systematic
assessment of patients with asthma in tertiary centres, and to provide a context for the 
observational studies described undertaken, we aimed to describe the characteristics 
of a cohort of new patient referrals to a Problem Asthma Clinic. Referrals to the clinic 
come from a number of sources. Firstly, there are patients from local general 
practitioners felt to need management input from secondary care, many of whom have 
been uncontrolled on escalating asthma treatment as recommended by British 
Thoracic Society Guidelines. Some of these will require a relatively brief period of 
assessment and optimisation of therapy allowing discharge from clinic, whereas 
others will have more severe disease requiring more intensive assessment and 
management. “In-house” referrals consist of patients with a recent asthma 
exacerbation requiring a brief period of treatment optimisation while others with 
severe asthma will be referred by other respiratory consultants within Glasgow Royal 
Infirmary. Finally there are some patients referred form other respfratory units from 
the suiTOunding region.
The aims of assessment were firstly to confirm (or refute) the diagnosis of asthma and 
to identify any co-existing or alternative respiratory diagnoses. In addition we aimed 
to identify the extent of psychological aspects which might impact on management, or 
be influenced by treatment optimisation and to examine the relationships between 
them. The clinic strategy, in terms of asthma management, was to optimise symptom 
control through appropriate inhaled and other therapy and encourage patients with 
exacerbations despite this to self manage effectively. We hypothesised that such an
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approach would have beneficial effects in terms of disease specific quality of life and 
level of perceived control of asthma.
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2.2 Methods
All new patient referrals (sources as previously decribed in section 2.1) to the PAC 
over a 1 year period (August 2003 to July 2004) were studied. As well as history and 
examination, baseline Mini-Asthma Quality of Life Questiomiake (Mini-AQLQ)( ^ ^ )^, 
Nijmegen ( °^^ ), Hospital Anxiety and Depression (HAD)(^^^) and Perceived Control 
of Asthma Questionnaire (PCAQ)(^^^) responses were collated (Appendix 1). We used 
the Mini-AQLQ because of concerns the full AQLQ would have over-burdened our 
patients. As shown in the clinic investigation protocol (Appendix 2), all patients who 
scored positively on the depression sub-scale of the HAD (>11) were offered an 
appointment with a clinical psychologist. All patients scoring positively on Nijmegen 
(> 23) were refen’ed for breathing control therapy with our respiratoiy physiotherapist. 
At initial clinic visit, all patients were asked to complete morning and evening PEFR 
diary until next seen (usually 2-4 weeks later). Full pulmonary function testing was 
aiTanged for all patients. If these tests did not confirm asthma, the next investigation 
depended on lung function. If post bronchodilator FEVi was <80% predicted, 2 weeks 
of prednisolone 30mg once daily was given with repeat PFT to determine best lung 
function and steroid responsiveness. If lung function was nonual, with no 
bronchodilator reversibility demonstrated (and PEFR diary showed no significant (< 
15%) diurnal variability) a histamine challenge was requested to determine presence 
or absence of bronchial hyper-reactivity.
Asthma treatment was adjusted according to current British Thoracic Society 
guidelines (^), based on symptoms and PEF readings where available. Patients who 
had persistent symptoms and / or sub-nonnal lung fimction during follow up were
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refeixed for pH studies to determine presence and degree of gastro-oesophageal reflux 
disease (GORD) and also for ENT assessment, which was directed to either a 
laryngologist or rhinologist depending on whether laryngeal or nasal symptoms were 
prominent. Specialist respiratory physiotherapy input was offered if disproportionate 
breathlessness was a feature as noted above
After one year or at discharge from clinic, follow up data as illustrated in Appendix 3 
along with repeat questionnaires were collected.
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2.3 Results
Baseline Clinical Data
59 patients (19 male, 49 female) were referred to the PAC over the 1 year period 
described above. 10 did not attend on any occasion despite being sent further 
appointments with encouragement to attend. Of the remaining 49, 34 were female and 
15 male with a mean (SD) age of 45.3 (16.7) years.
Baseline data were collected in 44 / 49 (89.8%) patients. In 22 of these patients prior 
objective evidence of asthma was available (7 with reversible airflow obstruction, 15 
with variable PEFR). Smoking status was documented in 42 / 44 patients, with 19 
never smokers, 14 ex-smokers and 9 (21%) current smokers. Pack year smoking 
history was recorded in 18 / 23 of the current or ex-smokers (mean 14.1 pack years). 
Baseline level of asthma treatment is shown in Figure 1. In 1 patient treatment was 
not documented.
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Figure 2: Baseline level of asthma treatment (n= 44, N/D = Not Documented)
2 3 4
BTS Treatment Step
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The exposure to oral corticosteroid (OCS) courses, A&E attendances and hospital 
admissions over the year prior to first clinic attendance are given in Table 1. Two 
patients had previously been admitted to ITU and 1 had been previously ventilated for 
acute asthma.
Table 1: Frequency of exposure to oral corticosteroid courses, A&E attendances and 
hospital admissions in year prior to clinic attendance
Range Median (IQR) Mean (SD)
OCS courses 0 -2 0 2 (0 -4 .5 ) 3.06 (3.61)
A & E  Attendances 0 - 4 0 ( 0 -1 ) 0.63 (1.8)
Hospital admissions 0 - 7 0 (0 -1 ) 1.0(1.41)
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Baseline Questionnaire Data
Only 36 / 49 patients who attended filled out all 4 questionnaires completely. Data 
was available for Mini-AQLQ in 42, HAD in 43, PCAQ in 37 and Nijmegen in 43 
patients. Baseline questionnaire results for all questionnaires and their relevant 
domains are shown in Table 2. As described in the Introduction, higher Mini-AQLQ 
indicates better asthma related quahty of life, higher PCAQ indicates better level of 
perceived asthma control. Individual Mini-AQLQ domain scores are the mean of 
relevant responses and total Mini-AQLQ is the mean of all 15 responses. Higher HAD 
and Nijmegen scores are associated with greater levels of anxiety / depression 
symptoms and possible dysfunctional breathing symptoms respectively. All 
parameters were normally distributed.
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Table 2: Baseline Mini-AQLQ, HAD, PCAQ and Nijmegen scores
QUESTIONNAIRE RANGE MEAN (SD)
Mini-AQLQ 
Domain 
(all range 1 -  7), 
n = 42
Symptom 1 -6 .8 3.33(1.31)
Environment 1.33-7.0 4.08 (1.55)
Emotion 1.0-7 .0 3.31 (1.35)
Activities 1 .0-7 .0 3.93 (1.52)
Total Mini-AQLQ 1.33-6.2 3.63 (1.23)
HAD, n = 43 Anxiety (0 -  21) 0 - 2 0 8.98 (4.74)
Depression (0 -2 1 ) 1 -1 6 6.70 (3.83)
PCAQ (11-55), n =  37 2 2 -4 7 33.24 (5.91)
Nijmegen (0 -  64), n = 43 1 -5 3 23.49 (10.89)
17 /43 (39.5 %) patients scored positively on the anxiety subscale of the HAD and 7 
(16.3 %) positive on the depression subscale. 23/43 (53.5 %) patients had positive 
Nijmegen scores.
The relationships between each questionnaire are shown in Table 3. All correlation 
coefficients are Pearson correlations, given the normal distribution of all parameters.
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Table 3: Inter-relationships between questionnaire scores
Questionnaire Congélation Coefficient, p value
Mini-AQLQ vs. Nijmegen -0.57, p <  0.001
HAD (Anxiety) -0.42, p = 0.006
HAD (Depression) -0.52, p <  0.001
PCAQ 0,71, p <  0.001
Nijmegen vs. HAD (Anxiety) 0.70, p <  0.001
HAD (Depression) 0.57, p <  0.001
PCAQ -0.30, p = 0.07
PCAQ vs. HAD (Anxiety) -0.33, p = 0.049
HAD (Depression) -0.41, p = 0.012
Although all except one of the above correlation reached statistical significance, 
Figures 3a- 3i demonstrate that the relationships appear much stronger for some 
parameters. In particular, Nijmegen had a very strong relationship with the anxiety 
component of HAD. The relationships for PCAQ with HAD and Nijmegen were less 
convincing, although that with Mini-AQLQ was very strong.
Follow Up Clinical Data
1/10 who never attended over the 12 months was subsequently admitted with acute 
asthma and had good documented evidence of peak flow variability, consistent with a 
diagnosis of asthma. In many cases follow up data was recorded through case note 
review rather than at the appropriate time point 1 year from initial clinic attendance, 
due to variable attendance at clinic. It was not possible to collect any follow up data
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for 2 patients. Of the 49 patients who did attend the clinic on at least one occasion, 39 
(79.6%) were found to have a definite diagnosis of asthma. Table 4 illustrates the 
frequency of various diagnostic features (best objective evidence of asthma available) 
of these 40 patients (including the 1 patient admitted with acute asthma).
Table 4: Best objective evidence of asthma available at follow up.
BEST OBJECTIVE EVIDENCE NUMBER OF PATIENTS
PEFR Variability (> 15%) 9
Airflow obstruction with Bronchodilator 
Reversibility
24
Bronchial Hyper-reactivity on Histamine 
Challenge
2
Trial of oral corticosteroids showing 
reversible airflow obstruction
5
In the 10 patients who had no objective evidence of asthma, 1 patient attended the 
clinic but never attended for relevant investigation and 9 had objective evidence of 
alternative diagnoses:
• COPD (5 patients -  all with irreversible airfow obstruction and all with 
smoking history of over 20 pack years)
• Gastro Oesophageal Reflux Disease (GORD) (2 patients with clinical 
diagnoses supported by laryngoscopic signs of reflux and improvement 
with anti-reflux treatment. Both failed to attend for pH studies)
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• GORD and Bronchiectasis (1 patient with abnormal pH study and 
HRCT evidence of bronchiectasis)
• Hyperventilation (1 patient -  demonstrated on progressive exercise 
testing)
Co-morbiditv in those with definite asthma
10 / 39 with definite asthma had evidence of respiratory co-morbidity, as follows:
• hyperventilation / dysfunctional breathing pattern (5 patients) which was 
diagnosed on the basis of combination of Nijmegen scores and specialist 
physiotherapy assessment,
• allergic bronchopulmonary aspergillosis (2 patients (elevated total IgE, 
positive aspergillus precipitans, CXR infiltrates improved with steroids), 1 
also with HRCT evidence of bronchiectasis),
• sub-pleural fibrosis on HRCT (presumed UIP, 1 patient),
• probable COPD component (1 patient with only minor bronchodilator 
reversibility (3%) and 10 pack year smoking history)
• tracheal tumour ( 1 ).
11 / 39 (28%) were referred for ENT assessment (9 rhino logical, 2 laryngo logical 
assessment). Of the 2 referred for laryngeal assessment, 1 had normal appearances 
and 1 had evidence of mild chronic laryngitis. In terms of nasal disease, significant 
pathology was identified in 7 patients - nasal polyps (3), rhinitis (2), sinusitis (1) and 
deviated nasal septum requiring further treatment (1). Gastro-oesophageal reflux 
(GORD) was suspected in 13 patients, on the basis of ongoing wheeze and /or reflux
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symptoms, and these were referred for pH studies. Only 1 of these patients attended 
and significant GORD was identified and treated. HRCT scans were not routinely 
requested to look for bronchiectasis.
Level of asthma treatment at follow up is shown below (Figure 4). In 8 patients the 
level of treatment was not documented. Of the 37 patients with known treatment level 
at baseline and follow up, 3 were up 2 BTS treatment levels, 8 were up 1 treatment 
level, 8 were down one, 1 was down two and 1 final patient down 3 treatment levels.
Figure 4: Level of asthma treatment at follow up (n = 41)
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Data on best lung fimction was available for 42 patients. This is shown in Table 5. 
Spii'ometric values are post-bronchodilator.
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Table 5: Best available lung function
Parameter Range Mean (SD)
FEVi (litres) 0.84-4.1 2.30 (0.94)
FEVi (% predicted) 30-119 80.4 (24.9)
FEVi/FVC 30-86 66.7 (12.3)
Bronchodilator reversibility 
(% of baseline FEVi, n = 22) 10-86 31.8(20.9)
S elf Management
19/40 patients with confirmed asthma had a self-management plan in place, of whom 
8 were felt to be self managing effectively, as judged from their reported management 
of interval exacerbations.
Follow Up Questionnaire Data
Follow up data for all 4 questionnâmes were only complete for 12 patients, although 
Mini-AQLQ was completed in 17, HAD in 18, PCAQ in 14 and Nijmegen in 16 
patients. The most frequent reason for this was non-attendance at the clinic by the 
time follow up data was due for collection, either due to prior discharge of failure to 
attend. Time restraints on patients' part when filling in questionnaires accounted for 
incomplete data in 6 patients. Table 6 illustrates the available follow up questionnaire 
scores. As with baseline data, all parameters were normally distributed. Table 6 also 
demonstrates that there were no differences between any parameters at follow up 
compared to baseline (Mann-Whitney U-tests). 7 / 1 7  with Mini-AQLQ data at
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baseline and follow up showed a clinically significant improvement of > 0.5 points. It 
is not possible to make definite comments from our data on featui'es that distinguished 
this sub-group from the whole cohort. There was no significant change in level of 
asthma treatment (1 patient had gone from BTS step 5 to step 4 treatment), 2 had 
GORD, 1 had ABPA, and 4 were felt to be self managing effectively.
Table 6: Available follow up questionnaire data.
QUESTIONNAIRE RANGE MEAN (SD) 95% Confidence 
Interval for difference 
compared to baseline
Mini-AQLQ 
Domain 
(all range 0 -  7), 
n =  17
Symptom 1.0-7 .0 3.42 (1.71) -1.0, 0.80
Environment 2 .0 -7 .0 4.0 (1.48) -0.67, 1.67
Emotion 1.67-7.0 3.84(1.69) -1.33,0.67
Activities 1 .0 -7 .0 3.81 (1.82) -1.50, 1.25
Total Mini- 
AQLQ
2.0 -7 .0 3.73 (1.55) -0.87, 0.87
HAD,n= 18 Anxiety (0 -2 1 ) 0 - 1 7 8.06 (5.06) -4.00, 4.00
Depression
(0 -2 1 )
0 - 1 4 6.0 (4.41) -3.00, 4.00
PCAQ (11-55), n =  14 2 8 - 4 4 35.57 (5.43) -7.00, 3.00
Nijmegen (0 -  64), n = 16 1 0 - 4 2 23.75 (10.70) -8.00, 5.00
Even in the small subgroup of patients who had clear self management plans in place 
and for whom baseline and follow up Mini-AQLQ and PCAQ were available (n= 10 
for Mini-AQLQ, n = 7 for PCAQ) , there were no differences at follow up (95% Cl’s
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for difference compared to baseline -1.67, 0.67 for Mini-AQLQ, -9.0, 2.0 for PCAQ). 
5 / 10 of these patients with Mini-AQLQ data had a clinically significant (> 0.5) 
improvement in their Mini-AQLQ.
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Figure 3a: Mini AQLQ (Total) vs Nijmegen
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Figure 3b: Mini-AQLQ (Total) vs. HAD (Anxiety)
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Figure 3 c : Mini-AQLQ (Total) vs HAD (Depression)
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Figure 3d: Mini-AQLQ (Total) vs PCAQ
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Figure 3e -  Nijmegen vs HAD (Anxiety)
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Figure 3 f -  Nijmegen vs HAD (Depression)
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Figure 3g -  Nijmegen vs PCAQ
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Figure 31: PCAQ vs. HAD (Depression)
HAD (Depression)
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2.4 Discussion
We have described a variety of characteristics of patients refeiTed to a Problem 
Asthma Clinic for assessment and treatment optimisation. The primary aim of 
assessment is to establish or refute the diagnosis of asthma, in order to avoid 
(potentially further) unnecessary treatment and direct attention elsewhere if a different 
diagnosis is made. In 9 / 4 9  (18%) we found no evidence of asthma and confirmed an 
alternative diagnosis. Furthermore 10 of the 39 (26%) patients with definite asthma 
had evidence of an additional diagnosis. Although these findings may under­
represent other diagnoses, since we selectively targeted investigations such as pH 
studies to those with persisting symptoms after asthma treatment optimisation, they 
shed light on the day to day reality of patients attending a problem asthma clinic.
In the study by Robinson et al (^ ^^ ), 12/100 patients refeiTed to a tertiary centre with 
difficult asthma were found not to have asthma (most frequently COPD) and those 
who did have asthma frequently had co-existing problems, especially rhino sinusitis 
(40 patients). Additional respiratory diagnoses in those with asthma were however 
less frequent (6 patients, most frequently bronchiectasis).
Heaney’s study (^ ^^ ) examined factors predictive of therapy resistant asthma in 73 
patients with asthma out of 86 originally referred for evaluation and 25 / 73 (34%) had 
evidence of respiratory co-morbidity, similar to our 26%.
It is not surprising that the level of treatment for the group did not change greatly, 
although individuals in whom co-morbid factors were identified and appropriately
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treated experienced significant reductions in asthma therapy, particularly in the use of 
oral corticosteroids.
18/49 (36.7%) patients at follow up were documented as having a self management 
plan (SMP) in place. The clinic protocol aimed to ensure all patients spent time with 
the clinic asthma specialist nurses to discuss self management skills, over a number of 
clinic visits. Clinical experience tells us that some patients are more receptive to this 
than others, this being influenced in part by the likelihood of exacerbations, rather 
than persistent symptoms.
We suspected GORD was a common co-existing problem in this patient group on the 
basis of reported symptoms, and the poor attendance for confiimatory pH studies (1 / 
13 requests) prevents further comment in this cohort. In a cohort from the same clinic 
seen over a more prolonged time period, GORD has been found to be a significant 
issue in asthma patients with persistent symptoms, after treatment optimisation. In this 
larger group, only 7 of 47 patients referred failed to attend for pH study (15%), with 
18 having no evidence of GORD (38%) and 22 having GORD proven (47%) (Dr CE 
Bucknall, personal communication). The inter relationship of these two common 
conditions and the impact of one on the other remains an area of controversy (^ ^^ ) 
which still requires further systematic investigation. Clinical experience confirms the 
existing literature, showing that some patients experience major improvements in 
asthma symptom levels and reduction in asthma treatment requirements when GORD 
is abolished, and this was the rationale underpinning this aspect of the clinic protocol.
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Our baseline questionnaire data demonstrated the frequent occurrence of anxiety (17 / 
43 (39%) and depression 7 / 4 3  (16%). Varying frequencies of anxiety and depression 
have been found in other studies using the HAD, which may relate to the asthma 
population being studied. In Janson’s study which looked more widely at respiratory 
symptoms in relation to anxiety and depression, 708 patients from a general 
population of 3600 completed HAD, with frequencies of 16% for anxiety and 22% 
for depression in the 108 patients with doctor diagnosed asthma Bosley found a 
complex interaction between various psychological parameters and compliance with 
asthma medication, but in the 72 patients studied (all on at least BTS step 3 treatment), 
respective frequencies of HAD positive anxiety and depression were 25% and 4.2% 
(^ ^^ ). In a further study of 114 primary care patients with asthma where only 30% 
were on BTS step 3 treatment or above (52% on BTS step 2), relative frequencies 
were 34% and 10% (^ "^^ ). The population studied by Heaney to predict therapy 
resistant asthma were evaluated thoroughly for psychiatric morbidity HAD 
scores were collected for all 73 patients with asthma (34 classified subsequently as 
therapy resistant asthma -  TRA) and 65 attended for psychiatric assessment. In the 
TRA and non-TRA groups, mean Anxiety scores were 10.7 and 11.2 respectively and 
depression scores 7.5 in both groups. These seem comparable to our results (mean 
anxiety 9.0, depression 6.7). Heaney found 32 / 65 patients who attended for 
psychiatric inteiwiew had an ICDIO psychiatric diagnosis, only 6 of whom had had 
this identified previously. Positive and negative predictive values, using a cut off of 
11 on the HAD were 74% and 73% respectively for all psychiatric diagnosis and 67% 
and 89% for depressive illness. We are not able to comment on the accuracy of this 
strategy in our cohort, not having any gold standard psychiatric assessment, but fr'om 
Heaney’s experience it is likely that we missed some cases of depression. A number
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of patients defaulted from clinical psychologist attendance, although there were 
notable examples of individuals who benefited greatly.
We found a statistically significant correlation between HAD scores for both anxiety 
and depression and Mini-AQLQ. Figures lb  and Ic however do show quite a spread 
of data within this relationship. This data is consistent with other studies which have 
demonstrated correlation between HAD and measures of asthma related quality of life 
i^24;i37^  Similarly, the relationship found between Mini-AQLQ and PCAQ is 
consistent with data from the validation of the PCAQ and also later work 
which found a reasonable relationship with Mark’s Asthma Quality of Life 
Questionnaire.
Nijmegen scores also correlated with Mini-AQLQ (-0.57, p < 0.001) and there was a 
very strong relationship seen between Nijmegen and HAD (Anxiety) (0.70, p < 0.001), 
perhaps reflecting the close relationship between symptouK assessed as related to 
dysfunctional breathing on the Nijmegen questionnaire and those related more 
generally to heightened awareness of bodily sensations as part of generalised anxiety.
Although statistically significant, the relationships between HAD / PCAQ and 
Nijmegen / PCAQ are not particularly convincing as illustrated by Figures Ig-i.
It is disappointing that we only were able to collect follow up questionnaire data in 18 
patients and that this was incomplete in 6 cases. Heaney (^ ^^ ) also observed a 
significant default rate in his clinic population. We did not demonstrate a change in 
any parameter (in particular Mini-AQLQ or PCAQ) in this small number with
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complete data. We did not mail questionnaires to patients who were not in attendance 
at the clinic or who had defaulted from attendance following earlier visits, as we felt 
the lack of information on cuiTent treatment and symptoms levels would have acted as 
an unquantified confounding variable.
In the subgroup with clear self management plans in place again we found no 
significant differences in Mini-AQLQ or PCAQ scores. We measured PCAQ 
specifically to assess its usefulness as a tool for judging benefit fr om self management. 
Given the small number of patients (n = 7) who had baseline and follow-up PCAQ 
and a SMP, it is difficult to comment on this further.
As discussed earlier there is only limited data available for PCAQ in the literature. In 
a non-randomised observational study, PCAQ was found to improve by a mean of 4.8 
points 3 months after completing a comprehensive asthma education and self 
management programme This compares with a median change of -2 in our 
patients, (95% Cl -7, 3 -  Table 6). Unlike the Mini-AQLQ however, the minimal 
clinically important change in score has not been deteimined.
In summary this description of a cohort of new refen'als to a problem asthma clmic 
illustrates the importance of seeking objective clarification of asthma. Our 
observational data is consistent with other reported cohorts and confirms the 
frequency of psychological issues in patients with asthma. We have examined the 
relationships between different psychological con'elates of asthma. This data has been 
used to adjust our clinic protocol (Appendix 4) and provides further information on 
the use of such questionnaires as screening tools for problems which may not be
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immediately apparent in the busy clinical setting. Further details of particular aspects 
of this patient group’s co-morbidities are described in greater detail in subsequent 
chapters.
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CHAPTER 3
THE SPECTRUM OF UPPER AIRWAY PROBLEMS IN A 
PROBLEM ASTHMA CLINIC
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3.1 Introduction
The purpose of this study was to examine the upper aii-way in patients attending the 
PAC. Patients were enrolled in a pilot study involving laryngeal, physiological, nasal 
and vocal assessment. As detailed in the Aims of the Thesis, there were a number of 
specific questions we set out to answer with this study. For purposes of clarity, the 
results and their discussion have been divided into (1) Laryngopharyngeal 
Assessment; (2) Physiological Assessment; (3) Vocal Assessment and (4) Nasal 
Assessment.
Firstly we aimed to identify the frequency of VCD in our clinic population. The 
relationship between upper airway symptoms and structural or functional 
abnormalities of the larynx was then explored.
We wished to evaluate the Forced Oscillation Technique in VCD diagnosis along with 
a thorough physiological assessment of the upper airway. We hypothesised that 
airway resistance in inspiration would correlate with upper aiiivay obstruction, such 
as occurs in VCD.
The aim of the vocal assessment aspect of the study was to characterise the vocal 
quality along with the laryngeal appearances above and to relate this to patients’ and 
SLT perception of vocal morbidity. A secondary aim was to assess the local inter­
rater reliability of the GRBAS scale among SLTs.
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The purpose of the nasal assessment arm of the study was to characterise the spectrum 
of nasal symptomatology and nasendoscopic abnoimalities in patients attending the 
PAC. We sought to examine the predictive value of key symptoms for abnormalities.
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3.2 Methods
All patients attending the PAC were eligible for inclusion. Initially 121 letters of 
invitation to take part in the study were sent to patients attending the clinic. If no 
response was obtained, attempts were made by telephone or when being seen at clinic 
to reiterate our invitation. Additional patients (who did not receive a letter) were 
invited to participate from the clinic. 60 patients (17 of whom subsequently withdrew) 
agreed to take part in the study and therefore 43 patients were ultimately included in 
the protocol which was approved by North Glasgow University Hospitals NHS Trust 
Local Research and Ethics Committee (REC Reference Number 03RE002 / 03RE008). 
The protocol involved attendance on a single afternoon. All patients gave written 
informed consent for then participation in the study. Assessments were made in the 
following order: Baseline data / physiological assessment, vocal assessment, nasal / 
laryngopharyngeal assessment.
Baseline data
Level of cun*ent treatment and symptoms of asthma morbidity(^^^) were recorded 
using the Royal College of Physicians (RCP) 3 symptom score (days and nights 
affected by asthma symptoms, and days of limited activity due to asthma over the 
previous seven days, giving a score ranging from 0 to 21).
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Forced oscillation technique (FOT)
Forced oscillometry was measured using the machine designed by Birch(^^^) 
following the practice described in recent g u i d e l i n e s . I n  brief, the subject 
performed tidal breathing through a mouthpiece with nose occluded and cheeks 
supported for two separate periods of one minute. A bias flow of 0.25L/s of air was 
fed into the breathing circuit to minimise re-breathing. Impedance was measured 
using a single sinusoidal excitation frequency of 5Hz and calculated from the flow 
and pressure waveforms using the method based upon power spectra adapted for 
within-breath a n a l y s i s , O n l y  the real part of the impedance value, resistance, was 
used in this study. This was low pass filtered to remove biological noise using a 
Butterworth 8-pole filter with a cut-off frequency of 5Hz. In line with current 
g u i d e l i n e s , d a t a  from the first 30 seconds of each recording was discarded, to 
allow the patient time to get used to the mouthpiece. In addition to an average value 
over all the breaths (Rt), separate values were obtained for the inspiratory (Ri) and 
expiratory (Re) phases by averaging over the relevant part of the respiratory cycle. 
Data from each sampling period was used to give the overall value for each phase.
Pulmonary Function Testing
Standard spirometry and flow volume loops were measured using a body 
plethysmograph. This was performed after FOT, Measured variables included Forced 
Expiratory Volume in 1 second (FEVJ, Forced Vital Capacity (FVC), maximum mid- 
inspiratory and expiratory flow (MIF^ ,^ MEF^J and MEF^/MIF^g ratio. All pulmonary 
function tests were performed to the guidelines of the British Thoracic Society and
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Association of Respiratory Technicians and Physio l e g i s t s . P r e d i c t e d  normal 
values were determined using the European Community for Steel and Coal equations 
for all variable s.
In addition to FOT measured airways resistance, Occlusion resistance (R^J was also 
measured as a further measure which has been shown to be helpful in the assessment 
of airway calibre. This has otherwise been termed inteiTupter resistance 
This was performed using the body plethysmograph and the method of Van Altena 
and Gimeno.(^'^) All measurements were carried out with the subjects seated with the 
neck slightly extended; the cheeks and pharynx were not supported during the 
measurements. During tidal breathing, a shutter closes automatically within 10ms 
after peak expiratory flow and stays closed for 100ms. Mouth pressure was estimated 
by linear back-extrapolation of the post occlusion signal. R^^^  was calculated by 
dividing mouth pressure by flow at the time of occlusion. The value of R^ ^^  was 
calculated as a mean value of 5 sequentially obtained satisfactory measurements 
during expiration.
Vocal Assessment
Patients completed the 30-item self administered VoiSS questionnaire (Appendix 5). 
Voice recordings were then performed in a soundproof booth housed within the 
Otolaryngology department. Recordings were made using digital tape recorder and 
digital audio tape (DAT). Patients were asked to speak approximately 10 to 15 cms 
away from the microphone. They were asked to give a few seconds of simple 
spontaneous speech (name, how they got to hospital that day, what they had for dinner
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and watched on TV the previous evening) before reading the standard “Rainbow 
passage’X^"^ )^- These recordings were made in the presence of one of 2 independent 
observers who were not involved in any further data analysis.
Digital audio tapes of the patients’ recordings were transferred on to two compact 
discs (CDs). Each CD had every patient’s recording, randomised, with anonymised 
personal details and in a different order. Each patient’s recording therefore 
corresponded to an individual track on each CD. A master list was kept with the track 
numbers linked to patient names which was not seen by the raters.
The raters were three experienced SLT’s familiar with the GRBAS scale. Raters 
graded the patients’ voices according to the GRBAS score with a further assessment 
of fluctuations in voice quality (Instability - (I)) (^ ^^ ). Each subscale was assessed on a 
4-point scale of 0-3 to determine the degree of vocal impairment. Each CD was 
listened to and independently rated by the same 3 experienced Speech and Language 
Therapists at least 7 days apart. Every patient therefore had their voice scored by the 
same 3 SLT observers on 2 occasions.
Mean values for each GRBAS (I) subscale for each patient were calculated from the 6 
scores. Total GRBAS scores were calculated using the means of each subscale with 
the exception of the Instability component, as this is not in widespread use.
The VoiSS questionnaires were scored according to the total score and the 3 subscales 
of voice impairment (15 items, score range 0 - 60), emotional reaction (8 items, score
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range 0 - 32) and physical symptoms (7 items, score range 0 - 28). A higher score 
indicates greater vocal morbidity.
Laryngopharyngeal Assessment
Patients were independently reviewed by a Consultant Otolaryngologist (Mr K 
MacKenzie) who was blinded to the severity of the asthma and results of above 
physiological evaluation. Patients were asked about a range of laryngopharyngeal 
symptoms and were asked to rank their symptoms. In addition we recorded a score 
from 3 symptoms felt to represent reflux -  abnormal sensation at the back of the 
tlu'oat, throat clearing and abnormal taste each graded 0-3 (none, mild, moderate, or 
severe), giving a maximum reflux score (RS) of 9. Laryngoscopy using a flexible 
fiberoptic laryngoscope was performed following topical application of local 
anaesthesia, co-phenylcaine®, to the nose and nasopharynx. The assessment of the 
larynx was based on structure and function. Laryngeal appearance was noted with the 
mobility of the vocal cords on phonation, inspiration and expiration.
Nasal Assessment
Patients were independently reviewed by a Consultant Otolaryngologist (Mr GW 
McGarry) who was also blinded to the severity of asthma and results of above 
physiological evaluation. Nasal symptoms were recorded - obstruction, congestion, 
hyposmia, rhinoniioea, sneezing, epistaxis, or other identified symptom, giaded as
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none (0), mild (1), moderate (2), severe (3), giving a maximum nasal symptom score 
(NSS) of 21. Standard 4mm 30 degree Rod Lens endoscopy was performed after 
topical decongestion and anaesthesia with co-phenylcaine®
Statistical Analysis
2 sample t-tests were used to compare unpaired interval data. Mann-Whitney U tests 
were used to compare unpaired sets of nominal data. Minitab (version 14) statistical 
software was used for these calculations. Sensitivity, specificity, positive and negative 
predictive values were calculated using conventional methods.(^"^ )^ Inter- and intra­
rater reliability coefficients were calculated using the methods of Generalisability 
Theory (^ "^ )^. Bootstrap methods were used to construct 95% confidence intervals 
(CIs) for all reliability estimates, based on 10,000 bootstrap samples from the 43 
patients (^ ^^ ).
3.3.1 Results -  Baseline Characteristics
43 patients were recruited, 14 male, 29 female, aged from 23 -  78 years, median 43 
years. Case notes were reviewed to determine how secure the diagnosis of asthma was 
in each case. We found that 34 (79%) of patients had prior objective evidence of 
asthma (16 bronchodilator reversibility, 2 bronchial hyper-reactivity, 2 
bronchodilator reversibility and bronchial hyper-reactivity, 13 significant peak 
expiratory flow rate variability and one with an improvement in FEVl of > 20% 
following a trial of oral corticosteroids). Of the remaining 9 patients, 4 gave only a 
good clinical histoiy of asthma in the presence of normal lung frmction when 
measured and the final 5 patients had no definite evidence of asthma.
27 patients were on BTS Step 4 treatment(^) or above (any treatment combination 
including more that low dose inhaled corticosteroids and a long acting beta agonist) 
(Figure 5).
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Figure 5: Baseline level of asthma treatment
Number of 
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BTS Step
Patients displayed the full range of RCP asthma morbidity scores (0 -  21, a higher 
score indicates more severe symptoms) with a mean score of 10.6 (SD 7.7). These 
bore no relation to degree of aii'flow obstruction as deteiTnined by % predicted FEV  ^
(r = -0.28, p = 0.073).
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3.3.2 Laryngopharyngeal Assessment
18 different laryngopharyngeal symptoms were reported by the study cohort, ranging 
from 0 to 14 (mean 6.5). The most frequent cardinal symptom was hoarseness (10), 
with a total of 20 (47%) patients acknowledging a change in their voice when asked 
directly. Only 7 patients reported no cardinal laryngeal symptom (Figure 6).
Figure 6: Cardinal Laryngopharyngeal symptom reported
Number of 
Patients
sO
Cardinal Symptom
Reflux scores ranged from 0 to 7, median (IQR) 3 (1-5).
There was a mild correlation between RS and asthma symptoms (RCP score, r = 0.34, 
p=0.026), although both varied widely. There was no relationship with lung frmction
(FEVpr = -0.17).
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Structural and functional abnormalities identified at laryngoscopy are shown in Table 
7.
Table 7: Laryngoscopic findings
Normal structure 25 Patients Normal function 31 Patients
Abnormal structure
• Mild/mod/ severe
laryngitis
• Miscellaneous*
18 (42%)
• 10/4/1
• 3
Abnormal function
• glottic chink
• phonating
with false 
cords
• reduced cord
mobility
12 (28%)
• 5
• 5
• 2
17 patients had normal appearances. The 3 miscellaneous abnormalities were 
abnormal arytenoids (1), vocal cord polyp (1) and pharyngeal narrowing (described in 
detail later). Only 1 patient had laryngeal thrush evident in addition to mild laryngitis.
Symptoms varied widely in those with a normal larynx (RS range 0-6, median 3). 
Laryngitis, defined as diffuse reddening and swelling of the glottis consistent with an 
inflammatory process, was the most frequent structural abnormality (10 mild, 4 
moderate and 1 severe). One patient had upper airway narrowing identified by 
laryngoscopy in the form of a thickened base of tongue and narrow pharyngeal inlet 
(confirmed as benign on MRI). 12 patients had fimctional laryngeal abnormalities as 
shown above. No patient had “classic” appearances of VCD of inspiratory adduction 
of the cords associated with glottic chink formation.
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Relationship between laryngeal symptoms and structure
We examined the predictive value of the “reflux symptoms” of abnormal sensation, 
abnormal taste and throat clearing for laryngoscopic features of reflux. For the 
purposes of this analysis each symptom was defined as either present or absent, rather 
than grading the severity of symptoms. Symptoms were analysed individually and in 
combination, comparing those who had any degi’ee of every symptom in combinations 
tested, with those having no symptoms in the combination. This showed that neither 
individual nor groups of “reflux” symptoms were good predictors of laryngoscopic 
signs of reflux (Table 8).
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Table 8: Predictive value of reflux symptoms for laryngoscopic signs of reflux.
SYMPTOM / 
SYMPTOM 
COMBINATION
Sensitivity
(%)
Specificity
(%)
NPV (%) PPV (%)
Abnormal
Sensation
66.6 32.1 64.3 34.5
Abnormal taste 533 67,9 73.1 47.1
Throat clearing 80 32,1 75 38.7
Abnormal sensation 
T Abnormal taste 
(23 patients)
66.6 50 70 46.1
Abnormal sensation 
+ throat clearing 
(26 patients)
75 50 81.8 40
Abnormal taste T 
tliroat clearing 
(31 patients)
88,9 27,3 85.7 333
All 3 “Reflux” 
Symptoms 
(19 patients)
833 46.1 85.7 41.7
We also determined the predictive value of symptoms for any structural or functional 
abnormality, including hoarseness and voice change (since these were the most 
frequent symptoms). These results are shown in Table 9 and suggest that 
combinations of laryngeal symptoms are better predictors of any laryngeal 
abnormality than specifically laryngitis.
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Table 9: Predictive value of laryngeal symptoms for functional or stmctural
abnormality in general (including laryngitis).
Sensitivity
(%)
Specificity (%) NPV (%) PPV (%)
Abnormal Sensation 73,1 41.2 50 65.5
Abnormal taste 51.9 81.5 50 82.4
Throat clearing 80.7 41.2 58.3 67.7
Hoarseness 42,3 29,4 25 47.8
Change in Voice 31,5 70.6 54,5 76.2
Voice change + abnormal 
taste 
(n-23)
66.7 90.1 71,4 88.9
Voice change + throat 
clearing 
(n-27)
86.7 58.3 77,8 72,2
Voice change + abnormal 
sensation 
(n = 33)
71.4 58.3 53.8 75
Voice change + 
hoarseness 
(n=27)
75 81.7 69.2 85.7
Voice change + 
hoarseness + abnormal 
taste 
(n= 16)
88.9 100 87.5 100
13 (30%) patients had management changed on basis of examination - 7 were refeiTed 
for Speech therapy, 4 had a change in therapy for laryngitis and 2 underwent further 
ENT evaluation.
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3.3.3 Results -  Physiological Assessment
In one patient we were unable to obtain adequate spirometry or FOT data, with 
inadequate FOT and inspiratory FVL data obtained in a further 2 patients.
FEVj (% predicted) ranged from 1.11 (31% predicted) to 4L (137% predicted). 15 
patients had an FEVj of < 80% predicted, and 20 patients had an FEV/FVC ratio of < 
70%.
The values for airway resistance deteimined by FOT and are illustrated in Table 
10 (all were normally distributed).
Table 10: Airway resistance measured by Forced Oscillation Technique (n=40)
Range (kPa/l/s) Mean (kPa/Fs) (SD)
Inspiratory Resistance (RJ 0.14-0.90 0.43 (0.17)
Expiratory Resistance (RJ 0.19-1.16 0.50 (0.22)
Total Resistance (R) 0.17-1.05 0.47 (0.19)
Occlusion Resistance 
(Rocc)
0.19-0.74 0.4 (0.12)
There are no clear data on the normal reference range for FOT measured airways 
resistance, but this probably lies in the region of 0.25-0.3 IkPa/l/s ("^ )^. 31 (72%) of our 
patients had values of R^  above this level. 32 (80%) patients had Rocc values over 0.3 
kPa/l/s, which is the generally accepted upper limit of normal.("^ )^
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The relationship between each component of FOT measured airways resistance and 
spirometric measurements which can suggest upper airway narrowing are shown in 
Table 11. Pearson Correlation Co-efficients were calculated given all parameters were 
normally distributed. Additionally, the relationships between FOT and Rocc and FEVj 
are shown.
Table 11: Pearson Conelation Coefficients of FOT with spfrometric measures of 
upper airway obstruction (MIF^ ,^ MEF^^/ MIF^J, R^ ^^  and FEVi.
Re R.
M IF ,, -0.14, p = 0.406 -0.26, p = 0.109 -0.23, p = 0.152
M E F ,/ M I F , , -0.44, p= 0.004 -0.24, p = 0.14 -0.32, p = 0.041
Kco 0.55, p <  0.001 0.66, p < 0.001 0.65, p <  0.001
F E V l -0.49, =0.001 -0.42, p = 0.007 0.47, p = 0.002
We copared the values obtained for R , R, and R^  ^obtained in the patients who were 
found to have functional abnormalities at laryngoscopy with the normals, in the 40 
patients with contemporaneous physiological data. These results are shown in Table 
12.
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Table 12: Ranges and mean (SD) values of R, and R^^^  subdivided by functional 
appearance at laryngoscopy (n = 40).
Functional status R, (kPa/l/s) Rj (kPa/l/s) R_(kPa/l/s)
Normal (29) Range 0.17-1.05 0.14-0.90 0.19-0.74
Mean (SD) 0.48 (0.20) 0.44 (0.18) 0.40 (0.21)
Glottic chink
(5)
Range 0.31-0.66 0.24-0.55 0.33 -  0.48
Mean (SD) 0.45 (0.13) 0.40 (0.16) 0.40 (0.06)
False cord 
phonation (4)
Range 0.29-0.65 0.29-0.64 0.26 -  0.47
Mean (SD) 0.44 (0.16) 0.44 (0.16) 0.37 (0.09)
Reduced cord 
mobility (2)
Range 0.34 - 0.53 0.34-0.35 0.26-0.59
Mean (SD) 0.43 (0.14) 0.35 (0.00) 0.44 (0.21)
All patients with glottic chinks had values of R^  and R^^^  which are higher than 
previously reported normal values('^^’^ ‘^ )^ as indeed had many of those with normal 
laryngeal appearances. There were no statistically significant differences observed 
between any of the groups according to functional abnormalities in terms of any of the 
above physiological parameter (2 sample t-tests). There was also no difference in 
MEFg/MIFgg between any of these groups.
There were 4 patients who were evaluated by ENT on a different day from their 
physiological evaluation. Given that we are unable to make any claim about the 
validity of EOT in the diagnosis of VCD it was felt appropriate to include their results 
for analysis of the relationship between all the physiological parameters discussed 
above.
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3,3.4 Results -  Vocal Assessment
The VoiSS scores are shown in Table 13. There was no relationship between VoiSS 
score and curi'ent inhaled corticosteroid dose (r = 0.23, p = 0.117).
Table 13: VoiSS questionnaire scores.
Range Mean (SD) Median (IQR)
Total score 3 - 8 3 30.5 (18.5) 26 (16-40)
Impairment 0 - 4 7 15.7(11.2) 16 (7-20)
Emotional
Reaction
0-21 3.1 (5.3) 0
Physical
Symptoms
3 - 2 7 11.0 (4.9) 10 (7-14)
The mean of the 6 GRBAS(I) assessments (2 from each reviewer) for each patient 
was calculated to give their final GRBAS(I) scores (Table 14). A GRBAS Grade of > 
1 is recognised as definitely abnormal, and 13 / 43 (30.2%) patients had this. A 
statistically significant corrélation was observed between GRBAS Grade and inhaled 
corticosteroid dose (Spearman r = 0.56, p < 0.001, Figure 7).
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Table 14: Mean GRBAS (I) scores
GRBAS(I) Subscale Range Mean (SD) Median (IQR)
Grade 0-2 .83 0.59 (0.57) 0.50 (0.17-1.0)
Roughness 0 - 2 . 5 0.88 (0.49) 0.83 (0.5-1.17)
Breathiness 0-2 .17 0.43 (0.53) 0.33 (0-0.5)
Asthenicity 0 - 1 . 5 0.27 (0.36) 0.17(0-0.5)
Strain 0-2 .83 0.62 (0.57) 0.50 (0.17-1.0)
Instability 0-1 .83 0.24 (0.38) 0.17 (0-0.33)
Total GRBAS 0.33-10.83 2.79 (2.1) 2.0 (1.25-3.83)
Figure 7: Relationship between inhaled corticosteroid dose and GRBAS Grade (BDP 
= Beclomethasone dipropionate) (Spearman r =0.56, p<0.001).
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Mean GRBAS Grade
The group with normal appearances had lower median VoiSS scores than those with 
any abnormality demonstrated at laryngoscopy, as shown in Table 15. The mean 
GRBAS Grade did not differ between these 2 subgroups. However when the sub-
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groups with functional or structural abnormalities were analysed seperately, the group 
with functional abnormalities were found to have higher mean GRBAS subscale 
scores in all but Roughness and Strain (Table 16). Full breakdown of VoiSS subscales 
and GRBAS related to laryngoscopic findings of structural or functional abnormalities 
are shown in Table 16.
Table 15: VoiSS and GRBAS Grade scores depending on laryngoscopic appearances
Laryngoscopic
findings
VoiSS GRBAS Grade
Range Median Range Median
Normal structure 
and function 
(n= 17)
4 — 46 22 0 - 1 . 0 0.34
Abnormal 
structure OR 
function 
(n = 26)
3 - 8 3 33 0 - 2 .8 0.67
95% Cl for 
difference vs. 
normals
0.0, 21.0, p=0.044 -5.0, 0.0, p = 0.15
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Table 16: VoiSS subscales and GRBAS related to laryngoscopic findings of structural 
or functional abnormalities
Functional Abnormality Structural Abnormality
Absent Present p-value Absent Present P-
Mean
(SD)
median (IQR) Mean (SD) median
(IQR)
Mean
(SD)
median
(IQR)
Mean
(SD)
median
(IQR)
value
impairment 14.7
(11.4)
14
(5-19)
18.3
(10.7)
18
(11.5-26)
N S 13.9
(10.0)
13
(5-19)
18.3
(12.5)
16
(10.8-25)
NS
5
Emotional
Reaction
3.5
(5.8)
0
(0-6)
2.1
(3.7)
1
(0-2.75)
NS 1.8
(3.3)
0
(0-2)
4.9
(6.9)
1
(0-9.25)
NS
ÎS Physical
Symptoms
11.7
(5.3)
11
(9-15)
8.9
(3.3)
9
(6.25-
10.75)
N S 10.4
(4.7)
10
(7.5-13)
11.7
(5.3)
11
(7-16.25)
NS
Total 30.5
(20.0)
25
(16-40)
30.6
(14.7)
32
(19-39.75)
N S 26.7
(13.6)
25
(16-37.5)
35.8
(23.0)
30
(21-49)
NS
Grade 0.45
(0.56)
0.17
(0.17-0.68)
0.94
(0.44)
1.00
(0.68-1.13)
0.0015 0.58
(0.49)
0.50
(0.17-1.00)
0.60
(0.68)
0.50
(0.17-
0.71)
NS
Roughness 0.82
(0.52)
0.83
(0.50-1.17)
1.04
(0.36)
1.00
(1.0-1.29)
NS 0.83
(0.46)
0.83
(0.42-1.17)
0.95
(0.53)
1.00
(0.79-
1.17)
NS
^S(I)
Breath in e ss 0.31
(0.48)
0.17
(0.00-0.33)
0.72
(0.56)
0.50
(0.33-1.00)
0.0043 0.39
(0.47)
0.33
(0.00-0.42)
0.47
(0.62)
0.25
(0.00-
0.75)
NS
Asthenicity 0.18
(0.26)
0.00
(0.00-0.33)
0.51
(0.48)
0.42
(0.17-0.83)
0.0154 0.25
(0.37)
0.00
(0.00-0.50)
0.31
(0.36)
0.17
(0.00-
0.50)
NS
Strain 0.55
(0.60)
0.33
(0.17-0.67)
0.81
(0.47)
0.75
(0.38-1.29)
NS 0.61
(0.47)
0.50
(0.25-1.00)
0.64
(0.70)
0.42
(0.17-
0.79)
NS
Instability 0.19
(0.36)
0.00
(0.00-0.17)
0.39
(0.40)
0.25
(0.17-0.5)
0.0335 0.23
(0.26)
0.17
(0.00-0.33)
0.27
(0.51)
0.00
(0.00-
0.33)
NS
Total 3.00
(2.90)
1.83
(1.17-4.50)
5.18
(2.67)
4.5
(3.42-7.00)
0.0062 3.55
(2.57)
2.67
(1.25-5.83)
3.69
(3.53)
2.42
(1.50-
4.50)
NS
The Spearman Rank correlations between the median GRBAS(I) rating and the VoiSS 
score and subscales are shown below in Table 17. Non significant p values are not 
shown.
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Table 17: Correlations between VoiSS and GRBAS(I)
VoiSS Subscale
Total Impairment Emotional Physical
Grade 0.24 0.33(p=0.034)
0.28 0.05
G
Roughness 0.08 0.15 0.09 -0.09
R
B
Breathiness 0.40(p=0.008)
0.43
(p=0.004)
0.38
(p=0.013)
0.06
A Asthenicity 0.47(p=0.002) 0.43(p=0.004) 0.33(p=0.032) 0.15
S
(T)
Strain 0.25 0.30(p=0.05) 0.26
0.21
\  / Instability 0.18 0.21 0.14 0.10
Total
GRBAS
0.34
(p=0.027)
0.38
(p=0.012)
0.32
(p=0.036)
0.13
Relationship between GRBAS / VoiSS and laryngoscopic appearances
VoiSS and GRBAS score predicted laryngoscopic abnormality equally (Table 18). A 
total VoiSS score of 30 was chosen as cut-off scores because of its relationship with 
the median total VoiSS score for the study group. A Grade of > 1 on the GRBAS 
scale is recognised as identifying significant vocal morbidity and was therefore used 
as the cut off for this analysis. GRBAS data in Table 5 is presented as mean (SD) 
sensitivity, specificity, NPV and PPV from the 6 assessments each patient had.
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Table 18: Predictive value of GRBAS and VoiSS for any laryngoscopic abnormality
Sensitivity
(%)
Specificity (%) NPV (%) PPV (%)
GRBAS Grade > 1 57.1 59.8 50.1 68.7
(mean (SD) of 6 SLT 
scorings)
(10.7) (11.4) (6.5) 5.8)
VoiSS > 30 53.8 70.6 50 73.7
SLT Rater Reliability
The full breakdown of both inter and intra-rater reliability for the whole study group 
is shown in Table 19. As demonstrated, the Total GRBAS scores show good overall 
agreement for inter-rater reliability at 78.1% and excellent agreement for overall intra­
rater reliability at 81.8%. However, this level of agreement is not sustained across the 
individual categories. Grade fairs best at an overall 64.7% for inter-rater reliability 
and 69.6% for intra-rater reliability. Asthenicity stands out as achieving the lowest 
inter-and intra-rater reliability at 43.4% and 49.6%, respectively. The level of 
reliability is not statistically different on the two occasions with the exception of 
improved agreement in the assessment of Instability on the second occasion. When 
examining the scores of the individual raters, it seems that Rater 3 achieves a high 
degree of consistency, dipping no lower than 62.3% across all categories. Rater 1, by 
comparison, appears much less consistent between the two scoring occasions with a 
low of 24.5% for Asthenicity. Rater 2 lies in the middle of the other two raters and 
seems to be consistently more reliable than Rater 1 with the exception of the GRBAS
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Strain category. There only appears to be a statistically significant difference in intra­
rater reliability between Rater 3 and Rater 1 in Asthenicity.
Separate analyses were undertaken for inter- and intra-rater reliability in respect of the 
GRBAS (I) categories for subjects with any laryngeal abnormality or with laryngeal 
abnormality as opposed to no observed laryngeal abnormality (Tables 20 and 21). 
This showed intra-rater reliability was significantly better in Grade assessment for 
patients with any laryngeal abnormality than those with normal appearances (78.8% 
versus 47.3%%, 95% Cl for difference 6.2, 59.1). In all other categories (except 
Roughness) there was only a trend seen towards improved inter and intra-rater 
reliability with no other statistically significant differences observed. Examining the 
differences for patients with functional abnormalities (versus none), there is a general 
trend to improved inter and intra-rater reliability for patients with functional 
abnormalities but a statistically significant difference was only observed for intra-rater 
reliability in Strain assessment.
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3,3.5 Results -  Nasal Assessment
Nasal Symptoms
Obstruction was the most common cardinal symptom (15 patients, Figure 3). Three 
patients reported no cardinal nasal symptoms.
Figure 8: Cardinal nasal symptom reported.
Number of 
Patients
o'
Symptom
The distribution of Nasal Symptom Scores (NSS) is shown in Figure 9.
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Figure 9: Distribution of total Nasal Symptom Score (NSS).
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Patients
0 0 0 0 0 0 0 
T— r  I  I— I "" I ' I —1
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 
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Median NSS was 5.3 (range 0-14) for the whole group. The NSS of the 12 patients 
taking nasal medication (10 were taking topical nasal steroids and 2 were taking 
antihistamines) at the time of the study was marginally higher than those who were 
not on nasal medication (medians of 6 and 4 respectively, p = 0.046 by Mann- 
Whitney U test, 95% confidence interval for difference -0.001 to -5). There was no 
correlation between NSS and severity of asthma symptoms (measured by the RCP 
score, r = -0.05) or FEVj (r = 0.01).
Nasendoscopv findings
Structural abnormalities at nasendoscopy were much less frequent than symptoms. 
Findings at nasendoscopy are shown in Figure 5. The two “other” findings were 
vestibulitis (1) and accessory sinus ostia (1, not thought to be pathological).
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Figure 10: Nasendoscopy findings.
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The NSS of patients with oedema and polyps were higher (Medians of 7 and 5 
respectively) than those with noimal nasendoscopy and deviated nasal septum (DNS) 
(both with medians of 4) but none of these differences reached statistical significance.
Initial analysis was performed to determine how well individual symptoms predicted 
the finding of any abnormality or the specific abnormalities of polyps or DNS for the 
whole study group. The results for predicting any abnormality are shown in Table 22. 
This indicates that individual nasal symptoms apart from hyposmia were poor 
predictors of any nasal abnormality (results for individual nasal pathologies were 
unremarkable and are shown separately in Table 23).
I l l
Table 22: Prediction of any nasal pathology by individual symptom.
SYMPTOM Sensitivity
(%)
Specificity
(%)
NPV
(%)
PPV
(%)
OBSTRUCTION 57,1 45.5 52.6 50
SNEEZING 61.9 36.4 50 48.1
CONGESTION 76.2 31,8 58.3 51.6
HYPOSMIA 57,1 86,4 67.9 80
RHINORRHOEA 57.1 59,1 59,1 57,1
Table 23: Prediction of nasal pathology by individual symptom.
SYMPTOM Sensitivity
(%)
Specificity
(%)
NPV
(%)
PPV
(%)
OBSTRUCTION
POLYPS 62.5 45.7 84.2 20.9
DNS 28,5 38.9 73.7 8.3
ANY ABNORMALITY 57.1 45.5 52.6 50
SNEEZING
POLYPS 62,5 37.1 81,3 18.5
DNS 42.9 33.3 75 11.1
ANY ABNORMALITY 6L9 364 50 48.1
CONGESTION
POLYPS 71.4 23.8 33.3 61
DNS 71.4 27.7 813 16,1
ANY ABNORMALITY 76.2 31.8 58.3 51.6
HYPOSMIA
POLYPS 62,5 71.4 89.2 313
DNS 28.6 63.9 82.1 13.3
ANY ABNORMALITY 57.1 86.4 67.9 80
RHINORRHOEA
POLYPS 62,5 54.3 86.4 23.8
DNS 57.1 52.8 86.4 19
ANY ABNORMALITY 57.1 59.1 59.1 57.1
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Further analysis of combinations of symptoms was then undertaken. This involved 
looking at smaller groups of patients, comparing those who had any degree of every 
symptom in combinations tested, compared to those with no symptoms in the 
combination. These results are shown in Table 24, indicating combinations of nasal 
symptoms which are strongly associated with nasendoscopic abnormality.
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Table 24: Predictors of nasal pathology by groups of symptoms
Sensitivity (%) Specificity (%) NPV (%) PPV(%)
Congestion & 
Hyposmia (21 
patients)
76,9 75 66.7 83.3
Rhinorrhoea & 
Hyposmia 
(21 patients)
66.7 91.7 78.6 85,7
Obstruction & 
Hyposmia 
(24 patients)
60 88.9 57.1 90
Congestion, 
Rhinorrhoea & 
Hyposmia 
(11 patients)
66.7 80 66.7 80
Obstruction, 
Rhinorrhoea & 
Hyposmia 
(12 patients)
80 100 87,5 100
Obstruction & 
Congestion 
(27 patients)
78.6 30.7 57.1 55
Obstruction & 
Rhinorrhoea 
(22 patients)
71.4 53.3 80 41.8
Rhinorrhoea & 
Congestion 
(24 patients)
83.3 50 77.8 5&8
Rhinorrhoea, 
Obstruction & 
Congestion 
(14 patients)
80 44.4 80 44.4
7 patients with structural abnoimalities had a change in their management on the basis 
of the nasal findings - 5 patients were started on topical nasal steroids, one was given
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topical antibiotic ointment and one was listed for surgery for grossly deviated nasal 
septum.
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3.4.1 Discussion -  Laryngopharyngeal Assessment
We studied the upper and lower airway of patients attending a problem asthma clinic, 
having a broad range of severity, in terms of FEVp symptom scores and BTS 
treatment step. Most of these patients had definite asthma. Our inability to attract 
consecutive patients to this study limits the generalisability of our findings, but this 
was a pilot study and nevertheless provides some important findings for further 
investigation.
Firstly, we did not identify the “classic” appearances of VCD (inspiratoiy cord 
adduction with associated glottic chink) in any of the 43 patients examined. Although 
true population figures for incidence and prevalence of VCD are not known, we might 
have expected to identify this in at least some patients, given the range of asthma 
severity and symptoms, previous clinical suspicions and prevalence rates of another 
tertiary referral centre(^^). In Denver 22/132 (16.7%) of patients with refractory 
asthma were found to have VCD in addition to asthma. It is known that asthma is 
very common in association with VCD, with co-existing asthma in 53/95 cases in one 
large case series of VCD patients (^ )^.
We did however identify 12 patients with some form of functional abnonnalities at 
laryngoscopy. Although not strictly meeting the cun'ently accepted VCD definition, in 
the absence of any otherwise accepted term, it seems reasonable to suggest that a 
spectrum of “upper airways dysfunction” exists, encompassing a variety of functional 
abnormalities, which may at one end include “classic” VCD. Although we did not 
have a control group, and selection bias has to be considered, the frequency of these
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abnormalities confirms our prior suspicion of reasonable prevalence of upper aii'way 
problems in our clinic population.
All laryngoscopies were performed by a single obseiwer so that although consistency 
has been achieved, the impact of recognised inter-observer variability in the reporting 
of laryngoscopic findings cannot be assessed in this study.
We found some correlation between degree of “reflux” related laryngeal and of 
asthma symptoms, perhaps mirroring the difficulty which doctors as well as patients 
may have, of differentiating between the upper and lower airways. Lung fonction 
showed no relationship with either laryngeal or asthma symptoms. The lack of 
relationship between asthma symptoms and FEVj highlights the need to identify other 
coexisting problems in patients with problem asthma. Although we did not objectively 
assess the degree of either gastro-oesophageal or laryngo-pharyngeal reflux in our 
patients, the symptoms we defined as “reflux” symptoms have been shown to be 
strongly associated with laryngo-pharyngeal acid reflux We do however
acknowledge that the reflux score used m this study has not been validated. Other 
than the study by Belafsly,(^^^) which validated a reflux symptom index iu 25 patients, 
no other validated questionnaire for laryngopharyngeal reflux disease is available. 
The association between this entity and asthma is much less well defined than the 
large body of work looking at asthma and gastro-oesophageal reflux disease 
Laryngo-pharyngeal acid reflux may provide the initial stimulus for VCD
Structural abnormalities at laryngoscopy were less common than symptoms and the 
degree of symptoms varied widely in patients with endoscopically normal larynges.
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These pilot data suggest that specific laryngeal symptoms are poor predictors of 
laryngeal reflux. Although the negative predictive value of the absence of all 3 reflux 
symptoms (85.7%) was much better than their positive predictive value (41.7%) 
(Table 8), symptoms were better predictors of any laryngoscopic abnormality, with 
abnormal taste the best individual predictor. Combination of symptoms increased the 
likelihood of any laryngoscopic abnormality, an obseiwation which may be of value in 
deciding on the utility of ENT assessment. This data suggests that prospective 
evaluation of such scores in correctly identifying laryngeal pathology is indicated.
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3.4.2 Discussion - Physiological Assessment
Since VCD was not identified, we cannot draw any conclusions about the utility of 
FOT in diagnosing this. Currently, the gold standard for diagnosis rests with direct 
visualisation of the cords and we were hopeful that a non-invasive method of 
assessing the upper airways physiologically would provide a further method of 
diagnosis. Perfbrmmg laryngoscopy when the patient with VCD is asymptomatic is 
often normal (26 out of 95 patients in Newman’s series(^^)) and this may be the 
reason we did not identify any cases. Challenge testing to identify VCD has been 
e x p l o r e d , a n d  discussed in Chapter 1, but its precise role is not clear and is 
investigated further in Chapter 5.
In any event, the 12 patients who had some other foims of functional abnormality at 
laryngoscopy did not however have measurable differences in their physiology as 
measured by R^ , R, R^ ^^  or MEFgg/MIF^g. There were 6 patients enrolled in the study 
who had clinical suspicion of a substantial upper airway contribution to symptoms, 
one of whom (who had pharyngeal / base of tongue thickening demonstrated) had had 
VCD documented during a previous symptomatic episode. Only one of these 6 
patients had a fimctional abnormality at laryngoscopy (glottic chink) and four had 
laryngitis.
FOT has the potential to be a non-invasive tool to identify upper airway narrowing. It 
has been known for some time that measurements of inspkatory flow are superior to 
FEVj for the diagnosis of upper airway obstruction('^^). Limitation of the inspiratory 
limb of the FVL has been well documented with VCD With the FOT
technique, it is possible to separate the airway resistance into expiratory and
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inspiratory components and we postulated that inspiratory resistance might provide a 
clue to the diagnosis.
Previous work in patients with fixed upper airflow obstruction in the form of tracheal 
stenosis demonstrated a clear correlation between FOT measurements and 
stenosis diameter, with less correlation between diameter and FEV .^ In addition, 
Rigau mimicked VCD in a model using variable resistance to mimic normal 
respiratory anatomy and found that the changes in oscillatory resistance were in 
agreement with the degree of area reduction in the model. There is also evidence from 
sleep literature that FOT is helpful in the identification of upper airway narrowing
1^57;158^
Our data suggest that aiiway narrowing in general is reflected by R. Our inability to 
demonstrate VCD in the resting state of any of our patients prevents further 
conclusions being drawn.
We also looked at the relationship between the inspiratory part of FOT measured 
resistance and MIF^ g since MIF50 (albeit in a small group of patients) has been found 
to correlate well with mid-inspiratory glottic area (^ )^. Rj did not correlate well with 
MIF50 in this study (r = -0.14). Although there was a reasonable conelation between 
Rj and MEF^/MIF^^ (r = -0.44, p = 0.004), Rj (along with R^  and R,) correlated well 
with FEVi. This makes it difficult to postulate that R, would have been a sensitive 
marker of upper airway obstruction, were we to have identified it.
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There was a very strong relationship between resistance measured by FOT in both 
parts of the respiratory cycle (R^ ) and that measured by R^ ^^ , although resistance 
measured by R^^^  was generally less than that measured by FOT (mean R^  0.469 
kPa/Vs vs. mean R^^^  of 0.396 kPa/Fs, p = 0.04 for difference by 2 sample t-test), as 
has been observed previously (^ ^^ ). The good relationship between FOT and FEV, 
supports FOT as a further technique for objective assessment of airflow obstmction 
which may be useful in those unable to perform forced expiratory manoeuvres
121
3.4.3 Discussion -  Vocal Assessment
We have identified that voice morbidity is a problem in our clinic population. While 
other studies have investigated the frequency of voice problems in patients with 
asthma these used self-administered questiomiafres only to identify voice
problems. Oui* study is novel, since it included a comprehensive vocal assessment by 
patient (VoiSS), SLT (GRBAS) and ENT specialist (direct visualization of the larynx). 
Although data from a control group would have strengthened our findings, this was a 
pilot, hypothesis generating study and further evaluation of VoiSS and or GRBAS in 
an asthmatic cohort should take this into account. Our analysis of the inter-relations of 
VoiSS, GRBAS and laryngeal appearance are not affected by these considerations.
The VoiSS has been extensively investigated and refined in over 800 subjects and its 
subscales have shown good iutemal consistencies, in contrast to self administered 
questionnaires used in earlier studies in patients with asthma (^ '^^ )^. Although there 
are other instruments available for the self assessment of voice quality such as the 
Vocal Handicap Index (VHI) and Voice related Quality of Life (V-RQOL), we chose 
VoiSS because it has been extensively investigated, has been derived from a UK 
population and has been shown to reflect vocal morbidity and associated pharyngeal 
symptoms (^ "^ ’^ )^. There are no VoiSS data in patients with asthma. Our patients’ 
scores are less abnormal than those of 144 functional dysphonies and 145 patients 
with structural laryngeal pathology (mean total scores of 43.3 and 46.5 respectively) 
The GRBAS scores from this study are not readily comparable to those reported 
elsewhere as these have been reported differently (for example using a visual 
analogue scale) (^ *^ )^ or reported to determine inter-rater reliability (^ )^.
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Higher VoiSS scores were associated with laryngeal pathology (Table 15). We did not 
evaluate quality of life (either in general or asthma-specific) in this study but the 
emotional domain of the VoiSS may reflect this. Dysphonia has been shown to 
adversely affect patients’ quality of life, (^ )^ and in a different study, self rated voice 
quality was significantly related to a range of personality, psychological distress and 
quality of life measui'es (^ ^^ ). The conti'ibution which dysphonia makes to impaired 
quality of life in patients with asthma merits further exploration.
As well as investigating the relationship between VoiSS responses and laryngoscopic 
findings, we have also shown a relationship between specialist GRBAS scoring and 
self reporting of symptoms by patients using VoiSS seen previously (Mr K 
MacKenzie -  personal communication of data submitted for publication). Since 
GRBAS “Grade” is a summary measure of voice deviance, the observed relationship 
with the Impairment domain of VoiSS was expected. There were also weak positive 
correlations between other GRBAS sub scales and total GRBAS with VoiSS. The lack 
of relationship between the Physical component of VoiSS and GRBAS was expected 
as this VoiSS subscale assesses non-vocal laryngopharyngeal symptoms. Muny (^ ^^ ) 
found a moderate correlation between total GRBAS score and voice related quality of 
life (V-RQOL) scores (a 10 item self administered questionnaire). There was no 
breakdown of the relationship with individual GRBAS sub scales in that study, and it 
is these, rather than the total score which are pertinent to clinical practice. Our study 
therefore adds to the evidence that patients’ perception of vocal morbidity relates to 
that of an experienced observer. Specialist, labour intensive GRBAS Grade was also 
no better than VoiSS at predicting laryngoscopic abnormality (Table 18). For these
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reasons, we therefore believe that further validation of the VoiSS as a screening test 
for patients with vocal morbidity in the asthmatic population is warranted.
There was a low incidence of laryngeal thrush (1 patient) suggesting that dysphonia 
should not immediately be attributed to this. Lavy also found a low incidence of 
candidiasis in a group of asthmatics complaining of dysphonia (4 out of 22 patients) 
but found a number of other laryngoscopic explanations for symptoms (mucosal 
changes, apposition problems and supraglottic hyperfunction) (^ ®).
As a secondary aim to the study we investigated our local SLT reliability in using the 
GRBAS score. Some authors have been able to report very high levels of reliability 
for the GRBAS scale. For example, Murry and colleagues have described reliability 
coefficients in a voice-disordered population, ranging from 0.88 for Strain to 0.98 for 
Grade and, in a normal population, of 0.99 for all GRBAS categories(^^^). Reliability 
of GRBAS in the present instance has been shown to be fairly robust for Total scores, 
both on an inter-rater and on an intra-rater basis. These scores, however, are not in 
common clinical use and probably have little clinical relevance. More commonly. 
Grade is extracted as a measure of overall severity and has been generally reported as 
showing best levels of agreement(^^’^ ’^^ ®^). By comparison our raters achieved a rather 
modest 64.7% for inter-rater reliability and 69.6% for intra-rater reliability for 
GRBAS Grade. It is not clear whether experience in using GRBAS would account for 
these differences. We found a tendency to improved reliability when the study group 
was split into patients with any and subsequently functional laryngeal abnormalities 
which has been demonstrated in a population of smokers(^^^), but the converse 
(improved reliability in judging voices of normal subjects) has also been seen(^ "^^ ).
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In conclusion, we have demonstrated laryngeal structural and functional abnormalities 
occur in significant proportions of patients attending a problem asthma clinic and that 
this is associated with significant differences in self reported VoiSS, but not in the 
more labour intensive GRBAS screening tool. Very few patients were found to have 
fungal infection as a result of use of inhaled corticosteroids and we suggest that vocal 
morbidity should not be attributed to this without positive evidence. We have 
confirmed the positive correlations between VoiSS scores, and our gold standard 
measurement, GRBAS total and subscales, suggesting that they are measuring similar 
attributes. This pilot study suggests that VoiSS is a useful screening tool in our 
population, but further work is required, as is comparative data for normal subjects.
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3.4,4 Discussion -  Nasal Assessment
We have studied nasal symptoms and endoscopic findings in a broad range of patients 
with asthma. There were no strict inclusion or exclusion criteria for this study as the 
principle aim was to characterise the spectrum of nasal symptomatology and 
nasendoscopic abnormalities in patients attending an asthma clinic in an observational 
fashion. As previously discussed we felt this would produce results that would be 
more generalisable to routine practice. We have shown that nasal symptoms are 
common in our asthmatic patients in keeping with previously published work.(^^’^ )^ 
Nasal symptoms were very firequently reported on direct questioning in our small 
group (40/43, 93%), with any degiee of rhinorrhoea reported by 18/43 (42%) but 
selection bias was probably contributing to this.
Structural abnormalities at nasendoscopy were less common than symptoms. There 
were 7 patients whose management was changed on the basis of the nasal 
examination, and their NSS ranged form 4 to 14 (median 6). Although higher than the 
median NSS for the remaining 36 patients (median of 4), this difference did not reach 
statistical significance.
To our knowledge, no previous study has looked at the predictive value of nasal 
symptoms for the finding of nasendoscopic abnormalities. We were not using a 
previously well validated questionnafre, but rather a simple scoring system of none, 
mild, moderate or severe to grade a range of common nasal symptoms which is easily 
applicable to an out patient clinic consultation. Our results show individual nasal 
symptoms are poor predictors of nasal pathology, with hyposmia having the best
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individual predictive value for abnormality (PPV of 80%). Combinations of 
symptoms increased the predictive value with every patient complaining of 
obstruction, rhinonhoea and hyposmia having a nasendoscopic abnormality. The 
choice of specific symptom combinations was based on theii* individual predictive 
values and frequency as cardinal symptoms. Combinations which did not include 
hyposmia had improved sensitivity but reduced specificity. These pilot data suggest 
that the threshold for ENT referral should be lower when the patient complains of a 
symptom complex including hyposmia, as the likelihood of finding an abnormality is 
much higher. Furthermore, concurrent hyposmia, obstruction and rhinorrhoea should 
be seen as an indication for ENT referral. The validity of this observation and possible 
impact of adequate treatment of nasal and sinus disease on upper airway hyper­
reactivity is worthy of further study.
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CHAPTER 4
THE VALUE OF ROUTINE RHINOSCOPY IN AN ASTHMA
CLINIC
A PROSPECTIVE STUDY
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4.1 Introduction
As we demonstrated in the nasal aspect of our pilot study, nasal symptomatology is 
more prevalent than stmctuml nasal pathology and that hyposmia was the best 
individual symptom predictive of structural nasal abnormalities. We therefore wanted 
to perform a more comprehensive observational survey of nasal symptomatology and 
nasal pathology to help determine the value of routine nasendoscopy in a problem 
asthma clinic by inviting as many patients with asthma as were attending the clinic to 
attend a simple study run in parallel with their clinic attendance. With this study, we 
also sought to characterise more accui’ately the relationship between nasal symptoms 
and disease on this occasion by means of a previously validated questionnaire, the 
Sino-Nasal Outcomes Test (SNOT) and to determine if the predictive values of nasal 
symptoms for structural abnormalities were similar using this tool to our pilot data. 
Given that in our pilot study we included patients only from the PAG (most of whom 
had objective evidence of asthma) and consequently cannot be sure whether these 
symptom predictors are applicable to patients with asthma specifically, we tested the 
hypothesis that nasal symptoms and pathology would be more common in patients 
with asthma by comparison with a non-asthmatic respiratory cohort. Since then, nasal 
symptoms have been reported to be common in patients with COPD (^ ^^ ).
Sino-Nasal Outcomes Test (SNOT)
The SNOT is an instrument which exists in several forms. It originated in the larger 
(31 item) Rhinosinusitis Outcome measure which has been shown to be a valid tool in 
the assessment of rhinosinusitis related health status and quality of life (^ ^^ ).
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Subsequently, studies have confumed that shorter versions of this questionnaire are 
suitable for such an assessment and we chose the SNOT-22 rather than other shorter 
versions as it includes questions about nasal obstruction or loss of smell / taste.
As was shown with our pilot study, these symptoms seem to be very important in the 
prediction of nasendoscopic abnormalities and we therefore felt it was necessary to 
include these in this study.
130
4.2 Methods
This study was run in parallel with patient attendance from two out patients clinics. 
The first group of patients were recruited from the Problem Asthma Clinic and were 
invited to attend if they had prior definite documented evidence of asthma and had not 
taken part in our pilot study. The second group (Control group) of patients were 
recruited fr om a separate respiratory clinic (Dr MC Cotton) running in the same clinic 
area and were invited to attend if they had definite evidence of Clii'onic Obstructive 
Pulmonary Disease or Interstitial Lung Disease (ILD), but had no evidence to suggest 
underlying asthma. All such patients were given patient information leaflets and gave 
written informed consent for their inclusion in the study which was approved by 
North Glasgow University Hospitals NHS Local Research and Ethics Department 
(Project Number 03RE007). Initially we collected baseline data on degree of asthma 
symptoms, level of medication and spirometry in the patients with asthma. This aspect 
of the protocol was later abandoned as we felt this extra time requir ed with study 
patients was compromising our ability to recruit adequate numbers to the study. Study 
patients were asked to complete the SNOT-22 questionnafre (Appendix 6) and to 
attend the ENT clinic after their attendance in the Respiratory clinic area. They were 
asked not to tell the ENT clinic which specific clinic (i.e. PAG or General Respiratory 
Clinic) they had attended to allow the ENT doctor to be blinded to the patients’ 
respiratory diagnosis. Furthermore ENT were not aware of patients treatment (for 
respiratory disease or otherwise) prior to thefr review. Nasendoscopy was performed 
as previously described by one of two doctors; G W McGany (Consultant ENT 
surgeon) or S Robertson (Specialist Registrar, ENT). If any further ENT review was
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needed, this was arranged accordingly. Therefore patients did not need to attend 
hospital on any separate occasions pm ely for the purposes of the study.
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4.3 Results
Patient Recruitment
A significant hurdle we faced in the imning if this study was recruitment to the study. 
We ran this study on every Wednesday afternoon when there was an ENT clinic 
mnning as well as both Respiratory clinics, following Research and Development 
approval of our study on 9^  ^ January 2004 until the end of December 2004. The 
average number of patients attending the PAC is around 14 each week, non-attendees 
at the clinic are not infrequent (usually 2 - 3  per week) with some patients attending 
more frequently than others. 43 patients had been included in the pilot study and were 
therefore not eligible to take part. Over the course of running this study, 79 patients 
with asthma attending the PAC were asked to take part. 45 refused and 8 were unable 
to give informed consent (unable to read Patient Information Sheet due to lack of 
reading glasses was most fr equent reason given for this). 26 patients with asthma were 
enrolled, but 5 of these did not attend for ENT review leaving only 21 with complete 
questionnafre and nasendoscopic data.
Recruitment of control patients proved even harder with only 7 (4 with COPD, 3 with 
ILD) recruited for this group.
In the Asthma group (10 male, 16 female), the mean age was 45.3 years (range 14 -  
81), and in the control gi'oup (5 male, 2 female), the mean age was 71 years (range 61 
- 88).
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SNOT-22 Scores
Each item in the SNOT-22 scores between 0 and 5 with a higher score indicating 
greater degree of impairment. The mean score for each domain (nasal symptoms (8 
items), physical symptoms other than nasal symptoms (4 items), functional 
impairment 7 items), emotional impairment (3 items)) is then calculated, along with 
the Total score being expressed as the mean of all 22 responses.
SNOT-22 scores are summarised in Table 25. With the exception of the physical 
domain, patients with asthma scored statistically significantly higher than control 
patients on the SNOT-22. In the Asthma group, patients scored higher in the nasal 
symptom domain than the physical (symptoms other than nasal) domain (95%CI for 
difference 0.50, 1.25, p = 0.0002 by Mann-Whitney U-test).
Table 25; SNOT-22 scores. Results are expressed as median (IQR), confidence 
intervals calculated by Mann-Wliitney U-test
SNOT-22 DOMAIN
Total Nasal Physical Functional Emotional
Asthma group 1.46 1.25 0.25 2.57 1.67
(n = 26) (1.14-2.15) (0.88-2.25) (0.0 -  0.88) (1.14-3.32) (0.25-2.42)
Control Group 0.5 0.5 0.0 0.43 0.0
(n = 7) (0.32 -  0.96) (0.13-1.25) (0.0-2.0) (0.29-1.29) (0.0-0.33)
95% Cl for 0.18, 1.64 0.00, 1.50 -0.500,0.50 0.286,2.714 0.00, 2.33
difference, p -value p = 0.017 p = 0.041 p -  0.55 p = 0.02 p = 0.009
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Nasendoscopic Findings
5 of the patients in the Asthma group, and 1 in the control group did not attend for 
ENT review. The main abnormalities found at nasendoscopy are shown in Figure 11.
Figure 11: Distribution of nasendoscopic abnormalities (DNS = Deviated Nasal 
Septum).
Number of 4 -
patients
■ Asthma Group (n = 21) 
0  Control Group (n = 6)
y
Main Abnormality
The “Other” findings were cmsting turbinate (1) and septal ulcer (1). On the basis of 
the ENT findings, 11 of the 15 patients in the Asthma group with abnormalities were 
recommended further ENT review (2 of whom were akeady known to ENT), with 5 
being commenced on nasal steroid and 1 listed for septoplasty for deviated nasal 
septum. Only 1 of the patients from the control group requii ed further ENT review for 
DNS.
The SNOT-22 scores for the Asthma Group according to whether specific 
nasendoscopic abnormalities were found are shown in Table 26. There were no 
statistically significant differences observed in either the Total SNOT or nasal
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symptom domain scores in groups with nasendoscopic abnormalities compared to 
those with normal appearances. Furthermore, there were no differences seen when the 
11 patients who required specific treatment or follow up of their findings were 
compared to the remaining patients (95% CPs for difference -1.45, 0.27 (Total 
SNOT), -0.75, 1.00 (Nasal SNOT).
Table 26; Total SNOT and Nasal SNOT scores according to nasendoscopic 
abnormalities.
NASENDOSCOPIC
FINDING
MEDIAN
SNOT-
TOTAL
(IQR)
95 % Cl FOR 
DIFFERENCE 
vs. NORMALS
MEDIAN
SNOT-
NASAL
SCORE
(IQR)
95 % Cl FOR 
DIFFERENCE 
vs. NORMALS
NORMAL (n = 6)
2.0
(1.31-2.62)
1.81
(0.78-3.15)
POLYPS (n= 6)
1.21
(0.88-2.35)
-1.55, 0.82 1.94
(1.34-2.71)
-1.25, 1.50
DNS(n = 5)
0.55
(0.18-2.04)
-2.23, 0.50 0.63
(0.44-1.00)
-2.62,0.12
OTHER (N = 4)
1.98
(1.46-2.53)
-1.86, 0.95 1.31
(1.16-2.03)
-2.00, 0.88
ANY 
ABNORMALITY 
(n = 14)
1.31
(0.64-2.13)
-1.59, 0.50 1.25
(0.88-2.00)
-1.75,0.63
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Predictive value of nasal symptoms
The sensitivity, specificity, negative and positive predictive values for the prediction 
of any nasendoscopic abnormality by each individual symptom from the nasal domain 
of SNOT-22 (Asthma Group) are shown in Table 27. This analysis was possible using 
data from the 21 patients in this group who attended for ENT review as per study 
protocol. Further analysis was performed to look at the combined value of SNOT 
items to predict abnormalities and this is shown in Table 28. This second analysis 
involved looking at smaller groups of patients, comparing those who had scored 
positively in all of the items tested with those scoring “zero” in all items tested.
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Table 27: Predictive value of nasal domain SNOT-22 items for finding any 
nasendoscopic abnormality.
NASAL
SYMPTOM
SENSITIVITY
(%)
SPECIFICITY
(%)
NPV
(%)
PPV
(%)
Need to blow 
nose
73.3 33.3 33.3 73.3
Sneezing 73.3 33.3 33.3 73.3
Runny Nose 66.7 33.3 28.6 71.4
Nasal
Obstruction
64.3 33.3 28.6 69.2
Loss of Smell / 
Taste
66.7 66.7 44.4 83.3
Cough 93.8 0 0 75
Post Nasal 
Discharge
40 33.3 18.2 60
Thick Nasal 
Discharge
60 50 33.3 75
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Table 28: Predictive value of combination of nasal domain SNOT-22 items for 
finding any nasendoscopic abnormality (Symptom combinations with PPV < 75% are 
not shown).
NASAL SYMPTOM 
COMBINATION
SENSITIVITY
(%)
SPECIFICITY
(%)
NPV
(%)
PPV
(%)
Need to Blow Nose 4- sneezing 
(11=12)
90 33.3 50 81.80
Need to Blow Nose + Loss of Smell / 
Taste (n= 10)
88.9 50 50 88.9
Sneezing + Post-nasal discharge 
(n= 12)
50 75 42.8 80
Sneezing + Loss of Smell / Taste 
(n = 12)
90 33.3 50 81.8
Runny Nose + Loss of Smell / Taste 
(n= 11)
77.8 50 33.3 87.5
Nasal Obstruction + Loss of Smell / 
Taste (n= 12)
70 33.3 25 77.8
Loss of Smell / Taste + Post Nasal 
Discharge (n = 10)
5.6 50 20 83.3
Loss of Smell / Taste + Thick Nasal 
Discharge (n=  16)
66.7 60 42.9 80
Runny Nose + Nasal Obstmction + 
Loss of Smell / Taste (n = 10)
75 50 33.3 85.7
Need to Blow Nose + Loss of Smell / 
Taste + Post Nasal Discharge (n = 6)
83.3 100 50 100
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4.4 Discussion
Our primary aim with this study was to determine the value of routine rhinoscopy in a 
problem asthma clinic. Clearly with the small numbers we recruited to this study we 
cannot make a firm conclusion regarding this. Our hope was that by iiinning the study 
in parallel with patients’ attendance at the clinic, this would have aided recmitment by 
not requiring the patients to attend the hospital on a separate day. Despite this, our 
recruitment rate was poor. Our initial protocol included a short interview with the 
patient to determine degree of asthma symptoms, level of therapy and measurement of 
lung function by spirometry. In our pilot study we did not show any relationship 
between degree of nasal symptoms and asthma symptoms or lung function. Given this 
and that in the initial few weeks of running the study it became clear that this was 
taking too long from the patients’ point of view, we felt collecting this data would not 
be productive, and was not necessary in answering our primary aim. Although 
dropping this aspect of the protocol did help in the nimiing of the study slightly, it 
remained difficult to recruit sequential patients to the study and thus we are unable to 
answer the primary research question. We had designed this study in the hope of 
reducing any potential selection bias which we feel may have accounted for the high 
prevalence of nasal symptomatology in the pilot study. It could be argued that this 
may have been more of a problem with this protocol given that there were 
proportionally less patients in the Asthma group with normal nasendoscopic findings 
(6/21, 29%) compared to our pilot study (22/43, 51%).
We feel that this study has however confirmed that nasal symptomatology is common 
in our clinic population and that structural nasal disease is not uncommon. The SNOT
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questionnake addresses more than simple nasal symptoms and it is clear that the items 
assessing functional and emotional impakment may be influenced by asthma as well 
as any co-existing nasal disease. In the small group we studied, no statistically 
significant difference in nasal symptom domain scores was seen in patients with either 
specific or general nasendoscopic abnormalities.
Another aim of the study was to compare the spectmm of nasal symptomatology and 
disease with a non asthmatic respkatory cohort. We chose patients attending a general 
respkatory clinic running alongside the PAC because again we felt this would aid 
recruitment of this control group and since it would not requke a separate attendance 
on account of the study. Furthermore, this had the benefit of blinding ENT to the 
respkatory diagnosis of the patient. It is not clear however if widening our appeal to 
other general respkatory clinics and therefore asking patients to return on a separate 
day would have helped recmitment in this group. We chose to target patients with 
diagnoses of COPD and ILD as we felt these would be the most appropriate control 
group. Although we found that patients in the control group had statistically 
significantly lower scores on all but the physical domain of SNOT, we feel the 
clinical relevance of this is uncertain given the much smaller number in the control 
group. Recent work in a cohort of patients with COPD found that nasal 
symptoms were common but there is a paucity of other data m this area. This group of 
65 patients had a mean total SNOT-20 score of 1.24 in comparison to our group’s 
median total SNOT-22 of 0.5.
There were proportionally more patients in the control group with a nasendoscopic 
abnormality (5/6, 83%) compared with the Asthma group (15/21, 71%) probably
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reflecting selection bias within the control group. Only one in the control group 
actually required further ENT review for this in comparison with 11 out of 21 patients 
with asthma requiring further ENT review. No further conclusions can be drawn from 
our data given the small number of recruited patients.
Lastly we sought to establish if the predictive value seen with nasal symptoms, either 
lone or in combination m our pilot study would be demonstrated using items from the 
SNOT-22. No firm conclusions regarding this can be made due to the smaller sample 
size in this study. The fact that individual symptoms (Table 27) seemed to be better 
individual predictors of a general abnormality than in our pilot study is not surprising 
given the much higher prevalence of nasendoscopic abnormalities in this study. 
However it is intriguing that the best individual predictor was the item asking about 
loss of smell or taste (PPV 83.3%), with hyposmia found to have PPV of 80% 
previously. The smaller numbers in groups with symptom combinations again make 
definite conclusions impossible although it is noteworthy that symptom combinations 
including the item “loss of smell or taste” were associated with greater likelihood of 
finding a nasendoscopic abnormality.
In conclusion, for the primary research question to be answered, the larger number 
and higher proportion of clinic attendees which needed to be studied to determine the 
true role of routine rhinoscopy in an asthma clinic was not achieved. Our data has 
failed to answer this question. This data does however add to our local evidence that 
not everyone with a nasal problem will necessarily volunteer symptoms prompting 
referral for ENT evaluation. Whether a validated instrument such as the SNOT adds 
more practical information regarding nasal symptomatology than a simple scoring
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system as was used in our pilot study (Chapter 3) is not clear and further work to 
evaluate these two tools together in the same patients together with nasendoscopy is 
warranted.
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CHAPTER 5
THE ROLE OF PROGRESSIVE EXERCISE TESTING AND 
HISTAMINE CHALLENGE IN THE DIAGNOSIS OF VOCAL 
CORD DYSFUNCTION (VCD)
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5.1 Introduction
Although we found evidence of a range of functional laryngeal abnormalities in our 
pilot study (Chapter 3), we did not identify any patients with classical appearances of 
VCD. Given this and prior studies which have discussed the separate role of 
methacholine(^ and exercise challenge testing(^^) in VCD diagnosis, we therefore 
sought to establish if a strategy of performing histamine challenge and progressive 
exercise testing in patients suspected of having VCD was of diagnostic value. We also 
evaluated FOT in this protocol to determine if it had the potential to provide a non- 
invasive alternative to laryngoscopy.
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5.2 Methods
Patients attending the PAC were invited take part in the study on the basis of two 
inclusion criteria:
• VCD was suspected on clinical grounds
• Patients with objective evidence of asthma who had persisting 
breathless and wheeze despite moderate doses of inhaled 
corticosteroids and long acting bronchodilators (Step 3 of British 
Thoracic Society treatment guidelines(^)).
Patients who would have been unable to midertake histamine challenge or progressive 
exercise testing because of severe asthma or any other reason were excluded from the 
study. All invited patients were given patient information sheets about the study. 
Those willing to take part gave written informed consent for their inclusion in the 
protocol which was approved by North Glasgow University Hospitals NHS Trust 
Research and Ethics Committee (Project Number 03RE005).
The following measui'ements were made on the study visits.
Visit 1
Baseline Data
Current asthma treatment and symptoms of asthma morbidity(^^^) were recorded using 
the Royal College of Physicians (RCP) 3 symptom score (days and nights affected by
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asthma symptoms, and days of limited activity due to asthma over the previous seven 
days). 24 hour monitoring of oesophageal pH and manometry, off all acid suppressing 
therapy, was requested in all patients.
Forced oscillation technique (FOT)
Forced oscillometry was performed as previously described (Chapter 3.2).
Standard Pulmonarv Function Testing
Standard spirometry and flow volume loops were measured using a body 
plethysmograph as described in Chapter 3.2. Occlusion resistance (R^ J^ was also 
measured as previously described.
Baseline Larvngoscopv
Laryngoscopy using a flexible fibreoptic laryngoscope was performed by a single 
observer (Mr K MacKenzie) following topical application of local anaesthesia, co- 
phenylcaine, to the nose and nasopharynx. The assessment of the larynx was based on 
structure and function. Laryngeal appearance was noted with the mobility of the vocal 
cords on phonation, inspiiation and expkation. This observer was blinded to all 
clinical details of the patients.
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Histamine Challenge Testing
In accordance with ATS guidelines(^^^), patients inhaled increasingly concentrated 
solutions of histamine (starting at 0.03 mg/ml, doubling on subsequent inhalations up 
to a maximum concentration of 16 mg/ml) via a nebuliser. Each dose was 
administered over two minutes. FEV i, MEF50, MIF50 MEF^/MIF^g ratio, Rocc and 
FOT were repeated after each inhalation as described above, with FOX being 
measured over only one 1-minute sampling period. The test was stopped once the 
patient’s FEV i dropped by > 20% from baseline. 2.5 mg of nebulised salbutamol was 
then administered to relieve bronchospasm.
Post-Challenge Larvngoscopv
Immediately after histamine challenge, the patient underwent repeat laryngoscopy as 
described above but without instillation of fui'ther local anaesthetic.
Visit 2
Baseline physiological parameters were recorded as described above. Laryngoscopy 
was not repeated at this stage.
Progressive Exercise testing
Symptom-limited exercise tests were performed using an electrically braked bicycle 
ergometer (SEGA Cardiotest 100, Salford, England). The patients were initially
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monitored for two minutes whilst seated at rest, to obtain baseline values, then asked 
to exercise for as long as possible until symptomatic limitation. A standard 12-lead 
electrocardiogram was displayed throughout the proceduie. During the first two 
minutes of exercise, no additional load was applied. Thereafter, the work load was 
increased by 10-25 watts, depending on the individual patient, every minute until 
symptomatic limitation. Throughout each test, minute ventilation (V’E), oxygen 
consumption (V’02) and carbon dioxide (V’C02) were measured breath by breath by 
on-line ventilation and expired gas analysis (MedGraphics CPX-D) and the 
ventilatory anaerobic threshold on exertion was calculated by the curve fitting method 
using a plot of V’02 against V’C02 (^ ™). These results are not reported however as 
the primary aim of performing the exercise test was to determine if VCD was 
precipitated.
Post-exercise evaluation
FEV i, MEF50, MIF50 MEFgo/MIFgg ratio, Rocc and FOT were repeated as described 
above (with a one minute sampling period for FOT was used) before laryngoscopy 
was performed as described above.
Other Study Visits
Given the variable nature of VCD, we also attempted to identify VCD by encouraging 
patients to attend during an attack of typical symptoms so that laryngoscopy could be 
undertaken at that time. All study patients were asked to contact AES (by radiopage 
via the hospital switchboard number given with the patient information sheet) in the
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event of an exacerbation of symptoms so that prompt laryngoscopy could be 
performed in our hospital’s ENT casualty clinic. This facility was available during 
office hours Monday to Friday.
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5.3 Results
9 patients agreed to take part in the study, but one was excluded completely on 
account of poorly controlled asthma with an FEVi of 0.821 (48% predicted) at 
baseline. Of 8 subjects therefore, there were 2 males and 6 female with a median age 
of 46 (range 37 -  79 years). All subjects had asthma with clinical featui'es to suggest 
VCD (upper aii'way noise with or without intermittent choking). 4 patients were on 
BTS Step 5 level of treatment (taking a mean daily dose of 11.5mg oral prednisolone). 
Of the remaining 4 patients two were on BTS Step 4 and two on BTS step 3. Mean 
(SD) RCP symptom score was 10.4 (9.3), range 0 - 2 1  (21 being maximum possible 
score).
Baseline FEVi ranged from 1,34 to 3.48 litres, mean (SD) of 2.39 (0.70) litres, 
equating to 59 to 106 % predicted, mean (SD) 86.8 (16.8). FEVi/FVC ranged from 50 
-8 5 , mean (SD) 70.4(11.6).
4/8 patients undertook oesophageal pH monitoring (the other 4 declined to attend for 
this). 3/4 patients who attended had abnormal oesophageal acid exposuie (AOE) (% 
time pH < 4 (normal being up to 4.5%) ranged from 13.8% to 67.6%, mean 37.3%).
Laryngoscopy findings
No patient was found to have evidence of VCD at baseline. Following histamine (n = 
8) and exercise testing (n = 7) VCD was not precipitated in any patient. In terms of
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laryngeal structure, at baseline 5 /8  patients had mild chronic laryngitis (including all 
3 patients with documented AOE) with the remaining 3 having normal appearances. 
All 8 patients had normal laryngeal function. There was no discrepancy between 
baseline and post challenge findings recorded. No study patient contacted us to 
arrange laryngoscopy during an acute attack of typical symptoms of breathlessness.
Physiological Evaluation -  1 -  Histamine Challenge testing
Baseline and post histamine challenge physiology data are shown in Table 29. No 
change in the appearance of the inspiratoiy limb of the flow-volume loops, performed 
at each stage of the histamine challenge, was seen in any patient. Data on MEF and 
MIF 50 were lost in a computing system accident. Histamine PC20 ranged from 0.02 
to 3.12 mg/ml, mean (SD) 1.13 (1.18).
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Table 29: Physiology data before and after histamine challenge. Data are expressed in
Mean (SD). Confidence Intervals for difference calculated by paired t-tests.
VARIABLE Baseline Post Histamine 
challenge
95% C l for difference 
compared to baseline
FEVi (1) 2.39 (0.70) 1.7(0.56) 0.45, 0.80, p <  0.001
Rocc (kPa/Fsec) 0.34 (0.07) 0.55 (0.13) -0.30, -0.12, p = 0.001
Rt (kPa/l/sec) 0.42 (0.15) 0.66 (0,18) -0.40, -0.08, p = 0.01
Re (kPa/I/sec) 0.46 (0.16) 0.66 (0.18) -0.38, -0.03, p = 0.027
Ri(kPa/Fsec) 0.41 (0.17) 0.69 (0.16) -0.45, -0.12, p = 0.005
MEFso (Fmin) 2.40 (1.38) ******
MlFso (Emin) 4.14(1.38) ****** îJC îjî îjî ÎÎÎ rfî rj*
There was a statistically significant correlation between FEVi and Ri (r = -0.69, p = 
0.041), but none between FEVi and Rocc (-0.56, p = 0.116), Rt (r = -0.64, p =0.063) 
or Re (r = -0.58, p = 0.101).
Resistance measui'ed by FOT during each part of the respiiatory cycle increased in 
parallel during histamine challenge (Figures 12,13 and 14, each line representing 1 
patient), with the largest percentage changes being seen in Ri (mean % increase of 
108.6% for Ri versus 65% for Rg)
153
Figure 12: Total Airways Resistance (Rt) during Histamine challenge
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Figure 13: Expiratory Airways Resistance (Re) during Histamine challenge
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Figure 14: Inspiratory Airways Resistance (Ri) during Histamine challenge
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Physiological Evaluation -  2 -  Progressive Exercise Testing
There was no significant difference observed between baseline physiology 
measurements before exercise testing and histamine challenge testing (Paked t-tests). 
Baseline and post exercise testing physiology data are shown in Table 30 (n = 7). 
There was no evidence of truncation of the inspiratory limb of the flow-volume loop 
seen following exercise in any patient. As these results show, there was no evidence 
of any intra or extrathoracic airway narrowing demonstrated with exercise challenge 
with the recognised bronchodilatation following exercise being documented by FOT 
measurements, but not spirometry. VO2 max ranged from 7.4 to 16.6 mls/kg/min, 
mean 11.4 (36.9 to 71.2 % predicted, mean 52.0)
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Table 30: Physiology data before and after exercise challenge. Data are expressed in
Mean (SD). Confidence Intervals calculated by paired t-tests.
VARIABLE Baseline Post Exercise 
Testing
95% Cl for difference 
compared to baseline
FEVi (1) 2.52 (0.49) 2.66 (0.75) -0.43, 0.14, p = 0.26
Rocc (kPa/Fsec) 0.38 (0.08) 0.38(0.10) -0.06, 0.05, p = 0.86
Rt(kPa/Fsec) 0.51 (0.18) 0.29 (0.10) 0.05, 0.39, p = 0.021
Re (kPa/Fsec) 0.54 (0.18) 0.37(0.10) 0.03, 0.32, p = 0.023
R i (kPa/l/sec) 0.46 (0.18) 0.25 (0.09) 0.04, 0.40, p = 0.025
MEF50 (Fmin) 2.72 (1.05) 2.65(1.13) -0.05, 0.19, p — 0.21
MIF50 (Emin) 4.67 (0.18) 5.12(1.36) -0.81,0.11,p = 0.11
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5.4 Discussion
The primary aim of our study was to determine the diagnostic value of challenging 
patients, in whom we suspected VCD as a contributing factor to their symptoms, with 
histamine and exercise. We did not identify a single case of VCD following either 
challenge in 7 patients, or following histamine challenge in a further patient. Clearly 
the small numbers included in our protocol have resulted in an underpowered study, 
but the negative results, as well as the intensive nature of the protocol, made further 
recruitment increasingly difficult. It is also unfortunate that none of our patients made 
use of the facility to have laryngoscopy at the time of an attack of symptoms. This 
would have been the gold standard to compare the negative results of challenge 
testing with in our study.
Estimating the appropriate number needed for this study is difficult due to the 
uncertainty of estimates of the true incidence and prevalence of VCD. Different 
studies have found prevalence ranging from 2.4% to 9.5% in samples of 1025 
and 105 respectively with the latter study made use of challenge testing. VCD has 
been found to co-exist with asthma in 22 out of 132 (16.7%) patients, although this 
was from a tertiary referral centre with a particular interest in VCD (^ )^. Given these 
figures we suspect we have a number of patients with VCD attending our clinic, and 
therefore likely to be included in our sample. In all patients recruited to the study, the 
suspicion of VCD arose from upper airway noise evident when seen in clinic with (4 
patients) or without choking.
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It is well recognised that examining patients in the resting state is frequently non 
diagnostic and studies which have looked at methacholine and exercise testing have 
suggested this will improve the diagnostic yield of VCD. Despite Newman’s case 
series describing how methacholine challenge can unmask VCD in some patients(^^), 
there has only been one prospective evaluation of methacholine challenge in VCD 
diagnosis("^^). In this study however, the patients in whom the challenge was positive 
were already known to have VCD, with only 2 of 10 such patients developing VCD 
post MCT. There were 12 patients with exercise induced asthma and 12 control 
patients also evaluated in that study none of whom developed VCD following MCT. 
This may therefore overestimate the usefulness of MCT in VCD diagnosis if the test 
is applied to a cohort of people with only suspected, rather than proven VCD. Our 
negative findings, albeit in a small cohort suggest that challenge testing is not a useful 
diagnostic strategy in this situation.
As well as direct visualisation of the cords we performed detailed physiological 
assessment during and after histamine and exercise challenge. The literature 
describing upper-airway hyperresponsiveness (or extra-thoracic airway 
hypenusponsiveness, EA-HR) resulting in upper afrway nanowing as a phenomenon 
that can occur in isolation or associated with lower airway hyperresponsiveness has 
been discussed in detail in Chapter 1. This has been defined as a 25% decrease in 
mid-inspiratory flow during histamine challenge(^^’^ ®). Perkins('^^) found flattening of 
the inspiratory limb of the flow-volume loop during histamine challenge in the 
absence of VCD. We did not demonstrate any changes in the inspfratory limb of the 
FVL during either our histamine or exercise challenges. We are however unable to 
clarify precisely whether MIF50 changed significantly during histamine challenge as
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this data was lost. Therefore we cannot quantify extra thoracic airway reactivity in our 
study group. Following exercise testing however there was no evidence of any extra- 
thoracic airway narrowing.
Measurements of aii'ways resistance (Forced Oscillation Technique (FOT) and Rocc) 
were used as further assessments of airway physiology because we hypothesised that, 
as in our pilot study (Chapter 3) if VCD was identified, the possibility of 
compartmentalising airways resistance between inspiration (Ri) and expiration (Re) 
might provide non-invasive diagnostic information. We also planned to compare FOT 
derived measurements of airways resistance with Rocc, if VCD had been identified. As 
VCD was not identified we cannot make any further comment on this but it is worth 
noting that Ri increased in parallel with Rt and Re during histamine challenge. The 
observed rise in Ri which was proportionately greater than the change in Re during 
HCT raises the possibility either that we were observing a subtle form of EA-HR, 
although no definite changes in the inspfratory FVL were seen, or that lower aii'ways 
narrowing in inspiration is a contributing factor to these patients’ “noisy breathing”.
We used histamine rather than methacholine because the foi*mer is available locally to 
us. Both agents are bronchoconstrictors that act dii’ectly on bronchial smooth muscle 
and although different molecules, the rationale for thefr use is similar. We gave 
patients nebulised bronchodilator immediately after the histamine challenge test and 
before performing laryngoscopy as, we felt it would be unethical not to abrogate the 
lower aii'way response promptly. There is no reason to believe that any paradoxical 
movement of the cords, if produced, would be abolished by beta-agonists, particularly 
when a common theme in case series of VCD is the lack of symptomatic response to
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anti-astlima therapy. No such paradoxical movement was seen at laryngoscopy, or 
suggested, prior to nebulised salbutamol, by any change in flow volume loops. 
Logistically it was impossible to perform laryngoscopy in the same room as the 
histamine challenge or exercise test, and the patients had to be transported (by chair 
after histamine challenge) 200 yards to the ENT department from the Pulmonary 
Function Lab.
In conclusion, in a small sample of patients with asthma in whom VCD was suspected, 
a strategy of undertaking histamine and exercise testing was of no diagnostic value in 
any patient. As far as we are aware our study is the first to prospectively evaluate both 
investigations in patients suspected of having VCD. For the time being, direct 
visualisation of the vocal cords at laryngoscopy at the time of symptoms remains the 
gold standard for VCD diagnosis, despite the logistic difficulty which this often 
imposes.
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CHAPTER 6
AN OBSERVATIONAL INVESTIGATION OF DYSFUNCTIONAL 
BREATHING AND BREATHING CONTROL THERAPY IN A 
PROBLEM ASTHMA CLINIC
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6.1 Introduction
It is increasingly recognised that dysfunctional breathing (or hyperventilation 
syndrome) can be an important co-existing factor in patients with asthma(^’^ )^. As 
discussed in Chapter 1, potential diagnostic instmments have not been extensively 
validated in patients with asthma.
This chapter describes attempts to identify dysfunctional breathing in our cohort of 
patients with moderate to severe asthma and to monitor the effect of breathing control 
therapy, delivered by a specialist physiotherapist. The measuiement of physiological 
aspects of breathing pattern are discussed separately in Chapter 7.
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6.2 Methods
All patients attending the PAC over a 5.5 month period who were being assessed 
using our standard protocol (Chapter 2), were included in this data set (new and 
existing patients). Baseline data on current treatment and current symptoms of asthma 
morbidity were recorded using the RCP score (as previously described) (^ ^^ ). Case 
notes were reviewed to determine the basis for patients’ diagnosis of asthma. Patients 
Nijmegen and Mini-AQLQ responses were reviewed and all patients who had a 
Nijmegen score > 23 were reviewed by the Respiratoiy Physiotherapy Specialist 
(PV), assessed for their individual requirement for breathing control therapy (BCT) 
and referred for progressive exercise testing. There were some occasions where the 
Physiotherapy Specialist was not present at the out-patient clinic, and in these 
circumstances, a separate out-patient review was aiTanged.
Assessment of Breathing Pattern and Breathing Control Therapy (BCT)
Patients with a score > 23 on their Nijmegen questionnaire were reviewed by a 
specialist physiotherapist with experience in breathing control (Mrs Pamela Vaughn, 
PV). Breathing pattern, including rate, depth and location and end inspiratoiy and 
expiratory breath holding times were assessed. Data on inspiratory breath hold time 
(in seconds) at end of inspiration at initial visit and subsequent follow up visits were 
collected (measured manually).
The possible relationship between asthma and over-breathing was discussed with the 
patient, followed by re-education of any specific components of patients’ breathing
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pattern which were identified as being dysfunctional (tidal volume, flow rate or 
respiratory rate). The breathing cycle was broken into 3 phases -  relaxed tidal 
inspiration, passive expiration to tidal volume and active effort to reach expiratory 
reserve with encouragement for a natural pause of a few seconds before the next 
inspiratory phase. Forced inspiratory or expiratory movements were discouraged as 
these were felt likely to reinforce or precipitate dysfunctional breathing pattern and 
therefore symptoms. Nasal breathing, to maximise conditioning of air reaching the 
lungs was encouraged. Patients were encouraged to practise the new breathing pattern 
6-8 times per day for 10 minutes at a time initially. Once learned, the new breathing 
pattern was advised during sitting, standing, walking and activities which would 
provoke breathlessness. This approach represents standard physiotherapy practice.
After the initial assessment, patients who required fuither intensive input were 
identified. These patients tended to be those who were unable to establish good 
abdominal breathing pattern or were unable to sustain an expiratoiy pause for more 
than 3 consecutive breaths. They were offered weekly outpatient review for 4 weeks 
followed by physiotherapy review coinciding with subsequent asthma clinic 
appointments. All patients were therefore followed up at subsequent clinic 
appointments.
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Progressive Exercise Testing
Symptom-limited exercise tests were performed using an electrically braked bicycle 
ergometer (SECA Cardiotest 100, Salford, England). The patients were initially 
monitored for two minutes whilst seated at rest, to obtain baseline values, then asked 
to exercise for as long as possible until symptomatic limitation. During the first two 
minutes of exercise, no additional load was applied. Thereafter, the work load was 
increased by 10-25 watts, depending on the individual patient, every minute until 
symptomatic limitation. Throughout each test, minute ventilation (V’E), oxygen 
consumption (V’0 2 ) and carbon dioxide (V’C0 2 ) were measured breath by breath by 
on-line ventilation and expiied gas analysis (MedGraphics CPX-D). An ECG 
recording was made thi’oughout the test. The ventilatory anaerobic tlireshold on 
exertion was calculated by the cuiwe fitting method using a plot of V’O] against 
V’C02.(^^^) The dead space to tidal volume ratio (VdA^t) and alveolar-arterial oxygen 
gradient (A-a0 2 ) was computed fi'om mixed expired gas concentrations and blood gas 
analysis (Chiron Diagnostics Rapid Lab 855) using an arterialised ear lobe capillary 
sample. The blood samples were obtained at rest and at peak exercise with the gas 
exchange values calculated using standard equations.(^^^) Trans-cutaneous pC02 was 
also measui'ed throughout the procedure.
Follow Up
Nijmegen and Mini-AQLQ responses, in addition to breathing pattern parameters 
were collected on review of all patients attending the clinic at approximately 6 months 
follow up in the clinic where available. Some patients had been discharged by this
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time point, and others defaulted. We were looking for a long term effect from this 
intervention and judged this to be an appropriate time to collect outcome data.
Statistical Analysis
Spearman rank correlations were used to examine relationships between parameters 
when one or both were non-normally distributed. Pearson correlations were used to 
examine relationship between normally distributed parameters. Baseline questiomiafre 
data in groups divided according to Nijmegen scores were compared using Mann- 
Whitney U tests. Follow up questionnaire data was compared to baseline with Mann- 
Whitney U tests. All data was analysed using Minitab (Version 14) statistical 
software.
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6.3 Results
Baseline Data
111 patients were assessed over a 5.5 month period. 9 had previously seen the 
Physiotherapy Specialist for BCT and so were excluded from analysis. There were 72 
females (71%) and 30 males. The average age (range) was 48 (13.5 -  83) years. Case 
notes were reviewed to determine best objective evidence of asthma available for each 
patient (Table 31).
Table 31: Basis of Asthma Diagnosis in study population (n = 102)
BEST OBJECTIVE EVIDENCE 
AVAILABLE
NUMBER OF PATIENTS
Bronchodilator reversibility >12% 52
Bronchial Hyper-reactivity (BHR) 8
PEFR variability 19
Steroid trial 1
Good clinical history only 11
No objective evidence 11
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The range of asthma treatment of the study group at baseline is shown in Figure 15.
Figure 15: Level of treatment of study group.
Number of 
Patients
BTS Step
28 patients were taking long term oral corticosteroids (range 5mg -  30mg per day, 
median lOmg).
Patients reported the hill range of RCP astlima morbidity scores (0 -2 1 , with a higher 
score indicating more severe symptoms) with a median score of 14 (IQR 3.8 - 21). 
There were 8 patients who did not have complete RCP symptom score data at 
baseline.
Baseline Nijmegen and mini-AQLQ scores for the whole study population are shown 
in Table 2. The mean (range) overall Mini-AQLQ score for the cohort was 3.30 (1.07 
-  6.93) and mean (range) Nijmegen score for the cohort was 26.4 (1 -  61). Maximum 
Nijmegen score is 64, with a score > 23 defining hyperventilation in non asthma 
patients. All parameters were normally distributed. The study group was separated
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into two groups, on the basis of a Nijmegen score < 23 (described as having no 
evidence of dysfimctional breathing syndrome (No DB)) or > 23 (those with evidence 
of dysfunctional breathing (DB)). Only the latter group received breathing control 
therapy and were referred for progressive exercise tests (PET) to confirm the presence 
of inappropriate hyperventilation. It was felt to be out-with the scope of our standard 
clinic protocol to perform PET in the Non-DB group. Due to pressure on our lung 
function laboratory, those patients who did not attend PET were not offered a further 
appointment unless they contacted the department to re-schedule their PET. There 
were significant differences between groups for total Mini-AQLQ scores (Table 32) 
and all Mini-AQLQ domains.
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Table 32: Baseline Questionnaire Data: Nijmegen and Mini-AQLQ scores (DB = 
Dysfunctional Breathing).
VARIABLE RANGE MEAN (SD)
95% Cl for 
difference between 
No-DB and DB, p- 
valne)
Mini-AQLQ
(Overall)
All Patients (n = 102) 1.07-6.93 3.30 (1.36)
0.87, 1.87
p < 0.0001
No DB (n = 37) 1.27-6.93 4.12(1.43)
D B (n=65) 1.07-5.47 2.83 (1.07)
Mini-AQLQ
(Symptom
Domain)
All Patients (n = 102) 1.00-6.80 3.11 (1.40)
0.8, 2.00, p <  0.0001No DB (n = 37) 1.00-6.80 4.01 (1.53)
D B (n=65) 1.00-5.40 2.60(1.03)
Mini-AQLQ
(Environment
Domain)
All Patients (n = 102) 1.00-7.00 3.43 (1.64)
0.33, 2.00, p = 0.004No DB (n = 37) 1.33-7.00 4.12(1.82)
DB (n = 65) 1.00-6.67 3.03 (1.40)
Mini-AQLQ
(Emotional
Domain)
All Patients (n = 102) 1.00-7.00 3.27 (1.56)
0.33, 1.67, p = 0.01No DB (n = 37) 1.00-7.00 3.84(1.66)
D B (n=65) 1.00-6.00 2.94(1.42)
Mini-AQLQ
(Activities
Domain)
All Patients (n = 102) 1.00-7.00 3.44 (1.63)
1.00,2.25, p <  0.0001No DB(n = 37) 1.25-7.00 4.45 (1.64)
DB (n = 65) 1.00-6.75 2.87(1.33)
Nijmegen
All Patients (n = 102) 1 -6 1 26.4(11.5) ******
No D B (n=37) 1 -2 2 14.5 (5.4) ******
D B (n=65) 2 3 -6 1 33.2 (7.9) ******
The overall Mini-AQLQ score and each domain (symptoms, environment, emotional 
and activities, data not shown as relationships very similar) correlated well with the 
Nijmegen scores, as shown in Figure 16.
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Figure 16: Relationship between Nijmegen and Mini-AQLQ (overall score)
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Nijmegen scores varied widely across the range of RCP symptom scores (Figure 17), 
although a statistically significant coiTelation was observed (Spearman Rank r = 0,43, 
p < 0.001). There was a better relationship between RCP symptom score and Mini- 
AQLQ (Spearman Rank r = -0.69, p < 0.001, Figure 18).
Figure 17: Relationship between level of asthma symptoms and Nijmegen score
60
50
40
30
20
10
0
0 105 15 20
RCP - Total
171
Figure 18: Relationship between level of asthma symptoms and Mini-AQLQ
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Progressive Exercise Testing (PET)
Of the 65 patients with positive Nijmegen scores, 21 (33%) had a co-morbidity which 
made progressive exercise testing impossible. Of those able to undertake PET (42), 24 
(57%) attended for this investigation. 7 patients were unable to complete this 
investigation due to wheeze (4) or locomotor problems (3). 17 PETs were therefore 
undertaken.
Mean (SD) VO2 Max attained was 11.5 (4.6) mls/kg/min, representing mean (SD) 
44.4 (14.9) % predicted values. All patients had a VE/VCO2 > 30 (range 34-73, mean 
(SD) 47.6 (9.1) indicating an elevated ventilatoiy response. In order to assess whether 
this was inappropriate, we looked at changes in trans-cutaneous paC0 2  during the test. 
A fall of trans-cutaneous paC02 to < 35 mmHg or by > 10% from baseline was 
defined as indicating inappropriate hyperventilation and 10/17 patients (59%) 
displayed this.
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There was no difference in Nijmegen scores of those patients with and without 
evidence of mappropriate hyperventilation on PET. This data is shown with the 
scatter of Nijmegen scores, in Figure 19.
Figure 19: Nijmegen scores for patients completing PET (n = 17), subdivided by the 
finding of no inappropriate hyperventilation and inappropriate hyperventilation.
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Physiotherapy assessment and attendance fo r Breathing Control Therapy (BCT)
All 65 patients who scored positively on the Nijmegen questionnaire were assessed by 
a specialist resphatory physiotherapist as outlined above, and offered breathing 
control therapy. 9 patients did not attend BCT at any given time with the remaining 56 
patients being reviewed on a median (range) of 3 (1-15) occasions. 8 patients were 
seen once only.
173
Follow up data
Follow up questionnake data was available for mini-AQLQ in 46 patients (17 No DB, 
29 DB) and Nijmegen scores in 44 (15 No DB, 29 DB), at an average (SD) 186 (23) 
days. 1 patient with a positive baseline Nijmegen score completed follow up 
questionnaires but had not attended BCT and so was excluded from analysis. The 
most frequent reasons for missing data were prior discharge from the clinic or failure 
to attend around the desired follow up of 6 months after baseline data collection; time 
restraints on the patients’ part when attending the clinic was a further contributing 
cause.
The results are grouped according to the baseline Nijmegen score (Table 33), with 
only those having baseline and follow up scores included. 95% Confidence intervals 
were calculated (Mann-Whitney U tests) for the difference between baseline and 
follow up scores (also shown in Table 33), and demonstrate no significant difference 
in either overall Mini-AQLQ (or any separate domain, data not shown) or Nijmegen 
scores in either No DB or DB gioups.
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Table 33: Follow up Mini-AQLQ and Nijmegen scores (DB = Dysfunctional 
Breathing).
VARIABLE RANGE MEAN
(SD)
95% C.I. FOR 
DIFFERENCE 
FROM 
BASELINE
Nijmegen
DB
(n = 29)
14-49 29.7 (9.3) -1,9
No DB 
(n-15)
6 -3 2 18.5 (7.3) -9,2
Mini-AQLQ
(Overall)
DB
(n = 29)
1.20-5.33 3.04 (1.07) -0.87, 0.33
No DB 
(n=17)
1.27-6.27 4.22 (1.47) -1.33, 1.00
Although there were no significant differences between baseline and follow up 
Nijmegen scores in either group, there were 8/29, 28% of patients in the DB group 
whose Nijmegen scores fell into the normal range following BCT. There was no 
significant difference in level of asthma symptoms following BCT compared with 
baseline in this subgroup of patients (RCP score, 95 % Cl for difference -9, 12 
(Mann-Whitney U-test).
There were 9 /2 9  (31%) of the patients who received BCT and completed follow up 
data who had a clinically significant improvements in Mini-AQLQ and this was 
observed in 6 /17 (35%) of those without evidence of DB.
In the 17 patients who completed PET, follow up Nijmegen and Mini-AQLQ were 
available in 5 of the 10 patients shown to have inappropriate hyperventilation on PET
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and 3 of the 7 not shown to have inappropriate hyperventilation. At follow up there 
was no difference seen in either parameter (Figures 20 and 21).
Figures 20 and 21: Available Baseline and follow up Questionnaire data for patients 
who had PET (n = 8, 3 no inappropriate hyperventilation (labelled No PET HVS), 5 
inappropriate hyperventilation (labelled PET HVS), Nij = Nijmegen). Mami-Wliitney 
U-tests show no significant differences in any group.
Figure 20
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Figure 21
Global physiotherapy assessment o f efficacy o f BCT
Inspiratory breath hold times (BHT) were improved in all patients following BCT 
from median (IQR) of 10 (7 -  15) seconds at baseline to 20 (15 -  22) seconds at 
follow up (95% C l-10, -5, p < 0.001 by Mann-Wliitney U-test, Figure 22, n = 55).
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Figure 22: Inspiratory breath hold times (BHT, seconds) at baseline and at follow up
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Followmg BCT, global assessment of compliance and benefit was made by PV. This 
was a subjective assessment, but was done with the knowledge of all objective 
measurements, including breath hold times and Nijmegen scores beforehand and 
aftei*wards. 7 / 2 9  patients who attended and had follow-up data were felt to have 
complied well and benefited from BCT. These patients had a mean (SD) fall in 
Nijmegen score of 5.1 (7.5).
There were 8 patients whose Nijmegen score fell to less than 23. Only 3 were 
included in the subgroup identified above, as having complied well and benefited 
from BCT suggesting regiession to the mean. Median BHT improved from 15 to 21 
seconds in this subgroup (95% Cl for difference -13.01, 0.0, p =0.049). All but 1 also 
had an improvement in Mini-AQLQ (range -0.27, 2.93, mean (SD) 0.96 (0.99)), and 5 
had >0.5 improvement in total Mini-AQLQ score with improvements in all 4 AQLQ
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domains and no significant difference in level of asthma symptoms (median RCP 
score of 8 at baseline and follow up).
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6.4 Discussion
In collating and analysing these data from as complete as possible a cohort of patients 
attending a problem asthma clinic, we have described the range of symptoms, quality 
of life and Nijmegen scores in a group, most of whom (78%) have objective evidence 
of asthma and most (76%) were on BTS step 4 or 5 asthma therapy. This analysis 
shows the impact on quality of life and the distribution of Nijmegen scores, which in a 
normal population would suggest dysfunctional breathing. Analysis of the inter­
relationships between symptoms and quality of life measures shows that Nijmegen 
responses and RCP symptom scores relate closely to Mini-AQLQ, although Nijmegen 
scores conelated less well with RCP symptom scores, raising the possibility that 
Nijmegen questions are assessing a different aspect of patients’ experience.
We attempted to identify patients with dysfunctional breathing in order to provide 
breathing control therapy, with a dedicated respfratory physiotherapist usually present 
at the clinic and able to work with patients in a time-efficient manner (for both 
parties). We defined dysfunctional breathing by Nijmegen score, but sought to 
confirm the presence of inappropriate ventilation by progressive exercise testing. 
Some of the Nijmegen questions relate to typical asthma symptoms with the 
possibility that dysfunctional breathing would thereby be over-estimated in this group.
Evidence suggesting Nijmegen scores have a role on the diagnosis of dysfunctional 
breathing has been discussed but in Thomas’ study (^ ^^ ) objective evidence of asthma 
was not detailed, with patients selected on the basis of a clinical diagnosis and 
receiving a prescription for bronchodilator therapy. In the subsequent randomised
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controlled trial of BCT however, most patients (28/33) had objective evidence of 
asthma,
The lack of a gold standard makes objective study of this phenomenon difficult and 
highlights the importance of global assessment by a specialist therapist as a further 
method of assessment.
Using the standard definition, based on Nijmegen score, to identify DB, our baseline 
data shows a high prevalence of this (65/102, 64%) in this cohort of patients with 
asthma. This is a higher frequency than in cohorts quoted above, which may reflect a 
higher prevalence of DB in patients with more severe disease (77 of 101 patients were 
on BTS Step 4 treatment or above) but may also be due to the Nijmegen questionnaire 
overestimating the prevalence of DB, by wrongly attiibuting symptoms of poor 
asthma control to dysfunctional breathing. In keeping with this interpretation, we 
found a significant relationship between level of asthma symptoms, using a numerical 
version of the RCP symptom score, with symptoms rated over the previous week, and 
Nijmegen scores (r = 0.43, p < 0.001). We found a stronger relationship between 
Nijmegen and Mini-AQLQ than between asthma symptom score and mini-AQLQ, 
raising the possibility that Nijmegen is measuring the perceived impact of symptoms, 
and thus, some aspect of asthma related quality of life.
We sought to confirm the presence of inappropriate hyperventilation by Progressive 
Exercise Testing. In the identification of this we considered a fall of trans-cutaneous 
pC02 to < 35mmHg or by > 10% from baseline in patients displaying an elevated 
ventilatory response to show mappropriate increased ventilation. There has been no
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prior validation of this definition, but we felt this was reasonable. This was seen in 10 
out of the 17 patients (59%) in whom we had PET data. Given that neither Nijmegen 
nor PET can be regarded as a gold standard, is not clear whether the lack of 
agreement between Nijmegen-identified DB and PET-identified inappropriate 
hyperventilation is explained by poor specificity of the Nijmegen or poor sensitivity 
of PET. From the scatter plot of Nijmegen scores in those with and without 
inappropriate hyperventilation on PET (Figure 19) it is clear that increasing the 
threshold Nijmegen score, in patients with asthma would not impact on this, if PET is 
considered the gold standard. Clearly it would have been interesting to look at PET 
findings in those with negative Nijmegen scores, but this would have been out-with 
the scope of our normal clinic protocol. Finally, it is important to note that the low 
attendance rate for PET limits the generalisability of these findings.
The second part of this observational study involved assessing the effect of breathing 
control therapy on Nijmegen and mini-AQLQ scores. We obseiwed no significant 
differences in Nijmegen or mini-AQLQ scores (either total or separate domain scores) 
after BCT in either group, with Nijmegen scores in particular showing evidence of 
regression to the mean.
There was a subgroup of 8 patients with a clinically coherent pattern of changes, 
whose Nijmegen scores fell into the normal range. In this subgroup, breathing control 
may have had a positive impact, since parallel changes in pharmacotherapy are 
unlikely to have had this effect. It is however also possible that parallel and unrelated 
change in these patients’ psychological state had an impact on both breath hold times 
and quality of life.
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The possibility that Nijmegen is measuring aspects of quality of life is suggested by 
the 7 patients who were felt to have complied well and benefited from BCT on 
subjective assessment, without any improvement in Nijmegen scores. Another pointer 
to the lack of specificity of the Nijmegen questionnaire in this population is the lack 
of any relationship between Nijmegen score and documented inappropriate 
hyperventilation on PET (Figure 19). Perhaps we are, as busy clinicians in the early 
21®^ century, identifying abnormal breathing pattern as a physical symptom, rather 
than as part of a syndrome of psychological distress.
Thomas’s data discussed already (^ ^^ ) can be interpreted as showing a non specific 
effect of breathing retraining which had a greater initial impact on asthma related 
quality of life than Nijmegen scores. We did not seen similar trends in either Mini- 
AQLQ or Nijmegen scores.
We used the Mini-AQLQ in our study because we felt its brevity was more suited to 
the clinic setting than the full AQLQ (^ ^^ ). We found similar proportions of patients 
with and without DB who had significantly improved (> 0.5) Mini-AQLQ scores 
(9/29, 31% and 6/17, 35%) Our study design makes it difficult to di'aw firm 
conclusions from this but certainly it does not suggest a definite treatment effect.
Inspiratory breath hold times (BHT) were measured by our physiotherapist delivering 
BCT. There are no published data supporting this as a diagnostic method for DB, and 
our routine use in the assessment of patients with suspected DB and subsequent 
monitoring is based on anecdote. One small study found lower BHT in a group of 
patients with symptoms suggestive of hyperventilation compared to controls (^ ^^ ). The
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fact that all patients had an improvement in their BHT suggests a lack of specificity of 
BHT as a good outcome measure in the treatment of DB, but clearly the lack of BHT 
data in the group who did not receive BHT and lack of any other go Id-standard 
outcome measure for comparison makes this purely speculative.
We had a huge loss to follow-up in both DB and Non-DB groups which was very 
disappointing. The potential confounding effect of this has to be acknowledged. The 
reasons for non-attendance is not clear, and it may be that the non-attendees had 
improved but one can only be speculative here. We did not feel it was appropriate to 
send out repeat questionnaires to those who did not attend as this would have been 
outwith the scope of our clinic protocol.
Clearly there are different methods of delivering breathing retraining. We judged the 
mtervention we used to be applicable to normal clinic practice and likely to be 
sufficiently intensive to produce benefits, but this has not been confirmed, by these 
observational results. Patient compliance may have limited our ability to influence 
deeply ingrained patterns of behaviour. Most Buteyko courses are more intensive, but 
of shorter dui'ation that the inteiwention we used, which was undertaken by a specialist 
respiratory physiotherapist in parallel with clinic attendance in order to maximise the 
chance of patients attending and completing this. Our data show no evidence that this 
strategy was successful and suggest that any formal RCT assessment of breathing 
control in this setting would need to be highly specific in terms of identification of 
patients likely to benefit, more intensive in nature and in the measurement of 
outcomes, since it is illogical to expect long term benefit if no short term advantage is 
identifiable. In such an RCT, it would also be important to compare a psychological
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intervention with breathing retraining, as well as having a control group, in order to 
test the specificity of any observed effect.
In summary this observational study has increased our understanding of two aspects 
of patients with moderate to severe asthma, as judged by having persistent symptoms 
despite high levels of treatment. Firstly, we have a better understanding of the range 
of Nijmegen, RCP symptom and mini AQLQ scores and the strong relationships 
which exist between these scores suggesting that they are measuring related 
phenomena. We have shown only a loose relationship between Nijmegen score and 
inappropriate hyperventilation measured by PET. Our second observation is that a 
moderate intensity breathing retraining programme, undertaken in parallel with 
patients’ normal clinic attendance had no benefit overall, with the pattern of benefit 
seen in subgroups raising the possibility that this intervention may not have had a 
specific physiotherapeutic effect. This will be useful in planning an RCT to address 
this issue, although we have also identified the problem caused by the lack of a gold 
standard method of identifying dysfunctional breathing ia patients with asthma, which 
is likely to hamper its further study, until this issue is definitively addressed.
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CHAPTER 7
BREATHING PATTERN IN PATIENTS WITH 
DYSFUNCTIONAL BREATHING AND THE EFFECT OF 
BREATHING CONTROL THERAPY
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7.1 Introduction
Very little is known about physiological characteristics of breathing pattern in patients 
with asthma felt to have dysfunctional breathmg. In parallel with identification of 
dysfunctional breathing (DB) in our cohort of patients with moderate to severe 
asthma, we aimed to characterise their breathing pattern. We hypothesised that 
patients with DB would have differences in physiological parameters of breathing 
pattern compared to “normals” and monitored this to determine if breathing control 
therapy had any effect on physiological parameters of breathing pattern.
This study represents an additional arm of the study described in Chapter 6.
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7.2 Methods
Patients were entered into this analysis as described in Chapter 6. We were using the 
Forced Oscillation Teclinique (FOT) at the time in the PAC as a routine non-invasive 
method in the assessment of airway calibre, which was often help fill in guiding 
asthma management. It was then possible to extrapolate various physiological 
parameters of breathing pattern at a later date.
Patients performed FOT on the same day as completing Nijmegen and Mini-AQLQ 
questionnaires as described in Chapter 6. FOT was performed as described in Chapter 
3.
Following acquisition of the raw data {AcqKnowledge® (Version 3.7.0) Software), 
processing by Matlab (Version 6.1) allowed data fi*om each recorded breath to be 
imported into a Microsoft Excel spreadsheet. Data on inspiratory time (T i), expiratory 
time (Te), expiratory / inspiratory time ratio (Te/Ti), Tidal volume (Vt) for each breath 
was available from each recording. Subsequently, minute ventilation (Vmin) and 
respiratory frequency (Rf) could be calculated. The average value of airway resistance 
over all the breaths (Rt), was obtained. This was used as a marker of airway calibre, 
rather than forced manoeuvres such as FEV .^ The mean values for each breathing 
pattern parameter were calculated from both sampling periods. Again, m line with 
current guidelinesf^^), data from the first 30 seconds of each recording was discarded, 
to allow the patient time to get used to the mouthpiece.
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Breath to breath variability was measured by determining the standard deviations of 
Ti, Te, Te/Ti and Vt for each patient during the sampling period. Since Vmin and Rf 
were calculated using data from the whole sampling period, these standard deviations 
for these parameters were not available.
Follow Up
Data on physiological parameters of breathing pattern collected on review of all 
patients at approximately 6 months follow up in the clinic where available. Since we 
sought a long term effect from this intervention, we judged this to be an appropriate 
time to collect outcome data.
Statistical Analysis
Baseline breathing pattern data was grouped according to Nijmegen score positivity 
and compared using 2 sample t-tests. Paired t-tests were used to compare follow up 
breathing pattern data to baseline. All data was analysed using Minitab (Version 14) 
statistical software.
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7.3 Results
Baseline Physiological Characteristics of Breathing Pattern
FOT was performed in 78 / 102 patients on the same day as completing the 
questionnaires (76% of whole study group). 31 had Nijmegen scores < 22 (Non-DB) 
and 47 scored > 23 (DB), Baseline data is demonstrated in Table 34, with the study 
group separated according to their Nijmegen scores. The only statistically significant 
difference observed was in the measurement of Tidal Volume (Vt) (95% Cl 0.01, 0.39, 
p = 0.044).
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Table 34: Baseline Physiological Characteristics of Breathing Pattern (78 patients)
VARIABLE Non-DB (n = 31) DB (n = 47) 95% C.I. FOR 
DIFFERENCERANGE MEAN
(SD)
RANGE MEAN
(SD)
Inspiratory Time 
(Tp seconds) 0.57-4.39 1.57 (0.70) 0 .55-
3.40
1.40 (0.53) -0.10, 0.45
Expiratory Time 
(fy, seconds) 0.75-7.15 2.29(1.17) 0 .82 -
4.85
2.03 (0.84) -0.19, 0.72
T„/T, 0.67-1.89 1.44 (0,25) 0 .88 -
2.44
1.48 (0.35) -0.18,0.11
Tidal Volume (V,, 
litres)
0.25-2.65 1.05 (0.53) 0 .38-
1.74
0.85 (0.32) 0.01,0.39
Minute Ventilation 
(Vn,in, Litres/minute) 5 .78-
31.94
16.60
(6.23)
6 .80 -
26.71
15.38 (4.85) -1.29,3.72
Respiratory 
Frequency (R  ^
breaths/minute)
5 .2-38 .0 17.4 (6.31) 7 .4-38 .8 19.2 (6.4) -4.79, 1.10
Respiratoiy 
resistance (R^ , 
kPa/Fs)
0.20-1.06 0.52 (0.24) 0 .22-
0.95
0.47 (0.16) -0.04, 0.14
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Breath to Breath Variability
As described above, we were able to assess breath to breath variability for Ti, Te, 
Te/Ti and Vt by calculating the Standard Deviation over the two FOT sampling 
periods. The results are shown in Table 35. Analysis by 2 sample t-tests confirmed 
there was no difference between the Non-DB and the DB group in any parameter.
Table 35: Breath to Breath Variability
VARIABLE RANGE MEAN
(SD)
MEDIAN (IQR) 95% Cl FOR 
DIFFERENCE
SD-T.
Non-DB 
(n = 31)
0.037- 1.08 0.19(0.19) 0.14(0.09-0.25)
-0.06, 0.09
DB 
(n = 47)
0.043 - 0.59 0.18(0.12) 0.14(0.10-0.21)
SD-T
Non-DB 
(n = 31)
0.071 -0.96 0.29 (0.20) 0.24(0.16-0.34)
-0.10, 0.11
DB 
(n = 47)
0.08 -1.49 0.28 (0.24) 0.21 (0.14-0.34)
SD - T/T;
Non-DB 
(n = 31)
0.05 - 0.50 0.19 (0.10) 0.17(0.12-0.25)
-0.10, 0.02
DB 
(n = 47)
0.05-0.66 0.23 (0.15) 0.20 (0.14-0.29)
SD-V,
Non-DB 
(n = 31)
0.03 - 0.37 0.14(0.08) 0.10(0.08-0.20)
-0.01,0.05
DB 
(n = 47)
0.05 - 0.32 0.12(0.06) 0.10(0.07-0.15)
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Follow up Data
We were able to reassess breathmg pattern in 31 patients (16 Non-DB, 15 DB). There 
were a number of reasons for the drop-out, the most frequent being non-attendance at 
clinic around the desired follow up point of 6 months after baseline data collection. 
Another less common reason was time restraint on the patients’ part when attending 
the clinic.
Follow up breathing pattern data is shown in Table 36. There were no statistically 
significant differences in any breathing pattern characteristic measuied at follow up 
between the Non-DB and the DB group (data not shown). Again, as with baseline data 
there was no difference in airway calibre as measured by Rt between the two gioups at 
follow up (95% Cl -0.09, 0.18 by 2-sample t-test). As demonstrated in Table 36, there 
was no significant difference at follow up from baselme measurement in any 
breathing pattern characteristic.
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Table 36: Breathing Pattern Follow up data
VARIABLE RANGE MEAN (SD)
MEAN (SD) 
CHANGE FROM 
BASELINE
95% C.I. FOR 
DIFFERENCE 
FROM BASELINE
Inspiratory Time 
(T., seconds)
Non-DB 
(n = 16)
0.95-3 .72 1.66(0.64) -0.01 (0.38) -0.19, 0.22
DB (n = 15) 0.76-2 .44 1.54(0.40) -0.02 (0.37) -0.19, 0.23
Expiratory Time 
(U, seconds)
Non-DB 
(n = 16)
1.56-5.34 2.40 (0.99) -0.05 (0.84) -0.39, 0.50
DB(n=15) 1.29-5.35 2.56(1.05) 0.16(0.5) -0.434, 0.12
T /T
Non-DB 
(n = 16)
1.09-1.98 1.45 (0.27) -0.00 (0.30) -0.16, 0.16
DB (n = 15) 1.16-2.33 1.65 (0.38) 0.05 (0.30) -0.22, 0.11
Tidal Volume 
( \ ,  litres)
Non-DB 
(n = 16)
0.53-2.01 1.01 (0.39) -0.12(0.35) -0.07, 0.31
DB (n = 15) 0.45-2 .02 1.04 (0.36) 0.02 (0.27) -0.17, 0.13
Minute Ventilation
(V.,„
Litres/minute)
Non-DB 
(n = 16)
8.04-31.22 15.98 (6.41) -1.13(5.33) -1.71,3.97
DB (n = 15) 7.50-24.13 15.94(1.77) -0.45 (4.55) -2.07, 2.97
Respiratory
Frequency
(Rf,
breaths/minute)
Non-DB (n = 16) 6.7-22.1 16.37(4.45) -0.33 (3.84) -1.72, 2.37
DB (n = 15) 7.7-29.31 15.97 (4.90) -1.34 (3.79) -0.76, 3.43
Respiratory 
resistance (R, 
kPa/l/s)
Non-DB (n = 16) 0.22 - 0.98 0.50 (0.20) -0.06 (0.13) -0.01,0.13
DB (n = 15) 0.22-0 .80 0.45 (0.18) -0.01 (0.10) -0.04, 0.06
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Breath to breath variability for Ti, Te, Te/Ti and Vt was assessed at follow up as 
described above and compared to baseline values (paired t-tests). As can be seen in 
table 7 there were no differences seen at follow up in either group in any parameter.
Table 37: Breath to Breath Variability - Follow up data
VARIABLE RANGE MEAN (SD) MEAN (SD) 
CHANGE FROM  
BASELINE
95% C.I. FO R 
DIFFERENCE 
FROM  BASELINE
SD- Tj
Non-DB 
(n = 16)
0.06 - 0.43 0.18(0.10) 0.02(0.19) -0.08, 0.12
DB
(n = 15)
0.09 - 0.65 0.18(0.14) 0.00(0.17) -0.10, 0.10
S D - T ,
Non-DB 
(n = 16)
0.09 - 0.49 0.25(0.13) 0.01 (0.19) -0.09, 0.11
DB
(n = 15)
0.10-0.51 0.28(0.12) -0.03 (0.15) -0.11,0.05
S D - T / T ,
Non-DB 
(n = 16)
0.07-0.41 0.17(0.09) 0.01 (0.15) -0.07, 0.09
DB
(n = 15)
0.07-0.38 0.20 (0.09) 0.03 (0.14) -0.05, 0.10
SD- V,
Non-DB 
(n = 16)
0.03 - 0.27 0.12(0.08) 0.00 (0.08) -0.04, 0.05
DB
(n = 15)
0.05 - 0.34 0.13 (0.08) -0.03 (0.1) -0.08, 0.03
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7,4 Discussion
In the 78 patients in whom we had complete breathing pattern data there was no 
discernable difference between the groups in any parameter. The difference in tidal 
volume (Vj) between the Non-DB and DB group only just reached statistical 
significance (95% Cl - 0.0056 - 0.39, p = 0.044). However there were no further 
statistically differences in other breathmg pattern parameters between the two groups, 
so the clinical significance of this observation is doubtful. Additionally we looked at 
breath to breath variability for inspiratory and expkatoiy time, expiratory/inspiratoiy 
time ratio and tidal volume, with the hypothesis that patients with dysflinctional 
breathing would display more variability in their breathing pattern. As demonstrated 
in Table 4 there was no such difference observed. This may be due to the variable 
nature of any abnormalities in breathing pattern in patients with DB and since our 
sampling periods were brief. We measured breathing pattern using data available from 
FOT recordings. FOT is primarily used for the measui'ement of aiiivays resistance and 
can be especially useful in the assessment of airways calibre in patient who have 
difficulty performing forced expiratoiy manoeuvres. With this technique the patient is 
asked to take normal tidal breaths while breathing thi'ough a mouthpiece and wearing 
a nose clip. Unsuiprisingly, breathing pattern can be influenced by such apparatus. 
Breathing through a mouth-piece has been shown to increase tidal volume(^^ '^^^^) and 
in one series decrease respiratory fi'equency(’^^ ) compared to natural breathing 
monitored with an external device. However, although mean values change, the breath 
to breath variability does not necessarily change when breathing via a mouthpiece and 
nose-clip (^ ^^ ). With this in mind we still felt our method of breathing pattern
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measurement would be valid, given we were looking to identify between group (and 
after BCT, within group) differences.
Several other methods exist for measuring breathing pattern objectively. Using 
respiratory inductive plethysmography (RIP), rib cage movements can be analysed to 
calculate respiratory fi’equency, tidal volume and minute ventilation, mean inspiratory 
time and fractional inspiratory time (^ ^^ ). Tobin recorded breathing pattern by RIP 
over a fifteen minute period (after ten minutes rest) in symptomatic patients with 
asthma and found an increased tidal volume, minute ventilation and shortened 
fractional inspiratory time without an increase in respiratory frequency compared to 
non-asthmatics(^°^'^^^). Asymptomatic patients with asthma had no difference in their 
breathing pattern compared to normals. Measuring breathing pattern with the RIP 
device would have been too time-consuming in the out-patient clinic setting of our 
study and it is not entirely clear if these long sampling periods in comparison with 
two sampling periods of 1 minute (with the last 30 seconds from each used for 
analysis) used in our study are important in determining differences not just in 
individual parameters, but in any breath to breath variability.
The second phase of our observational study involved assessing the effect of 
breathing control therapy. This was done in an uncontrolled manner reflecting the 
normal clmical management of patients in our clinic. In the patients in whom we 
were able to obtain follow up measurements of breathing pattern, we observed no 
difference compared to baseline in the patients who had attended BCT in either 
individual parameters or in breath to breath variability. Also the group who did not 
attend BCT showed no change. It may be that the sampling method used in our study
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is not sensitive enough to pick up any changes, if indeed any effect was ever going to 
be produced in these parameters with BCT. As far as we are aware, there are no prior 
studies that have examined the effect of breathing control therapy on physiological 
parameters of breathing pattern in patients with asthma. One study which evaluated 
the effect of breathing therapy in 92 patients with DB alone found mean values of 
iuspiratory and expiratory time and tidal volume increased following treatment(^°^).
In conclusion we found no evidence that measuring breathing pattern with the forced 
oscillation technique was helpful in discriminating between Nijmegen identified DB 
and non-DB, with no evidence of any differences in baseline physiological aspects of 
breathing pattern. These parameters were unchanged following a moderate intensity 
breathing retraining programme, undertaken in parallel with patients’ nonnal clinic 
attendance.
198
Conclusions
We have studied a number of aspects of the upper airway and breathing pattern in a 
cohort of patients attending a Problem Asthma Clinic and to place these studies in 
context we have described a New Patient cohort seen over a 12 month period. Here 
we found the proportion of definite asthma comparable to other reported series and 
also similar levels of co-morbidities or alternative diagnoses.
Firstly, we were disappointed not to identify Vocal Cord Dysfunction as classically 
described, but despite potential selection bias, we did confirm a range of functional 
and structui'al laryngeal abnormalities in our pilot study. There were no detectable 
differences in measurements of airway calibre in the patients with abnormalities, 
although the wide variation found suggests using the Forced Oscillation Technique 
may not be specific in the identification of glottic narrowing such as occurs in VCD. 
We subsequently found a strategy of performing challenge testing in the form of lab 
based exercise testing and histamine challenge testing was of not diagnostic value, but 
in only a small group of patients. Until further larger studies can be performed, 
visualisation of the vocal cords during an attack of suggestive symptoms remains the 
gold standard for the diagnosis of VCD.
We explored the relationship between upper airway symptoms and presence of 
structui'al laryngeal and nasal abnormalities and found groups of symptoms which 
have better predictive values for abnormality, which is pertinent to routine clinical 
practice. Vocal morbidity was found to be a problem which should not be 
immediately attributed to laryngeal candidiasis, and is clearly a complicated issue in
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patients with asthma. Assessment tools originally developed for use in an 
otolaryngological setting appear to be able to shed some light on this area.
The issue of dysfunctional breathing continues to present difficulties in diagnosis, and 
while we found no evidence of overall benefit JBrom our routinely delivered breathing 
control therapy in our observational study (in terms of questionnaire parameters, or in 
any physiological measurements), the lack of well validated diagnostic instruments 
and outcome measures will continue to hamper further work in this field. Further 
research should target these issues.
We have observed relationships between Nijmegen and Mini-AQLQ which suggests 
the former may be measuring quality of life in patients with asthma.
While we have found negative answers to some of our primary research questions, our 
observational data has provided valuable insights into this complicated area of asthma 
management, which will be helpful in the planning of further investigation in such 
areas.
Firstly the inter-relationships between the questionnaire scores (HAD, Mini-AQLQ, 
Nijmegen, PCAQ) need to be further explored, for example using factor analysis with 
the data from our cohort baseline questionnaires. The correlations we observed 
suggest different questionnaires may be measuring similar attributes. In particular the 
very close relationship between Nijmegen scores and HAD (Anxiety) raises important 
questions about the approach to treatment of dysfunctional breathing. While we found 
no evidence of overall benefit from our physiotherapy delivered breathing control, it
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may be that in the patients who do seem to derive benefit, this may be no different or 
better than from a psychological intervention such as cognitive behavioural therapy 
(CBT). If a method can be validated to identify dysfunctional breathing in patients 
with asthma (for example using a modified Nijmegen with some physiological 
evidence of dysfunctional breathing) then entering patients into a randomised 
controlled trial of CBT would be of great interest.
Secondly, a closer investigation of the VoiSS in patients with asthma is warranted, in 
particular whether higher VoiSS correlates with objectively defined gastro- 
oesophageal reflux by pH studies. If so, further investigation of its role as an outcome 
measure in the treatment of reflux with appropriate therapy should be undertaken.
201
References
(1) British Thoracic Society, Scottish Intercollegiate Guidelines Network. British 
Guideline on the Management of Asthma. Thorax 2003; 58(Supplement l):il~ 
i94.
(2) Barnes PJ, Woolcock AJ. Difficult asthma. Eur Respir J 1998; 12(5): 1209- 
1218.
(3) Chung KF, Godard P, Adelroth E, Ayres J, Bames N, Bames P et al. 
Difficult/therapy-resistant asthma: the need for an integrated approach to 
define clinical phenotypes, evaluate risk factors, understand pathophysiology 
and find novel therapies. ERS Task Force on Difficult/Therapy-Resistant 
Asthma. European Respiratory Society. Eur Respir J 1999; 13(5): 1198-1208.
(4) Ayres J. Severe asthma phenotypes: the case for more specificity. J Royal Soc 
Med 2001;94(3):115-118.
(5) Ayres JG, Miles JF, Bames PJ. Brittle asthma. Thorax 1998; 53(4):315-321.
(6) The ENFUMOS A Study Group. The ENFUMOS A cross-sectional European 
multicentre study of the clinical phenotype of chi onic severe asthma. 
European Network for Understanding Mechanisms of Severe Asthma. Eur 
Respir J 2003; 22(3):470-477.
(7) Walsh LJ, Wong CA, Cooper S, Guhan AR, Pringle M, Tattersfield AE. 
Morbidity from asthma in relation to regular treatment: a community based 
study. Thorax 1999; 54(4):296-300.
202
(8) Liard R, Leynaert B, Zureik M, Beguin FX, Neukirch F. Using Global 
Initiative for Asthma guidelines to assess asthma severity in populations. Eur 
Respir J 2000; 16(4):615-620.
(9) Andrianopoulos MV, Gallivan GJ, Gallivan KH. PVCM, PVCD, EPL, and 
irritable larynx syndrome: what are we talking about and how do we treat it? J 
Voice 2000; 14(4):607-618.
(10) Kenn K, Wilier G, Bizer C, Eich A, Henkel D, Jacob B et al. Prevalence of 
VocalCord Dysfunction in patients with exertional dyspnoea. First prospective 
study. Am J Respir Grit Care Med 1997. 155[4 part 2], A965.
(11) Morris MJ, Deal LE, Bean DR, Grbach VX, Morgan JA. Vocal cord 
dysfunction in patients with exertional dyspnea. Chest 1999; 116(6): 1676- 
1682.
(12) Newman KB, Mason UG, III, Schmaling KB. Prospective study of vocal cord 
dysfunction. Am J Respir Crit Care Med 1995. 151 [4], A674.
(13) Newman KB, Mason UG, III, Schmaling KB. Clinical features of vocal cord 
dysfunction. Am J Respir Crit Care Med 1995; 152(4:Pt 1): 1382-1386.
(14) Christopher KL, Wood RP, Eckert RC, Blager FB, Raney RA, Souhiada JF. 
Vocal-cord dysfunction presenting as asthma. N Engl J Med 1983;
308(26): 1566-1570.
203
(15) Seiner JC, Staudenmayer H, Koepke JW, Harvey R, Christopher K. Vocal 
cord dysfunction: the importance of psychologic factors and provocation 
challenge testing. J Allergy Clin Immunol 1987; 79(5):726-733.
(16) Perkner JJ, Femielly KP, Balkissoon R, Bartelson BB, Ruttenber AJ, Wood 
RP et al. Irritant-associated vocal cord dysfunction. J Occup Environ Med 
1998;40(2):136-143.
(17) Newman KB, Dubester SN. Vocal cord dysfiinction: masquerader of asthma. 
SemResp Crit Care Med 1994; 152:161-167.
(18) Powell DM, Karanfilov BI, Beechler KB, Treole K, Trudeau MD, Forrest LA. 
Paradoxical vocal cord dysfunction in juveniles. Arch Otolaryngol Head Neck 
Surg 2000; 126(l):29-34.
(19) Freedman MR, Rosenberg SJ, Schmaling KB. Childhood sexual abuse in 
patients with paradoxical vocal cord dysfunction. J Nerv Ment Dis 1991; 
179(5):295-298.
(20) Maschka DA, Bauman NM, McCray PB, Jr., Hoffman HT, Karnell MP, Smith 
RJ. A classification scheme for paradoxical vocal cord motion. Laryngoscope 
1997; 107(1 l:Pt 1):1429-1435.
(21) Rusakow LS, Blager FB, Barkin RC, White CW. Acute respiratory distress 
due to vocal cord dysfunction in cystic fibrosis. J Asthma 1991; 28(6):443-446.
(22) Martin RJ, Blager FB, Gay ML, Wood RP. Paradoxical vocal cord motion in 
presumed asthmatics. SemResp Med 1987; 8:332-337.
204
(23) Heatley DG, Swift E. Paradoxical vocal cord dysfiinction in an infant with 
stridor and gastroesophageal reflux. Int J Pediatr Otorhinolaryngol 1996; 34(1- 
2):149-151.
(24) Ayres JG, Gabbott PL. Vocal cord dysfunction and laryngeal 
hyperresponsiveness: a function of altered autonomic balance? Thorax 2002; 
57(4):284-285.
(25) Morrison M, Rammage L, Emami AJ. The iiTitable larynx syndrome. J Voice 
1999; 13(3):447-455.
(26) Rodenstein DO, Francis C, Stanescu DC. Emotional laryngeal wheezing: a 
new syndrome. Am Rev Respir Dis 1983; 127(3):354-356.
(27) Remirez RJ, Leon I, Rivera LM. Episodic laryngeal dyskinesia; clinical and 
psychiatric characterisation. Chest 1986; 90:716-721.
(28) Newman KB. Vocal cord dysfuction: an asthma mimic. Pulmonary 
Perspectives 1993; 10:3-5.
(29) Bucca C, Rolla G, Scappaticci E, Baldi S, Caria E, Oliva A. Histamine 
hyperresponsiveness of the extrathoracic airway in patients with asthmatic 
symptoms. Allergy 1991; 46(2): 147-153.
(30) Bucca C, Rolla G, Brussino L, De R, V, Bugiani M. Are asthma-like 
symptoms due to bronchial or extrathoracic airway dysfunction? Lancet 1995; 
346(8978):791-795.
205
(31) Bucca C, Rolla G, Scappaticci E, Chiampo F, Bugiani M, Magnano M et al. 
Extrathoracic and intrathoracic airway responsiveness in sinusitis. J Allergy 
Clin Immunol 1995; 95(1 :Pt l):t-9.
(32) Archer GJ, Hoyle JL, McCluskey A, Macdonald J. Inspiratory vocal cord 
dysfunction, a new approach in treatment. Eur Respir J 2000; 15(3):617-618.
(33) Corren J, Newman KB. Vocal cord dysfunction mimicking bronchial asthma. 
Postgrad Med 1992; 92(6): 153-156.
(34) Mobeireek A, Alhamad A, A1 Subaei A, Alzeer A. Psychogenic vocal cord 
dysfunction simulating bronchial asthma. Eur Respir J 1995; 8(11): 1978-1981.
(35) Murray DM, Lawler PG. All that wheezes is not asthma. Paradoxical vocal 
cord movement presentmg as severe acute asthma requiring ventilatory 
support. Anaesthesia 1998; 53(10): 1006-1011.
(36) Vlahakis NE, Patel AM, Maragos NE, Beck KC. Diagnosis of vocal cord 
dysfunction: the utility of spirometry and plethysmography. Chest 2002; 
122(6):2246-2249.
(37) Warburton CJ, Niven R, Higgins BG, Pickering CA. Functional upper akways 
obstruction: two patients with persistent symptoms. Thorax 1996; 51(9):965- 
966.
(38) Weir M. Vocal cord dysfunction mimics asthma and may respond to heliox. 
Clin Pediatr (Phila) 2002; 41(1):37-41.
206
(39) McFadden ER, Jr., Zawadski DK. Vocal cord dysfunction masquerading as 
exercise-induced asthma, a physiologic cause for "choking" during athletic 
activities. Am J Respir Crit Care Med 1996; 153(3):942-947.
(40) Shim C, Corro P, Park SS, Williams MH, Jr. Pulmonary function studies in 
patients with upper airway obstruction. Am Rev Respir Dis 1972; 106(2):233- 
238.
(41) Brugman S, Newman KB. National Jewish Medical Scientific Update 1993; 
11(5).
(42) Bahrainwala AH, Simon MR, Harrison DD, Toder D, Secord EA. Atypical 
expiratory flow volume curve iu an asthmatic patient with vocal cord 
dysfunction. Ann Allergy Asthma Immunol 2001; 86(4):439-443.
(43) Perkins PJ, Morris MJ. Vocal cord dysfunction induced by methacholine 
challenge testing. Chest 2002; 122(6): 1988-1993.
(44) Kivity S, Bibi H, Schwarz Y, Greif Y, Topilsky M, Tabachnick E. Variable 
vocal cord dysfunction presenting as wheezing and exercise-induced asthma. J 
Asthma 1986; 23(5):241-244.
(45) Lakin RC, Metzger WJ, Haughey BH. Upper aiiway obstruction presenting as 
exercise-induced asthma. Chest 1984; 86(3):499-501.
(46) Roksund OD, Heimdal JH, Skadberg B, Halvorsen.T. Exercise induced 
laryngeal dysfunction. Eur Respir J 2004; 24[Supp 48]: 502s.
207
(47) Oostveen E, MacLeod D, Lorino H, Faire R, Hantos Z, Desager K et al. The 
forced oscillation technique in clinical practice: methodology, 
recommendations and future developments. Eur Respir J 2003; 22(6): 1026- 
1041.
(48) Rigau J, Farre R, Trepat X, Shusterman D, Navajas D. Oscillometric 
assessment of airway obstruction in a mechanical model of vocal cord 
dysfunction. J Biomech 2004; 37(l):37-43.
(49) Nastasi KJ, Howard DA, Raby RB, Lew DB, Blaiss MS. Airway fluoroscopic 
diagnosis of vocal cord dysfunction syndrome. Ann Allergy Asthma Immunol 
1997; 78(6):586-588.
(50) Zelcer S, Henri C, Tewfik TL, Mazer B. Multidimensional voice program 
analysis (MDVP) and the diagnosis of pediatric vocal cord dysfunction, [see 
comment]. Ann Allergy Asthma Immunol 2002; 88(6):601-608.
(51) Anbar RD, Hehir DA. Hypnosis as a diagnostic modality for vocal cord 
dysfunction. Pediatrics 2000; 106(6):E81.
(52) Sullivan MD, Heywood BM, Beukelman DR. A treatment for vocal cord 
dysfunction in female athletes: an outcome study. Laryngoscope 2001; 
111(10):1751-1755.
(53) Goldman J, Muers M. Vocal cord dysfunction and wheezing. Thorax 1991; 
46(6):401-404.
(54) Lisboa C, Jardim J, Angus E, Macklem PT. Is extrathoracic airway obstmction 
important in asthma? Am Rev Respir Dis 1980; 122(1): 115-121.
208
(55) Khanlou H, Eiger G. Safety and efficacy of heliox as a treatment for upper 
airway obstruction due to radiation-induced laryngeal dysfunction. Heart Lung 
2001;30(2):146-147.
(56) Maillard I, Schweizer V, Broccard A, Duscher A, Liaudet L, Schaller MD.
Use of botulinum toxin type A to avoid tracheal intubation or tracheostomy in 
severe paradoxical vocal cord movement. Chest 2000; 118(3):874-877.
(57) Bames.P. Corticosteroids. In: O’Byrne PM, Thomson NC, editors. Manual of 
Asthma Management. WB Saunders, 2001: 173-196.
(58) Williamson IJ, Matusiewicz SP, Brown PH, Greening AP, Crompton GK. 
Frequency of voice problems and cough in patients using pressurized aerosol 
inhaled steroid preparations. Eur Respir J 1995; 8(4):590-592.
(59) Crompton GK, Sanderson R, Dewar MH, Matusiewicz SP, Ning AC,
Jamieson AH et al. Comparison of Pulmicort pMDI plus Nebuhaler and 
Puhnicort Turbuhaler in asthmatic patients with dysphonia. Respir Med 2000; 
94(5):448-453.
(60) Lavy JA, Wood G, Rubin JS, Harries M. Dysphonia associated with inhaled 
steroids. J Voice 2000; 14(4):581-588.
(61) Baker BM, Baker CD, Le HT. Vocal quality, articulation and audio logical 
characteristics of children and young adults with diagnosed allergies. Ann 
Otol RhinolLaryngol 1982; 91(3:Pt l):277-280.
209
(62) Ihre E, Zetterstrom O, Ihi*e E, Hammarberg B. Voice problems as side effects 
of inhaled corticosteroids in asthma patients—a prevalence study. J Voice 
2004; 18(3):403-414.
(63) Wilson JA, Deary IJ, Millar A, MacKenzie K. The quality of life impact of 
dysphonia. Clin Otolaryngol 2002; 27(3):179-182.
(64) Carding P. Voice Pathology clinics in the UK. Clin Otolaryngol 2003; 
28(6):477-478.
(65) Carding P, Carlson E, Epstein R, Mathieson L, Shewed C. Formal perceptual 
evaluation of voice quality in the United Kingdom. Logoped Phoniatr Vocol 
2000; 25(3): 133-138.
(66) De Bodt MS, Wuyts FL, Van de Heyning PH, Croux C. Test-retest study of 
the GRBAS scale: influence of experience and professional background on 
perceptual rating of voice quality. J Voice 1997; 1 l(l):74-80.
(67) Dejonckere PH, Obbens C, de Moor GM, Wieneke GH. Perceptual evaluation 
of dysphonia: reliability and relevance. Folia Phoniatr (Basel) 1993; 45(2):76- 
83.
(68) Dejonckere PH, Remade M, Fresnel-Elbaz E, Woisard V, Crevier L, Millet B, 
Reliability and clinical relevance of perceptual evaluation of pathological 
voices. Rev Laryngol Otol Rhinol (Bord) 1998; 119(4):247-248.
(69) Webb AL, Carding PN, Deary IJ, MacKenzie K, Steen N, Wilson JA. The 
reliability of three perceptual evaluation scales for dysphonia. European 
Archives of Oto-Rhino-Laryngology 2004; 261(8):429-434.
210
(70) Piccirillo JF, Painter C, Fuller D, Haiduk A, Fredrickson JM. Assessment of 
two objective voice function indices. Ann Otol Rhinol Laryngol 1998;
107(5:Pt l):396-400.
(71) Yu P, Ouaknine M, Revis J, Giovanni A. Objective voice analysis for 
dysphonie patients: a multiparametric protocol including acoustic and 
aerodynamic measurements. J Voice 2001; 15(4):529-542.
(72) Jacobson BH, Johnson A, Grywalski C, Silbergleit G, Jacobson G, Bemiinger 
MS et al. The Voice Handicap Index (VHI): Development and validation. 
American Journal of Speech-Language Pathology 1997; 6:66-70.
(73) Hogikyan ND, Sethuraman G. Validation of an instrument to measure voice- 
related quality of life (V-RQOL). J Voice 1999; 13(4):557-569.
(74) Deary IJ, Wilson JA, Carding PN, MacKenzie K. VoiSS: a patient-derived 
Voice Symptom Scale. J Psychcosom Res 2003; 54(5):483-489.
(75) Wilson JA, Webb A, Carding PN, Steen IN, MacKenzie K, Deary IJ. The 
Voice Symptom Scale (VoiSS) and the Vocal Handicap Index (VHI): a 
comparison of stmcture and content. Clin Otolaryngol 2004; 29(2): 169-174.
(76) Simons FE. Allergic rhinobronchitis: the asthma-allergic rhinitis link.
[Review] [35 refs]. Journal of Allergy & Clinical Immunology 1999; 104(3:Pt 
l):534-540.
(77) Bousquet JM, van Cauwenberge PMP, Khaltaev NM, In collaboration with the 
World Health Organization. Allergic Rhinitis and Its Impact on Asthma . 
Journal of Allergy & Clinical Immunology 2001; 108(5, part 2):147s~334s.
211
(78) Hedman J, Kaprio J, Poussa T, Nieminen MM. Prevalence of asthma, aspirin 
intolerance, nasal polyposis and chronic obstructive pulmonary disease in a 
population-based study. International Journal of Epidemiology 1999;
28(4):717-722.
(79) Larsen K. The clinical relationship of nasal polyps to asthma. Allergy Asthma 
Proc 1996; 17(5):243-249.
(80) Settipane GA. Epidemiology of nasal polyps. Allergy & Asthma Proceedings 
1996; 17(5):231-236.
(81) Lund VJ. The effect of sinonasal surgery on asthma. Allergy 1999; 54:Suppl-5.
(82) Corren J, Adinoff AD, Buchmeier AD, Irvin CG. Nasal beclomethasone 
prevents the seasonal increase in bronchial responsiveness in patients with 
allergic rhinitis and asthma. J Allergy Clin Immunol 1992; 90(2);250-256.
(83) Henriksen JM, Wenzel A. Effect of an intranasally administered corticosteroid 
(budesonide) on nasal obstruction, mouth breathing, and asthma. Am Rev 
Respir Dis 1984; 130(6):1014-1018.
(84) Pedersen B, Dahl R, Lindqvist N, Mygind N. Nasal inhalation of the 
glucocorticoid budesonide from a spacer for the treatment of patients with 
pollen rhinitis and asthma. Allergy 1990; 45(6):451-456.
(85) Watson WT, Becker AB, Simons FE. Treatment of allergic rhinitis with 
intranasal corticosteroids in patients with mild asthma: effect on lower airway 
responsiveness. J Allergy Clin Immunol 1993; 91(1 :Pt 1):97-101.
212
(86) Blair H. Natural history of childhood asthma. 20-year follow-up. Arch Dis 
Child 1977; 52(8):613-619.
(87) Pedersen PA, Weeke ER. Asthma and allergic rhinitis in the same patients. 
Allergy 1983; 38(l):25-29.
(88) Montnemery P, Svensson C, Adelroth E, Lofdahl CG, Andersson M, Greiff L 
et al. Prevalence of nasal symptoms and their relation to self-reported asthma 
and chronic bronchitis/emphysema. Eur Respir J 2001; 17(4):596-603.
(89) Gardner WN. The pathophysiology of hyperventilation disorders. Chest 1996; 
109(2):516-534.
(90) Kerr WJ, Gliebe PA, Dalton JW. Physical phenomena associated with anxiety 
states: the hyperventilation syndrome. Cal Western Medicine 1938; 48:12-16.
(91) Thomas PS, Geddes DM, Barnes PJ. Pseudo-steroid resistant asthma. Thorax 
1999; 54(4):352-356.
(92) Han JN, Stegen K, Simkens K, Cauberghs M, Schepers R, Van den BO et al. 
Unsteadiness of breathing in patients with hyperventilation syndrome and 
anxiety disorders. European Respiratory Journal 1997; 10(1): 167-176.
(93) van Dixhoom J. Hyperventilation and dysfiinctional breathing. Biological 
Psychology 1997; 46:90-91.
(94) Han JN, Stegen K, Schepers R, Van den BO, Van de Woestijne KP. 
Subjective symptoms and breathing pattern at rest and following 
hyperventilation in anxiety and somatoform disorders. Journal of 
Psychosomatic Research 1998; 45(6):519-532.
213
(95) Ringsberg KC, Akerlind I. Presence of hypei*ventilation in patients with 
asthma-like symptoms but negative asthma test responses: provocation with 
voluntary hyperventilation and mental stress. Journal of Allergy & Clinical 
Immunology 1999; 103(4):601-608.
(96) Vansteenkiste J, Rochette F, Demedts M. Diagnostic tests of hyperventilation 
syndrome. European Respiratoiy Journal 1991; 4(4):393-399.
(97) Homsveld H, Garssen B. The low specificity of the Hyperventilation 
Provocation Test. Journal of Psychosomatic Research 1996; 41(5):435-449.
(98) Hornsveld HK, Garssen B, Dop MJ, van Spiegel PI, de Haes JC. Double-blind 
placebo-controlled study of the hyperventilation provocation test and the 
validity of the hyperventilation syndrome. Lancet 1996; 348(9021): 154-158.
(99) Homsveld H, Garssen B, Dop MF, van Spiegel P. Symptom reporting during 
voluntary hyperventilation and mental load: implications for diagnosing 
hyperventilation syndrome. Journal of Psychosomatic Research 1990; 
34(6):687-697.
(100) Roll M, Zetterquist S. Acute chest pain without obvious organic cause before 
the age of 40 years: response to forced hyperventilation. Journal of Internal 
Medicine 1990; 228(3):223-227.
(101) van Dixhoom J, Duivenvoorden HJ. Efficacy of Nijmegen Questiomiaire in 
recognition of the hyperventilation syndrome. Joumal of Psychosomatic 
Research 1985; 29(2): 199-206.
214
(102) Thomas M, McKinley RK, Freeman E, Foy C. Prevalence of dysfunctional 
breathing in patients treated for asthma in primary care: cross sectional survey. 
BMJ2001; 322(7294):1098-1100.
(103) McLean AN, Howells J, Chaudii G, Boyd G. Use of the Nijmegen 
hyperventilation questionnaire and hyperventilation provocation test in a 
hospital asthma clinic. Am J Respir Crit Care Med 1999; 159, A652.
(104) Thomas M, McKinley RK, Freeman E, Foy C, Prodger P, Price D. Breathing 
retraining for dysfunctional breathing in asthma: a randomised controlled trial. 
Thorax 2003; 58(2):110-115.
(105) Han JN, Stegen K, De Valck C, Clement J, Van de Woestijne KP. Influence of 
breathing therapy on complaints, anxiety and breathing pattern in patients with 
hyperventilation syndrome and anxiety disorders. Joumal of Psychosomatic 
Research 1996; 41(5):481-493.
(106) Cooper S, Obome J, Newton S, Harrison V, Thompson CJ, Lewis S et al. 
Effect of two breathing exercises (Buteyko and pranayama) in asthma: a 
randomised controlled trial. Thorax 2003; 58(8):674-679.
(107) Holloway E, Ram FSF. Cochi ane Database of Systematic Reviews 2004;(2).
(108) Tobin MJ, Mador MJ, Guenther SM, Lodato RF, Sackner MA. Variability of 
resting respiratory diive and timing in healthy subjects. Joumal of Applied 
Physiology 1988; 65(1):309-317.
(109) Tobin MJ, Chadha TS, Jenouri G, Birch SJ, Gazeroglu HB, Sackner MA. 
Breathing patterns. 2. Diseased subjects. Chest 1983; 84(3):286-294.
215
(110) Tobin MJ, Chadha TS, Jenouri G, Birch SJ, Gazeroglu HB, Sackner MA. 
Breathing patterns. 1. Normal subjects. Chest 1983; 84(2):202-205.
(111) Askanazi J, Silverberg PA, Foster RJ, Hyman AI, Milic-Emili J, Kinney JM. 
Effects of respfratoiy apparatus on breathing pattern. Joumal of Applied 
Physiology: Respiratory, Environmental & Exercise Physiology 1980; 
48(4):577-580.
(112) Gilbert R, Auchincloss JH, Jr., Brodsky J, Boden W. Changes in tidal volume, 
frequency, and ventilation induced by their measurement. Journal of Applied 
Physiology 1972; 33(2):252-254.
(113) Sackner JD, Nixon AJ, Davis B, Atkins N, Sackner MA. Effects of breathing 
through external dead space on ventilation at rest and during exercise. II. 
American Review of Respiratory Disease 1980; 122(6):933-940.
(114) Bucknall CE, Slack R, Godley CC, Mackay TW, Wright SC. Scottish 
Confidential Inquiry into Asthma Deaths (SCIAD), 1994-6. Thorax 1999; 
54(ll):978-984.
(115) Campbell DA, McLennan G, Coates JR, Frith PA, Gluyas PA, Latimer KM et 
al. A comparison of asthma deaths and near-fatal asthma attacks in South 
Australia. Eur Respir J 1994; 7(3):490-497.
(116) Campbell DA, Yellowlees PM, McLemran G, Coates JR, Frith PA, Gluyas PA 
et al. Psychiatric and medical features of near fatal asthma. Thorax 1995; 
50(3):254-259.
216
(117) ten Brinke A, Ouwerkerk ME, Zwinderman AH, Spinhoven P, Bel EH. 
Psychopathology in patients with severe asthma is associated with increased 
health care utilization. American Joumal of Respiratory & Critical Care 
Medicine 163(5): 1093-6, 2001; 163(5):1093-1096.
(118) Miles JF, Garden GM, Tunnicliffe WS, Cayton RM, Ayres JG. Psychological 
morbidity and coping skills in patients with brittle and non-brittle asthma: a 
case-control study. Clin Exp Allergy 1997; 27(10):1151-1159.
(119) Heaney LG, Conway E, Kelly C, Gamble J. Prevalence of psychiatric 
morbidity in a difficult asthma population: relationship to asthma outcome. 
Respir Med 2005; 99(9): 1152-1159.
(120) Nascimento I, Nardi AE, Valenca AM, Lopes FL, Mezzasalma MA, 
Nascentes R et al. Psychiatric disorders in asthmatic outpatients. Psychiatry 
Res 2002; 110(l):73-80.
(121) Shavitt RG, Gentil V, Mandetta R. The association of panic/agoraphobia and 
asthma. Contiibuting factors and clinical implications. General Hospital 
Psychiatry 1992; 14(6):420-423.
(122) Janson C, Bjornsson E, Hetta J, Boman G. Anxiety and depression in relation 
to respiratory symptoms and asthma. Am J Respir Crit Care Med 1994; 149(4 
Pt l):930-934.
(123) Adams RJ, Wilson DH, Taylor AW, Daly A, Tursan dE, Dal Grande E et al. 
Psychological factors and asthma quality of life: a population based study. 
Thorax 2004; 59(ll):930-935.
217
(124) Rimington LD, Davies DH, Lowe D, Pearson MG. Relationship between 
anxiety, depression, and morbidity in adult asthma patients. Thorax 2001; 
56(4):266-271.
(125) Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta 
Psychiatrica Scandinavica 1983; 67(6):361-370.
(126) Juniper EF, Guyatt GH, Ferrie PJ, Griffith LE. Measuring quality of life in 
asthma. Am Rev Respir Dis 1993; 147(4):832-838.
(127) Juniper EF, Guyatt GH, Cox FM, Ferrie PJ, King DR. Development and 
validation of the Mini Asthma Quality of Life Questionnaire. Eur Respir J 
1999; 14(l):32-38.
(128) Price D, Haughney J, Lloyd A, Hutchinson J, Plumb J. An economic 
evaluation of adjustable and fixed dosing with budesonide/fbrmoterol via a 
single inhaler in asthma patients: The ASSURE study. Current Medical 
Research & Opinion Vol 2004; 20(10): 1671-1679.
(129) Rosenhall L, Elvstrand A, Tilling B, Vinge I, Jemsby P, Stahl E et al. One- 
year safety and efficacy of budesonide/fbrmoterol in a single inhaler 
(Symbicort Turbuhaler ) for the treatment of asthma. Respir Med 2003; 
97(6):702-708.
(130) Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal 
important change in a disease-specific Quality of Life Questionnake. J Clin 
Epidemiol 1994; 47(l):81-87.
218
(131) Katz PP, Yelin EH, Eisner MD, Blanc PD. Perceived control of asthma and 
quality of life among adults with asthma. Ann Allergy Asthma Immunol 2002; 
89(3):251-258.
(132) Olajos-Clow J, Costello E, Lougheed MD. Perceived control and quality of 
life in asthma: impact of asthma education. J Asthma 2005; 42(9):751-756.
(133) Heaney LG, Conway E, Kelly C, Johnston BT, English C, Stevenson M et al. 
Predictors of therapy resistant asthma: outcome of a systematic evaluation 
protocol. Thorax 2003; 58(7):561-566.
(134) Robinson DS, Campbell DA, Durham SR, Pfeffer J, Bames PJ, Chung KF et 
al. Systematic assessment of difficult-to-treat asthma. Eur Respir J 2003; 
22(3):478-483.
(135) Gibson PG, Henry RL, Coughlan JL. Gastro-oesophageal reflux treatment for 
asthma in adults and children. Cochrane Database of Systematic Reviews 
2006;(1).
(136) Bosley CM, Fosbuiy JA, Cochrane GM. The psychological factors associated 
with poor compliance with treatment in asthma. Eur Respir J 1995; 8(6): 899- 
904.
(137) Nishimura K, Hajiro T, Oga T, Tsukino M, Ikeda A. Health-related quality of 
life in stable asthma: what are remaining quality of life problems in patients 
with well-controlled asthma? J Asthma 2004; 41(l):57-65.
(138) Pearson MG, Bucknall CE. Measuriug Clinical Outcome in Asthma; a patient 
focussed approach. London: Royal College of Physicians, 1999.
219
(139) Birch M, MacLeod D, Levine M. An analogue instrument for the 
measurement of respiratory impedance using the forced oscillation technique. 
Physiol Meas 2001; 22(2):323-339.
(140) Horowitz JG, Siegel SD, Primiano FP, Jr., Chester EH. Computation of 
respiratory impedance from forced sinusoidal oscillations during breathing. 
Computers & Biomedical Research 1983; 16(6):499-521.
(141) Guideliues for the measurement of respiratory function. Recommendations of 
the British Thoracic Society and the Association of Respiratory Technicians 
and Physiologists. Respir Med 1994; 88(3): 165-194.
(142) Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yemault JC. 
Lung volumes and forced ventilatoiy flows. Report Working Party 
Standardization of Lung Function Tests, European Community for Steel and 
Coal. Official Statement of the European Respiratory Society. Eur Respir J 
Suppl 1993; 16:5-40.
(143) Lombardi E, Sly PD, Concutelli G, Novembre E, Veneruso G, Frongia G et al. 
Reference values of interrupter respiratory resistance in healthy preschool 
white children. Thorax 2001; 56(9):691-695.
(144) van Altena R, Gimeno F. Respiratory resistance measured by flow- 
intermption in a normal population. Respiiation 1994; 61(5):249-254.
(145) Vooren PH, van Zomeren BC. Reference values of total respiratory resistance, 
determined with the "opening" interruption technique. Eur Respir J 1989; 
2(10):966-971.
220
(146) Fairbanks G. Voice and articulation drillbook. 2nd ed. New York: Harper and 
Brothers, 1960.
(147) De Bodt MS, Van de Heyning PH, Wuyts FL, Lambrechts L. The perceptual 
evaluation of voice disorders. Acta Oto-Rhino-Laryngologica Belgica 
50(4):283-91, 1996.
(148) Altman DG. Practical Statistics for Medical Research. First ed. London: 
Chapman and Hall, 1991.
(149) Gleser GC, Cronbach LJ, Rajaratnam N. Generalizability of scores influenced 
by multiple sources of variance. Psychometrika 30(4):395-418, 1965.
(150) Efron B, Tibshirani R. An Introduction to the Bootstrap. London: Chapman & 
Hall, 1993.
(151) Carrau RL, Khidr A, Crawley JA, Hillson EM, Davis JK, Pashos CL. The 
impact of laryngopharyngeal reflux on patient-reported quality of life. 
Laryngoscope 2004; 114(4):670-674.
(152) Belafsky PC, Postma GN, Koufinan JA. Validity and reliability of the reflux 
symptom index (RSI). J Voice 2002; 16(2):274-277.
(153) Coughlan JL, Gibson PG, Henry RL. Medical treatment for reflux 
oesophagitis does not consistently improve asthma control: a systematic 
review. Thorax 2001; 56(3):198-204.
(154) Field SK, Sutherland LR. Does medical antireflux therapy improve asthma in 
asthmatics with gastroesophageal reflux?: a critical review of the literature. 
Chest 1998; 114(l):275-283.
221
(155) Groen JN, Smout AJ. Supra-oesophageal manifestations of gastro-oesophageal 
reflux disease. Eur J Gastroenterol Hepatol 2003; 15(12); 1339-1350.
(156) Horan T, Mateus S, Beraldo P, Araujo L, Urschel J, Urmenyi E et al. Forced 
oscillation technique to evaluate tracheostenosis in patients with neurologic 
injury. Chest 2001; 120(1):69-73.
(157) Badia JR, Farre RO, John KR, Ballester E, Hernandez L, Rotger M et al. 
Clinical application of the forced oscillation technique for CPAP titration in 
the sleep apnea/hypopnea syndrome. Am J Respir Crit Care Med 1999; 
160(5:Pt l):t-4.
(158) Navajas D, Farre R, Rotger M, Badia R, Puig-de-Morales M, Montserrat JM. 
Assessment of airflow obstruction during CPAP by means of forced 
oscillation in patients with sleep apnea. Am J Respir Crit Care Med 1998; 
157(5:Pt l):t-30.
(159) Delacourt C, Lorino H, Fuhrman C, Heiwe-Guillot M, Reinert P, Harf A et al. 
Comparison of the forced oscillation technique and the interrupter technique 
for assessing airway obstruction and its reversibility in children. Am J Respir 
Crit Care Med 2001; 164(6):965-972.
(160) Millet B, Dejonckere PH. What determines the differences in perceptual rating 
of dysphonia between experienced raters? Folia Phoniatr Logop 1998; 
50(6);305-310.
(161) Deary IJ, Wilson JA, Carding PN, MacKenzie K. The dysphonie voice heard 
by me, you and it: differential associations with personality and psychological 
distress. Clin Otolaryngol 2003; 28(4):374-378.
222
(162) Murry T, Medi'ado R, Hogikyan ND, Aviv JE. The relationship between 
ratings of voice quality and quality of life measures. J Voice 2004; 18(2): 183- 
192.
(163) Dedivitis RA, Barros AP, Queija DS, Alexandre JC, Rezende WT, Corazza 
VR et al. Interobserver perceptual analysis of smokers voice. Clin Otolaryngol 
2004; 29(2): 124-127.
(164) Kreiman J, Genatt BR, Precoda K, Berke GS. Individual differences in voice 
quality perception. Journal of Speech & Hearing Research 1992; 35(3):512- 
520.
(165) Hurst JR, Wilkinson TM, Donaldson GC, Wedzicha JA. Upper airway 
symptoms and quality of life in chronic obstructive pulmonary disease 
(COPD). Respiratory Medicine 98(8):767-70, 2004.
(166) Picchillo JF, Edwards DE, Haiduk A, Yonan C, Thawley SE. Psychometric 
and clinimetric validity of the 31-item Rhino sinusitis Outcome Measure 
(RSOM-31). Am J Rhinol 1995; 9:297-306.
(167) Anderson ER, Murphy MP, Weymuller EA, Jr. Clmimetric evaluation of the 
Sinonasal Outcome Test-16. Student Research Award 1998. Otolaryngology - 
Head & Neck Surgery 121(6):702-7, 1999.
(168) Piccirillo JF, Merritt MG, Jr., Richards ML. Psychometric and clinimetric 
validity of the 20-Item Sino-Nasal Outcome Test (SNOT-20). Otolaryngology 
- Head &Neck Surgery 126(l):41-7, 2002.
223
(169) Crapo RO, Casaburi R, Coates AL, Enright PL, Hankinson JL, Irvin CG et al. 
Guidelines for methacholine and exercise challenge testing-1999. American 
Journal of Respiratory & Critical Care Medicine 2000; 161(l):309-329.
(170) Beaver WL, Wasserman K, Whipp BJ. A new method for detecting anaerobic 
threshold by gas exchange. Journal of Applied Physiology 1986; 60(6):2020- 
2027.
(171) Carter R, Banham SW. Use of transcutaneous oxygen and carbon dioxide 
tensions for assessing indices of gas exchange dui'ing exercise testing. 
Respiratory Medicine 2000; 94(4):350-355.
(172) Jack S, Rossiter HB, Warburton CJ, Whipp BJ. Behavioral influences and 
physiological indices of ventilatory control in subjects with idiopathic 
hyperventilation. Behavior Modification 2003; 27(5):637-652.
224
APPENDIX 1
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GRI ASTHMA CLINIC QUESTIONNAIRE -  NEW PATIENTS
W e would be most grateful if you could spend a few  minutes completing this questionnaire.
Your answers w ill help us in the long-term management of patients attending the asthma clinic.
Thank you for your time.
NAME:__________________________________ DATE:_________________
SECTION 1
Please complete all questions by circling the number that best describes how you have been during the last 2 weeks as 
a result of your asthma.
In general, how much of the time during the last 2 weeks did you:
All of the Most of A good Some of A Little of Hardly None of
time the time Bit of the the time the time Any of the time
time
1 Feel SHORT OF BREATH 
as a result of your asthma?
2 Feel bothered by or have to 
avoid DUST in the environment?
3 Feel FRUSTRATED as a result 
of your asthma?
4 Feel bothered by COUGHING?
5 Feel AFRAID OF NOT HAVING 
YOUR ASTHMA MEDICATION 
AVAILABLE?
6 Experience a feeling of 
CHEST TIGHTNESS or 
CHEST HEAVINESS?
7 Feel bothered by or have to avoid 
CIGARETTE SMOKE
in the environment?
8 Have DIFFICULTY GETTING 
A GOOD NIHGHT’S SLEEP 
as a result of your asthma?
9 Feel CONCERNED ABOUT 
HAVING ASTHMA?
10 Experience WHEEZE in your 
chest?
11 Feel bothered by or have to avoid 
going outside because of
1
the
time
6
226
WEATHER OR AIR POLLUTION?
How limited have you been during the last 2 weeks doing these activities as a result of your asthma?
Totally Extremely Very Moderate Some A Little Not at all 
Limited Limited Limited Limitation Limitation Limitation Limited
12 STRENUOUS ACTIVITIES
(such as hurrying, exercising, 1 2 3 4 5 6 7
running up stairs, sports)
13 MODERATE ACTIVITIES
(such as walking, housework, 1 2 3 4 5 6 7
gardening, shopping, climbing
stairs)
14 SOCIAL ACTIVITIES (such as
talking, playing with ets/children, 1 2 3 4 5 6 7
visiting friends/relatives)
15 WORK RELATED ACTIVITIES
(tasks you have to do at work, 1 9 /i c; n 7
OR if you do not work, tasks you 
have to do most days)
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SECTION 2
Doctors and nurses are aware that emotions play an important part in most illnesses. If your doctor or nurse 
knows about these feelings they will be able to help you more.
This questionnaire is designed to help your Doctor or Nurse know how you feel. Read each item and place a 
firm tick in the box opposite the reply which com es closest to how you have been feeling in the past week. 
Do not take too long over your replies: your immediate reaction to each item will probably be more accurate 
than a long though-out response.
Tick only one box in each section
I feel tense or wound up
most of the time
I feel as if I am slowed down
nearly all the time
a lot of the time very often
time to time, occasionally sometimes
not at all not at all
I still enjoy the things I used to enjoy
I get a sort of frightened feeling 
like “butterflies in the stomach
definitely as much not at all
not quite as much occasionally
only a little quite often
hardly at all very often
I get a sort of frightened feeling as if 
something awful is about to happen
very definitely and quite badly 
yes, but not too badly 
a little, but it does not worry me 
not at all
I have lost interest in ray 
appearance
definitely
I don’t take so much care as I should 
I may not take quite as much cai e 
I take just as much care as ever
I can laugh and see the funny side of things
I fee! restless as if I have to be on 
the move
as much as I always did very much indeed
not quite as much now quite a lot
definitely not so much now not very much
not at all not at all
Worrying thoughts go through ray mind
I look forward with enjoyment to 
things
a great deal of the time as much as I ever did
a lot of the time rather less than I used to
fi-om time to time but not too often definitely less than I used to
only occasionally hardly at all
I feel cheerful I get sudden feelings of panic
not at all very often indeed
not often quite often
sometimes not very often
most of the time not at all
I can sit at ease and feel relaxed
definitely 
usually 
not often 
not at all
I can enjoy a book or radio/ tv programme
often
sometimes 
not ofl:en 
very seldom
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SECTION 3
For each of the following statements, please tick the box for the most appropriate response
1 I can reduce asthma by staying 
calm and relaxed
2 Too often, my asthma just 
seems to hit me out of the blue
3 If I do all the right things, I can 
successfully manage my asthma
4 I can do a lot of things myself 
to cope with my asthma
5 When I manage my personal life 
well, my asthma does not affect 
me as much
6 I have considerable ability to 
control my asthma
7 I would feel helpless if I couldn’t 
rely on other people for help 
when I’m not feeling well from 
asthma
8 No matter what I do, or how hard 
I try, I Just can’t seem to get 
relief from my asthma
9 I am coping effectively with 
my asthma
10 it seems as though fate and 
other factors beyond my control 
affect my asthma
11 Asthma is controlling my life
STRONGLY
AGREE
AGREE NEUTRAL DISAGREE STRONGLY
DISAGREE
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SECTION 4
Please mark with a tick how often you suffer from the following complaints;
NEVER RARE SOMETIMES OFTEN VERY
OFTEN
CHEST PAIN
FEELING TENSE
BLURRED VISION
DIZZY SPELLS
FEELING CONFUSED / DISORIENTATED
FASTER OR DEEPER BREATHING
SHORT OF BREATH
TIGHT FEELING IN CHEST
BLOATED FEELING IN STOMACH
TINGLING FINGERS
UNABLE TO BREATHE DEEPLY
STIFF FINGERS OR ARMS
TIGHT FEELING ROUND MOUTH
COLD HANDS OR FEET
HEART RACING (PALPITATION)
FEELINGS OF ANXIETY
Thank you for taking the time to fill in this questionnaire. 
Please hand it to the nurse when you are finished.
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GRI/Stobhill Hospital Problem Asthma Clinic
Strategy:
1. Does this patient have asthma?
2. What is their cnnrent psychological profile and history of use of resources?
3. Which combination of associated/aggravating factors does he/she have? (poor compliance, 
allergy, acid reflux, upper airway/sinus, hyperventilation, vocal cord dysfunction, 
depression)
4. What is the treatment needed to optimise control? (asthma and any aggravating/associated 
conditions)
5. Do they need to learn to self manage (those with acute admissions or poor control after Rx 
optimisation)? Are they (subsequently) self managing effectively?
6. Is there any change in psychological profile and use of resources after this process has been?
New patient Clinic attendance
asthma nurse gives out questionnaires, checks BP, inhaler and PEP teclmique, takes blood for 
random glucose, total IgE and RASTs to eommon allergens (HDM, pollen, cat, dog, aspergillus), 
FBC (eosinophils), U&E, LFTs
Self completed questionnaires (HAD, PCAQ, mini-AQLQ, Nijmegen,)*
- Give to AS
Clinical evaluation, inc review of questionnaires -  if Nijmegen positive (>/=23)- book PET and 
refer for breathing control (physio)
Complete new patient summary sheet and checklist
Start 2 week PEF diary
FOX
Book PFT for 2 weeks hence (phone lung lab), to coincide with next clinic appointment
232
#First review (2 weeks)
Review & consideration of need for trial of steroids for best function ( if FEVl <80%)
Full PFTs, skin tests, flow volume loop before clinic attendance 
Review of PEF diary and PFTs:
• Prednisolone 30mg daily for two weeks if FEV1<80%
• Optimise inhaled therapy if lung function normal, depending on cuiTent therapy and level of 
symptoms/PEFs
• If uncontrolled, and PEFs/PFT normal -  proceed to histamine challenge 
Continue PEF monitoring and diary card
Arrange further appointment accordingly
Second Review
Review of those on steroid trial with repeat PFTs to determine need for prolongation of trial; if lung 
function now normal, optimise inhaled/oral astluna therapy depending on residual symptoms and 
PEF levels/variability
IDENTIFY PATIENTS AT THIS STAGE AS GREEN OR ORANGE STREAM
Green stream patients (normal lung function and well on inhaled Rx)- self management training 
and monitor/adjust asthma R x , aiming to discharge when stable for 3 months. Repeat questionnaires 
before discharge
Orange stream (Step 4 or more or persistent symptoms or subnormal PFTs):
• Continue to optimise therapy, if asthma confirmed (guided by degree of sputum 
eosinophilia -  induced sputum -  Physio will do this at clinic)
• Sinus CT/ ENT evaluation (esp nose and vocal cords)
• Oesophageal and pharyngeal pH monitoring, off PPI
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• Dexa scan
• PET and PC20 (once best function achieved)
• Review of therapy to include PPI (with repeat pH monitroing on Rx), bisphosphonates, 
breathing control (with repeat Nijmegen score), S&L therapy, nasal
steroids/antihistamines/cons ideration of need for surgery (repeat ENT evaluation) as 
appropriate, depending of results of investigations
• Self management training, if persistent exacerbations or symptoms
• repeat PFTs & questionnaires when assessment complete and patient stable
Change innning of clinic so there are 3 streams -  
Red (New) patient -  seen by anyone, discussed with CEB
Orange - those with poorly controlled asthma, requiring full evaluation (seen by CEB or AS). 
Green - seen by CEB or rotating SHO and discussed 
Identify different streams with sticker on front of casenotes.
Christine E Bucknall 
Consultant Respiratory Physician 
14^  ^August 2003
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GRI ASTHMA CLINIC
COHORT FOLLOW UP DETAILS
PATIENT
LABEL
Date
Definite Asthma Diagnosis
Basis of Asthma Diagnosis
Variable Symptoms 
Variable PEF 
AFO with BD reversibility 
Histamine Challenge 
Steroid Trial
Respiratory co-morbidity
COPD
Bronchiectasis
GORD
Basis of diagnosis 
Other
□□□
Yes □
□□□□□
No □
(if only reason -  justify) 
% BD reversibility _
Current Therapy
BTS Step 
Detail
Best Lung Function
Date
FEV1
FVC
Ratio
%pred)
Degree of BD reversibility (%)_
Self management plan in place? Yes □  No □
Is patient self-managing effectively? Yes □  No □
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GRI Problem Asthma Clinic January 2006
Does this patient have objective evidence of asthma?
• BD reversibility documented?
• Good quality PEF chart variability?
• PC 20 in keeping with asthma (< 2mg/ml, but
not an absolute)
• Raised FEno?
I f  no objective evidence of 
asthma, what about 
alternative diaqnoses?
I f  asthma confirmed, are symptoms all 
due to asthma?
GORD -  Don't know/no/yes
I f  yes, has this been abolished? 
What dose of PPI required to 
abolish?
Dysfunctional breathing -  DK/no/yes
I f  yes, basis of diagnosis 
Benefit from Rx?
Using breathing control effectively?
Any indication of Vocal cord 
Dysfunction -  DK/no/yes 
Details
Psychological/psychiatric issues 
DK/no/yes
Details of management strategy
I f  asthma confirmed:
has Rx been optimised? 
Is  compliance an issue? 
Inhaler technique?
Self management plan? 
Using SMP effectively? 
(review handling of 
recent exacerbation) 
S ide-effects from Rx? 
(BP, glucose, 
osteoporosis) Are these 
being adequately 
managed?
Allergic Broncho-pulmonary 
Aspergillosis?
Total IgE? ( not more th a t 6 
monthly, maybe less) 
Itraconazole/LFTmonitoring?
Physio input
Upper airway evaluation:
No symptoms 
Normal
Abnormal -  detail, inc management
Bronchiectasis?
Physio input 238
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The VoiSS- Voice Symptoms Scale
Your Name....................................
Your Date of Birth.................... .
Today’s Date / ......./........
Please circle one answer for each item 
Please do not leave any blank items
1. Do you have difficulty attracting 
attention?
Never Occasionally Some of 
the time
Most of 
the time
Always
2. Do you have problems singing? Never Occasionally Some of the time Most of the time Always
3. Is your throat sore? Never Occasionally Some of the time Most of the time Always
4. Is your voice hoarse? Never Occasionally Some of the time Most of the time Always
5. When talking in company do people fail to 
hear you?
Never Occasionally Some of 
the time
Most of 
the time
Always
6. Do you lose your voice? Never Occasionally Some of the time Most of the time
Always
7. Do you cough or clear your tliroat? Never Occasionally Some of the time Most of the time Always
8. Do you have a weak voice? Never Occasionally Some of the time Most of the time Always
9. Do you have problems talking on the 
telephone?
Never Occasionally Some of 
the time
Most of 
the time
Always
10. Do you feel miserable or depressed 
because of your voice problem?
Never Occasionally Some of 
the time
Most of 
the time
Always
11. Does it feel as if there is something stuck 
in your throat?
Never Occasionally Some of 
the time
Most of 
the time
Always
12. Do you have swollen glands? Never Occasionally Some of the time Most of the time Always
13. Are you embarrassed by your voice 
problem?
Never Occasionally Some of 
the time
Most of 
the time
Always
14. Do you find the effort of speaking tiring? Never Occasionally Some of the time Most of the time Always
15. Does your voice problem make you feel 
stressed and nervous?
Never Occasionally Some of 
the time
Most of 
the time
Always
16. Do you have difficulty competing against 
background noise?
Never Occasionally Some of 
the time
Most of 
the time
Always
Please Turn Over =>
240
-page2-
VoiSS
Please circle the correct answer for each item 
Please do not leave any blank items
17. Are you unable to shout or raise your 
voice?
Never Occasionally Some of 
the time
Most of 
the time
Always
18. Does your voice problem put a strain on 
your family and friends?
Never Occasionally Some of 
the time
Most of 
the time
Always
19. Do you have a lot of phlegm in your 
throat?
Never Occasionally Some of 
the time
Most of 
the time
Always
20. Does the sound of your voice vary 
tlu'oughout the day?
Never Occasionally Some of 
the time
Most of 
the time
Always
21. Do people seem irritated by your voice? Never Occasionally Some of the time Most of the time Always
22. Do you have a blocked nose? Never Occasionally Some of the time Most of the time Always
23. Do people ask what is wrong with your 
voice?
Never Occasionally Some of 
the time
Most of 
the time
Always
24. Does your voice sound creaky and dry? Never Occasionally Some of the time Most of the time Always
25. Do you feel you have to sti ain to produce 
voice?
Never Occasionally Some of 
the time
Most of 
the time
Always
26. How often do you get throat infections? Never Occasionally Some of the time Most of the time Always
27. Does your voice ‘give out’ in the middle of 
speaking?
Never Occasionally Some of 
the time
Most of 
the time
Always
28. Does your voice make you feel 
incompetent?
Never Occasionally Some of 
the time
Most of 
the time
Always
29. Are you ashamed of your voice problem? Never Occasionally Some of the time Most of the time Always
30. Do you feel lonely because of your voice 
problem?
Never Occasionally Some of 
the time
Most of 
the time
Always
Thank you for completing this questionnaire 
Have you remembered to circle one response for each item?
For Office use:
Total VoiSS=  .......
Impairment: 1, 2,4, 5, 6, 8, 9, 14, 16, 17, 20, 23, 24, 25, 27 (max 60) = 
Emotional: 10, 13,15,18,21, 28,29,30 (max 32) =
Physical: 3, 7, 11, 12, 19, 22, 26 (max 28) =
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SINO-NASAL OUTCOMES TEST 
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Below you will find a list of sytïiptoïm and sociai/cmotional consequences of y our nasal 
i s^order. We would like m know more about these problems md would appreciate your 
Mswcring tile following questions to the best of your ability. There are no lij^t or wrong 
Mswers  ^m d  only yon can proride os with this mtbrmation. Please rate your problems ss 
they’ have been over the past two weeks. Thank you, for your participation.
A. Considmng how severe the problem z % < ^  % g M . g  gis when you espcncncc it and how a | 3 1 1# 1frequentiy it happens, please rate each 
item below on how’ “bad” if is by I* i  ^ TS ff ^ 1 1 g^l ’^W yScircling the number that corresponds É f f g* iwith how you feel using this scale ^ I K 1.
1. Meed to blow nose _ _ _ _ _ 3 ' ""^ 0...
2. Sneezing 0 1 2 3 4 5 D
i .  Runny nose Ô 1 2 3 4 5 0
4-, Nasal obsfcruelion 0 1. 2 3 4 5 0
5. Loss of smell or taste ..0 ■ I 2 3 4 5 □
6 , Cough 0 ! 1 2 3 4 5 0
7. P ost-n^  diicharge 0 1 2 3 4 5 □
8, lliick nasal dischaige 0 1 2 3 4 5 0
9. Ear fullness 0 i 2 3 4 5 a
10, Dizziness 0 i i '  ' 3 4 5 0
11. Ear pain 0 I 2 3 4 5 0
12^  Facial prin/pressiire 0 I 2 3 4 5 Cl
13. Difïîûully falling asleep 0 T 2 3 4 5 ...p...14. Wake up st night 0 I a 3 4 5 0
15. Lack of a good, night’s sleep 0 I 2 3 4 5 □
16. Wake up tir®J 0 1 2 3 4 0
17. Fatigue 0 1 2 3 4 5 □
IS. Reduced productivity Ü 1 2 3 4 5 Cl
19, Reduced cottcetMration 0 I 2 3 4 5 □
20. Frustrate i^e&des& i^mt l^e 0 I 2 3 4 5 □
21. Sad 0 1 2 3 4 5 □
22. Embarrassed 0 1 2 3 4 5 : . □
B.. Please tick the most important items affecting your health (maximum of 5 items)......... i>
GLA .^%0\V
UNl#f{SITY
